Ipilimumab Clinical Trials (2026): 791 Studies for Melanoma & Metastatic Melanoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
791 Ipilimumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 366 indications (including Melanoma & Metastatic Melanoma) and 123,028 total planned enrollment. 64 Phase 3 Ipilimumab trials and 344 Phase 2, 7 Phase 4 are listed. 120 Ipilimumab clinical trials are actively recruiting at 1,761 U.S. sites across 51 states. Most recent activity: NCT05732389 (Feb 2052).
Where to Participate: All Ipilimumab Trial Sites in the U.S. (1,761 sites across 51 states)
Every actively recruiting Ipilimumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Research Site | Birmingham35294 | NCT05536141 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT06364917 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT04511013 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05112601 | Map |
| AL | University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham35294 | NCT02693535 | Map |
| AL | Thomas Hospital | Fairhope36532 | NCT04511013 | Map |
| AL | Mobile Infirmary Medical Center | Mobile36607 | NCT04511013 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT04511013 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT05647265 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT04511013 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT05647265 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT04511013 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05647265 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT04511013 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT05647265 | Map |
| AK | Anchorage Oncology Centre | Anchorage99508 | NCT04511013 | Map |
| AK | Anchorage Radiation Therapy Center | Anchorage99504 | NCT04511013 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT04511013 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT05647265 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT04511013 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT05647265 | Map |
| AK | Fairbanks Memorial Hospital | Fairbanks99701 | NCT04511013 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT05647265 | Map |
| AZ | Cancer Treatment Centers of America-Phoenix | Phoenix85338 | NCT02693535 | Map |
| AZ | Exelixis Clinical Site #67 | Phoenix85054 | NCT05176483 | Map |
| AZ | Mayo Clinic | Phoenix85054 | NCT06743126 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT05647265 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT03866382 | Map |
| AZ | Honor Health Research Institute | Scottsdale85258 | NCT06743126 | Map |
| AZ | HonorHealth Research Insisute | Scottsdale85258 | NCT06581406 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT05647265 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT03866382 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT03017820 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT06508463 | Map |
| AZ | Exelixis Clinical Site #1 | Tucson85711 | NCT05176483 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT07383441 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT04511013 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT07383441 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05327686 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT07383441 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT07383441 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05327686 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05647265 | Map |
| CA | Sutter Auburn | Auburn95602 | NCT02693535 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT07166406 | Map |
| CA | Sutter Alta Bates | Berkeley94705 | NCT02693535 | Map |
| CA | Precision NextGen Oncology | Beverly Hills90212 | NCT06047379 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT04511013 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT05647265 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT05327686 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT07166406 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06399419 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT07128680 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT05361720 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT06743126 | Map |
| CA | Epic Care-Dublin | Dublin94568 | NCT04511013 | Map |
| CA | Bay Area Breast Surgeons Inc | Emeryville94608 | NCT04511013 | Map |
| CA | Epic Care Partners in Cancer Care | Emeryville94608 | NCT04511013 | Map |
| CA | UC San Diego Health System - Encinitas | Encinitas92024 | NCT05327686 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT07166406 | Map |
| CA | OPN Healthcare, Inc | Glendale91203 | NCT06047379 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05327686 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05904080 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT07166406 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05327686 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05647265 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05896839 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92037 | NCT06581406 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06743126 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06594991 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT05896839 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT05904080 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT03866382 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05327686 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05896839 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05904080 | Map |
| CA | The Angeles Clinic and Research Institute | Los Angeles90025 | NCT05533697 | Map |
| CA | The Angeles Clinic and Research Institute | Los Angeles90025 | NCT06581406 | Map |
| CA | The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles90025 | NCT02693535 | Map |
| CA | The Angeles Clinic at Cedars Sinai | Los Angeles90025 | NCT05428007 | Map |
| CA | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles90095 | NCT04511013 | Map |
| CA | UCLA Hematology/Oncology | Los Angeles90024 | NCT06743126 | Map |
| CA | University of California Los Angeles | Los Angeles90095 | NCT06581406 | Map |
| CA | University of Southern California | Los Angeles90033 | NCT06047379 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05327686 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05896839 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05904080 | Map |
| CA | Contra Costa Regional Medical Center | Martinez94553-3156 | NCT04511013 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT05327686 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT07166406 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT04511013 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT05647265 | Map |
| CA | USC Newport Beach | Newport Beach92663 | NCT06624644 | Map |
| CA | USC Norris Oncology/Hematology-Newport Beach | Newport Beach92663 | NCT05904080 | Map |
| CA | Bay Area Tumor Institute | Oakland94609 | NCT04511013 | Map |
| CA | Kaiser Permanente - Oakland Medical Center | Oakland94611 | NCT02693535 | Map |
| CA | Chao Family Comprehensive Cancer Center | Orange92868 | NCT05361720 | Map |
| CA | Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange92868 | NCT04472767 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05327686 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05904080 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT07166406 | Map |
| CA | Exelixis Clinical Site #123 | Palo Alto94304 | NCT05176483 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT07166406 | Map |
| CA | Stanford Cancer Institute | Palo Alto94304 | NCT06581406 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT05904080 | Map |
| CA | Stanford University | Palo Alto94304 | NCT06712927 | Map |
| CA | Sutter Palo Alto Medical Foundation: Palo Alto | Palo Alto94301 | NCT02693535 | Map |
| CA | Kaiser Permanente - Roseville Medical Center | Roseville95661 | NCT02693535 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT05327686 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT07166406 | Map |
| CA | Sutter Roseville | Roseville95661 | NCT02693535 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT05327686 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT07166406 | Map |
| CA | Kaiser Permanente - Sacramento Medical Center | Sacramento95814 | NCT02693535 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT05327686 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT07166406 | Map |
| CA | Sutter Sacramento | Sacramento95816 | NCT02693535 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT03816345 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT07166406 | Map |
| CA | Research Site | San Diego92093 | NCT05536141 | Map |
| CA | Sharp Memorial Hospital | San Diego92123 | NCT04511013 | Map |
| CA | UC San Diego Medical Center - Hillcrest | San Diego92103 | NCT05327686 | Map |
| CA | California Pacific Medical Center Research Institute | San Francisco94115 | NCT02693535 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT07166406 | Map |
| CA | Kaiser Permanente - San Francisco Medical Center | San Francisco94115 | NCT02693535 | Map |
| CA | Kaiser Permanente - South San Francisco Medical Center | San Francisco94080 | NCT02693535 | Map |
| CA | Sutter Cancer Research Consortium | San Francisco94115 | NCT02693535 | Map |
| CA | UCSF | San Francisco94143 | NCT06624644 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT05533697 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94158 | NCT04665206 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT06743126 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT05327686 | Map |
| CA | Kaiser Permanente - San Jose Medical Center | San Jose95119 | NCT02693535 | Map |
| CA | Kaiser Permanente - San Leandro Medical Center | San Leandro94577 | NCT02693535 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT05327686 | Map |
| CA | Exelixis Clinical Site #59 | Santa Barbara93463 | NCT05176483 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT05327686 | Map |
| CA | Sutter Sansum Clinic | Santa Barbara93105 | NCT02693535 | Map |
| CA | Kaiser Permanente - Santa Clara Medical Center | Santa Clara95051 | NCT02693535 | Map |
| CA | Sutter Palo Alto Medical Foundation: Fremont | Santa Cruz994538 | NCT02693535 | Map |
| CA | Sutter Palo Alto Medical Foundation: Santa Cruz | Santa Cruz95065 | NCT02693535 | Map |
| CA | Research Site | Santa Monica90404 | NCT05536141 | Map |
| CA | Sarcoma Oncology Research Center | Santa Monica90403 | NCT03138161 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT04511013 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT05647265 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT04511013 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT05647265 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT05327686 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT07166406 | Map |
| CA | Stanford | Stanford94305 | NCT06624644 | Map |
| CA | Stanford Cancer Center | Stanford94305 | NCT06743126 | Map |
| CA | Stanford University (Data Collection Only) | Stanford94305 | NCT06594991 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT07166406 | Map |
| CA | Sutter Palo Alto Medical Foundation: Sunnyvale | Sunnyvale94086 | NCT02693535 | Map |
| CA | Kaiser Permanente - Vallejo Medical Center | Vallejo94589 | NCT02693535 | Map |
| CA | Epic Care Cyberknife Center | Walnut Creek94597 | NCT04511013 | Map |
| CA | Kaiser Permanente - Walnut Creek Medical Center | Walnut Creek94596 | NCT02693535 | Map |
| CO | Rocky Mountain Cancer Centers-Aurora | Aurora80012 | NCT04511013 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05327686 | Map |
| CO | University of Colorado Anschutz | Aurora80045 | NCT06624644 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT05533697 | Map |
| CO | University of Colorado Cancer Center | Aurora84005 | NCT06362369 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT04511013 | Map |
| CO | University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) | Aurora80045 | NCT06581406 | Map |
| CO | University of Colorado, Anschutz Medical Campus | Aurora80045 | NCT06743126 | Map |
| CO | Boulder Community Foothills Hospital | Boulder80303 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Boulder | Boulder80304 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers - Centennial | Centennial80112 | NCT04511013 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT04511013 | Map |
| CO | Presbyterian - Saint Lukes Medical Center - Health One | Denver80218 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Midtown | Denver80218 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Rose | Denver80220 | NCT04511013 | Map |
| CO | The Women's Imaging Center | Denver80209 | NCT04511013 | Map |
| CO | UCHealth - Cherry Creek | Denver80206 | NCT05327686 | Map |
| CO | University of Colorado | Denver80204 | NCT06624644 | Map |
| CO | Mountain Blue Cancer Care Center - Swedish | Englewood80113 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers - Swedish | Englewood80113 | NCT04511013 | Map |
| CO | Swedish Medical Center | Englewood80113 | NCT04511013 | Map |
| CO | The Melanoma & Skin Cancer Institute | Englewood80113 | NCT06581406 | Map |
| CO | The Melanoma and Skin Cancer Institute | Englewood80113 | NCT04511013 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05327686 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT07166406 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05327686 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT07166406 | Map |
| CO | Saint Mary's Hospital and Regional Medical Center | Grand Junction81501 | NCT07166406 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05327686 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT07166406 | Map |
| CO | UCHealth Highlands Ranch Hospital | Highlands Ranch80129 | NCT05327686 | Map |
| CO | Rocky Mountain Cancer Centers-Lakewood | Lakewood80228 | NCT04511013 | Map |
| CO | Exelixis Clinical Site #87 | Littleton80124 | NCT05176483 | Map |
| CO | Rocky Mountain Cancer Centers-Littleton | Littleton80120 | NCT04511013 | Map |
| CO | Rocky Mountain Cancer Centers-Sky Ridge | Lone Tree80124 | NCT04511013 | Map |
| CO | UCHealth Lone Tree Health Center | Lone Tree80124 | NCT05327686 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05327686 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT07166406 | Map |
| CO | Rocky Mountain Cancer Centers-Thornton | Thornton80260 | NCT04511013 | Map |
| CT | Saint Vincent's Medical Center (SVMC) | Bridgeport06606 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital-Hamden Care Center | Hamden06518 | NCT07166406 | Map |
| CT | Hartford Healthcare Alliance (Data Collection Only) | Hartford06102 | NCT06594991 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT07166406 | Map |
| CT | Midstate Medical Center (MSMC) | Meriden06451 | NCT02693535 | Map |
| CT | The Hospital of Central Connecticut (HOCC) Cancer Center | New Britain06053 | NCT02693535 | Map |
| CT | Exelixis Clinical Site #62 | New Haven06510 | NCT05176483 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT03816345 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT07166406 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT06743126 | Map |
| CT | Yale University | New Haven06520 | NCT03816345 | Map |
| CT | Yale University | New Haven06520 | NCT07166406 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT07166406 | Map |
| CT | William W. Backus Hospital | Norwich06360 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT07166406 | Map |
| CT | Charlotte Hungerford | Torrington06790 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT07166406 | Map |
| CT | Windham Hospital (WH) | Willimantic06226 | NCT02693535 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT05327686 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT05327686 | Map |
| DE | Christiana Care Health System- Site Number : 8400011 | Newark19713-2072 | NCT05584670 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT05327686 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05327686 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05327686 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT05327686 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT05327686 | Map |
| DC | George Washington University | Washington D.C.20037 | NCT05533697 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT06581406 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT03816345 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT03866382 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT05896839 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT07293351 | Map |
| FL | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05327686 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05896839 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Aventura | Aventura33180 | NCT02693535 | Map |
| FL | Exelixis Clinical Site #48 | Celebration34747 | NCT05176483 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05896839 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Lennar | Coral Gables33146 | NCT02693535 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05896839 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Deerfield Beach | Deerfield Beach33442 | NCT02693535 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT02693535 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT03866382 | Map |
| FL | Exelixis Clinical Site #11 | Gainesville32610 | NCT05176483 | Map |
| FL | University of Florida Health | Gainesville32610 | NCT02693535 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT05327686 | Map |
| FL | Exelixis Clinical Site #78 | Jacksonville32224 | NCT05176483 | Map |
| FL | Mayo Clinic - Jacksonville FL | Jacksonville32224 | NCT06581406 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05327686 | Map |
| FL | Moffitt Cancer Center at Speros | Land O' Lakes34638 | NCT07227012 | Map |
| FL | Exelixis Clinical Site #47 | Miami33136 | NCT05176483 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT05327686 | Map |
| FL | Research Site | Miami33136 | NCT05536141 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT06581406 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05896839 | Map |
| FL | University of Miami | Miami33136 | NCT06889493 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Cente | Miami33136 | NCT06743126 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05896839 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Alex's Place | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Kendall | Miami33176 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Sole Mia | Miami33181 | NCT02693535 | Map |
| FL | Mount Sinai Medical Center | Miami Beach33140 | NCT05327686 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT05896839 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT04511013 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT03866382 | Map |
| FL | Orlando Health UF Health Cancer Center | Orlando32806 | NCT05533697 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05327686 | Map |
| FL | Exelixis Clinical Site #61 | Plantation33322 | NCT05176483 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05896839 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Plantation | Plantation33324 | NCT02693535 | Map |
| FL | Moffitt Cancer Center at SouthShore | Ruskin33570 | NCT07227012 | Map |
| FL | Exelixis Clinical Site #8 | Tampa33612 | NCT05176483 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04996823 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04511013 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04562129 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06295159 | Map |
| FL | Moffitt Cancer Center | Tampa87535 | NCT06624644 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06743126 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07227012 | Map |
| FL | Moffitt Cancer Center - International Plaza | Tampa33607 | NCT07227012 | Map |
| FL | Moffitt Cancer Center - McKinley Campus | Tampa33612 | NCT04511013 | Map |
| FL | Moffitt Cancer Center - McKinley Campus | Tampa33612 | NCT07227012 | Map |
| FL | Moffitt Cancer Center-International Plaza | Tampa33607 | NCT04511013 | Map |
| FL | Moffitt McKinley Hospital | Tampa33612 | NCT07227012 | Map |
| FL | Moffitt Cancer Center at Wesley Chapel | Wesley Chapel33544 | NCT07227012 | Map |
| GA | University Cancer and Blood Center LLC | Athens30607 | NCT05112601 | Map |
| GA | Cancer Treatment Centers of America - Atlanta | Atlanta30265 | NCT02693535 | Map |
| GA | Emory Proton Therapy Center | Atlanta30308 | NCT07166406 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06324240 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT07166406 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT05904080 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT03690986 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT03866382 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06324240 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT07166406 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT03866382 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06324240 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT07155317 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT07166406 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322 | NCT02693535 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT06581406 | Map |
| GA | Grady Health System | Atlanta30303 | NCT06324240 | Map |
| GA | Grady Health System | Atlanta30303 | NCT07166406 | Map |
| GA | Research Site | Atlanta30322-1013 | NCT05536141 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT05112601 | Map |
| GA | Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute | Savannah31405 | NCT02693535 | Map |
| GA | Summit Cancer Care | Savannah31405 | NCT02693535 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT02693535 | Map |
| HI | The Queen's Medical Center | Honolulu96813 | NCT07075120 | Map |
| HI | The Queen's Medical Center - Kuakini | Honolulu96817 | NCT02693535 | Map |
| HI | The Queen's Medical Center - POB I | Honolulu96813 | NCT02693535 | Map |
| HI | The Queen's Medical Center - Punchbowl | Honolulu96813 | NCT02693535 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05327686 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT04511013 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT03866382 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05112601 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05327686 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT04511013 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT03866382 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT04511013 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05904080 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT03866382 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05112601 | Map |
| ID | Walter Knox Memorial Hospital | Emmett83617 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05112601 | Map |
| ID | Idaho Urologic Institute-Meridian | Meridian83642 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05112601 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05327686 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04511013 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT03866382 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83686 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05647265 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05112601 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT04511013 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05904080 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT03866382 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05112601 | Map |
| ID | Kootenai Cancer Clinic | Sandpoint83864 | NCT04511013 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05904080 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT03866382 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05112601 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT04511013 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05647265 | Map |
| IL | Saint Anthony's Health | Alton62002 | NCT04511013 | Map |
| IL | Rush - Copley Medical Center | Aurora60504 | NCT04511013 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05647265 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT04511013 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT07383441 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT04511013 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT07383441 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT04511013 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT04511013 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT04511013 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT07383441 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05327686 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04511013 | Map |
| IL | Saint Mary's Hospital | Centralia62801 | NCT04511013 | Map |
| IL | Cancer Treatment Centers of America-Chicago | Chicago60099 | NCT02693535 | Map |
| IL | Exelixis Clinical Site #26 | Chicago60612 | NCT05176483 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT06581406 | Map |
| IL | Northwestern University | Chicago60611 | NCT05327686 | Map |
| IL | Northwestern University | Chicago60611 | NCT05647265 | Map |
| IL | Northwestern University | Chicago60611 | NCT05896839 | Map |
| IL | Northwestern University | Chicago60611 | NCT05904080 | Map |
| IL | Rush MD Anderson Cancer Center | Chicago60612 | NCT03866382 | Map |
| IL | The University of Chicago Medicine | Chicago60637 | NCT05533697 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05327686 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05647265 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05904080 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT03866382 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT07166406 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT04665206 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT06581406 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT06743126 | Map |
| IL | University of Illinois | Chicago60612 | NCT05904080 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05327686 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04511013 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05647265 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05904080 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05112601 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05327686 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04511013 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT03866382 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT07383441 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05327686 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT04511013 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT07383441 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05647265 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05904080 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT04511013 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05327686 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04511013 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05647265 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05904080 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05112601 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05327686 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04511013 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT03866382 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT04511013 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT07383441 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05904080 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT04511013 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT07383441 | Map |
| IL | Western Illinois Cancer Treatment Center | Galesburg61401 | NCT04511013 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05647265 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05904080 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05904080 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05327686 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05647265 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05904080 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05327686 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05647265 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05904080 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05327686 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05904080 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05904080 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT04511013 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT07383441 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05327686 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05647265 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05904080 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT04511013 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT07383441 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05327686 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05647265 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05904080 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05112601 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT03866382 | Map |
| IL | Good Samaritan Regional Health Center | Mount Vernon62864 | NCT04511013 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05327686 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05904080 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT07166406 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT05112601 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05112601 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05327686 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04511013 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT05327686 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT05327686 | Map |
| IL | Rush MD Anderson Cancer Center at Rush Oak Park | Oak Park60304 | NCT03866382 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05327686 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05647265 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05904080 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05327686 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05904080 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT07166406 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT04511013 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT07383441 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT04511013 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT07383441 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT04511013 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT07383441 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT04511013 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT04511013 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT07383441 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT04511013 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT04511013 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT07383441 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05327686 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05896839 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT03866382 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT07166406 | Map |
| IL | Memorial Medical Center | Springfield62781 | NCT04511013 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05327686 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04511013 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT03866382 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT07383441 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05327686 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04511013 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT03866382 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05327686 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT03866382 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05327686 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04511013 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05647265 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05904080 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05112601 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT05327686 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT04511013 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05327686 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05647265 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05904080 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT04511013 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT07383441 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT04511013 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05647265 | Map |
| IN | IU Health North Hospital | Carmel46032 | NCT05112601 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05327686 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT07166406 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT05112601 | Map |
| IN | Community Health Network (The University of Texas MD Anderson Cancer Center) | Indianapolis46250 | NCT02693535 | Map |
| IN | Exelixis Clinical Site #4 | Indianapolis46250 | NCT05176483 | Map |
| IN | Franciscan Health Indianapolis | Indianapolis46237 | NCT05327686 | Map |
| IN | Franciscan Health Mooresville | Mooresville46158 | NCT05327686 | Map |
| IN | Reid Health | Richmond47374 | NCT04511013 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05327686 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04511013 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT03866382 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05327686 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04511013 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05904080 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT07166406 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT03866382 | Map |
| IA | McFarland Clinic - Boone | Boone50036 | NCT04511013 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04511013 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT07383441 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT07383441 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT05904080 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05904080 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT07166406 | Map |
| IA | Methodist Jennie Edmundson Hospital | Council Bluffs51503 | NCT05904080 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT07166406 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04511013 | Map |
| IA | Iowa Lutheran Hospital | Des Moines50316 | NCT04511013 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05327686 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04511013 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05904080 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT03866382 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT07166406 | Map |
| IA | Medical Oncology and Hematology Associates-Des Moines | Des Moines50309 | NCT04511013 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05904080 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT03866382 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05904080 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05904080 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT07166406 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04511013 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT03866382 | Map |
| IA | Trinity Regional Medical Center | Fort Dodge50501 | NCT04511013 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06581406 | Map |
| IA | University of Iowa- Site Number : 8400014 | Iowa City52242-1009 | NCT05584670 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT03866382 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05112601 | Map |
| IA | McFarland Clinic - Jefferson | Jefferson50129 | NCT04511013 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04511013 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05327686 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05904080 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT03866382 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT07166406 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT07166406 | Map |
| IA | Methodist West Hospital | West Des Moines50266-7700 | NCT04511013 | Map |
| IA | The Iowa Clinic PC | West Des Moines50266 | NCT07166406 | Map |
| KS | University of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008 | Fairway66205-2528 | NCT05584670 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT03816345 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT04511013 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT04511013 | Map |
| KS | HaysMed | Hays67601 | NCT03816345 | Map |
| KS | HaysMed | Hays67601 | NCT03866382 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT03816345 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT03816345 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT03866382 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT03816345 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT03866382 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT03816345 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT03816345 | Map |
| KS | Freeman Physician Group of Pittsburg | Pittsburg66762 | NCT03866382 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT03816345 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT03866382 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT03816345 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT03866382 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT03816345 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT03866382 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05896839 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT03816345 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT03866382 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT07166406 | Map |
| KY | Exelixis Clinical Site #122 | Louisville40202 | NCT05176483 | Map |
| KY | Research Site | Louisville40202 | NCT05536141 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05112601 | Map |
| KY | University of Louisville-James Graham Brown Cancer Center | Louisville40202 | NCT03899155 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05112601 | Map |
| KY | Mercy Health - Paducah Medical Oncology and Hematology | Paducah42003 | NCT04511013 | Map |
| LA | Louisiana Hematology Oncology Associates LLC | Baton Rouge70809 | NCT05327686 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809 | NCT05327686 | Map |
| LA | Mary Bird Perkins Cancer Center - Metairie | Metairie70002 | NCT05327686 | Map |
| LA | Research Site | New Orleans70121 | NCT05536141 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT02693535 | Map |
| ME | Jackson Laboratory - Maine Cancer Genomics Initiative | Augusta04330 | NCT02693535 | Map |
| ME | Waldo County General Hospital | Belfast04915 | NCT02693535 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Biddeford | Biddeford04005 | NCT02693535 | Map |
| ME | Northern Light Cancer Care | Brewer04412 | NCT02693535 | Map |
| ME | Raish Peavey Haskell Children's Cancer and Treatment Center | Brewer04412 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -Brunswick | Brunswick04011 | NCT02693535 | Map |
| ME | New England Cancer Specialist | Kennebunk04043 | NCT02693535 | Map |
| ME | York Hopsital Oncology & Infusion Care in Kittery | Kittery03904 | NCT02693535 | Map |
| ME | Stephens Memorial Hospital | Norway04268 | NCT02693535 | Map |
| ME | Penobscot Bay Medical Center | Rockport04856 | NCT02693535 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Sandford | Sanford04073 | NCT02693535 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT02693535 | Map |
| ME | Maine Medical Partner's Women's Health | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05112601 | Map |
| ME | New England Cancer Specialist | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -South Portland | South Portland04106 | NCT02693535 | Map |
| ME | New England Cancer Specialist | Topsham04086 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in Wells | Wells04090 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in York | York Village03909 | NCT02693535 | Map |
| MD | Exelixis Clinical Site #14 | Baltimore21201 | NCT05176483 | Map |
| MD | Johns Hopkins Hospital | Baltimore21231 | NCT03521830 | Map |
| MD | Johns Hopkins Hospital | Baltimore21287 | NCT07293351 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05896839 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT03816345 | Map |
| MD | Research Site | Baltimore21287 | NCT05536141 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center | Baltimore21231 | NCT04248569 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center | Baltimore21231 | NCT06941857 | Map |
| MD | University of MD Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT06743126 | Map |
| MD | National Cancer Institute Developmental Therapeutics Clinic | Bethesda20892 | NCT03816345 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03866382 | Map |
| MD | FMH James M Stockman Cancer Institute | Frederick21702 | NCT03866382 | Map |
| MA | Beverly Hospital | Beverly01915 | NCT05327686 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06708949 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06743126 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT05327686 | Map |
| MA | Dana Farber | Boston02215 | NCT06624644 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05428007 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05533697 | Map |
| MA | Dana_Farber Cancer Institute (DFCI) | Boston02215 | NCT03899155 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05327686 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04665206 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT03816345 | Map |
| MA | Exelixis Clinical Site #7 | Boston02215 | NCT05176483 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05428007 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05533697 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04665206 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06581406 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06743126 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT05327686 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT05779423 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT03816345 | Map |
| MA | Research Site | Boston02215 | NCT05536141 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05904080 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT05327686 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT03866382 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT07383441 | Map |
| MA | Addison Gilbert Hospital | Gloucester01930 | NCT05327686 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT05327686 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT03866382 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT07383441 | Map |
| MI | Trinity Health Ann Arbor Hospital | Ann Arbor48106 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05327686 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT03866382 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06743126 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT04511013 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT06866262 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05327686 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT04511013 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05112601 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT07383441 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05327686 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT03866382 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT04511013 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT03866382 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT07166406 | — |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT07383441 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05327686 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT03866382 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05327686 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT07383441 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT03866382 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT03866382 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05327686 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT03866382 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT07166406 | Map |
| MI | Barbara Ann Karmanos Cancer Institute - Detroit- Site Number : 8400006 | Detroit48201 | NCT05584670 | Map |
| MI | Exelixis Clinical Site #13 | Detroit48202 | NCT05176483 | Map |
| MI | Exelixis Clinical Site #65 | Detroit48201 | NCT05176483 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT02693535 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT03866382 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05533697 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT03866382 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT07166406 | Map |
| MI | Research Site | Detroit48201 | NCT05536141 | Map |
| MI | Research Site | Detroit48202 | NCT05536141 | Map |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT03866382 | — |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05327686 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT03866382 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT02693535 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT03866382 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT03866382 | Map |
| MI | Cancer Research Consortium of West Michigan | Grand Rapids49503 | NCT02693535 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05112601 | Map |
| MI | Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids49503 | NCT04511013 | Map |
| MI | Spectrum Health at Butterworth Campus | Grand Rapids49503 | NCT04511013 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT04511013 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05112601 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT03866382 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT03866382 | Map |
| MI | Allegiance Health | Jackson49201 | NCT03866382 | Map |
| MI | Allegiance Health | Jackson49201 | NCT07166406 | Map |
| MI | Ascension Borgess Cancer Center | Kalamazoo49009 | NCT04511013 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT05112601 | Map |
| MI | Borgess Medical Center | Kalamazoo49048 | NCT04511013 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04511013 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05112601 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT04511013 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05112601 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT02693535 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05327686 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT03866382 | Map |
| MI | Trinity Health Livonia Hospital | Livonia48154 | NCT02693535 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05327686 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT03866382 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT07383441 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT03866382 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT04511013 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05112601 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05112601 | Map |
| MI | Lakeland Hospital Niles | Niles49120 | NCT04511013 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT04511013 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05112601 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT03866382 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT07166406 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT03866382 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT03866382 | Map |
| MI | Trinity Health Oakland Hospital | Pontiac48341 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT03866382 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05112601 | Map |
| MI | Spectrum Health Reed City Hospital | Reed City49677 | NCT04511013 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05327686 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT02693535 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT03866382 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05112601 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT05112601 | Map |
| MI | Lakeland Medical Center Saint Joseph | Saint Joseph49085 | NCT04511013 | Map |
| MI | Marie Yeager Cancer Center | Saint Joseph49085 | NCT04511013 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT03866382 | Map |
| MI | Michigan Cancer Research Consortium | Traverse City48341 | NCT02693535 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT04511013 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05112601 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05327686 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT02693535 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT03866382 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT03866382 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT03866382 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT07166406 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT03866382 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT07166406 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT04511013 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05112601 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05327686 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT03866382 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT07383441 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05327686 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05904080 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05327686 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT07166406 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT04511013 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT04511013 | Map |
| MN | Allina Health Cancer Institute - Mercy Hospital | Coon Rapids55433 | NCT07227012 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04511013 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05112601 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05327686 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT03866382 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05112601 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT07166406 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05327686 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT03866382 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05112601 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT07166406 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT05327686 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT07166406 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05327686 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05112601 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT07166406 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05327686 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT04511013 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT03866382 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05112601 | Map |
| MN | Unity Hospital | Fridley55432 | NCT04511013 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05327686 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT03866382 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05112601 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT07166406 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05327686 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT04511013 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT04511013 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT04511013 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05327686 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04511013 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05112601 | Map |
| MN | Allina Health Cancer Institute - Abbott Northwestern Hospital | Minneapolis55407 | NCT07227012 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT04511013 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05327686 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT04511013 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT03866382 | Map |
| MN | M Health Fairview University of Minnesota Medical Center | Minneapolis55455 | NCT04665206 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT05327686 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT05647265 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT04511013 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT04511013 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT04511013 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT04511013 | Map |
| MN | Exelixis Clinical Site #68 | Rochester55905 | NCT05176483 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05327686 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05647265 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03866382 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03017820 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06508463 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT07510334 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT06581406 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04511013 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05112601 | Map |
| MN | Allina Health Cancer Institute - United Hospital | Saint Paul55102 | NCT07227012 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05327686 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04511013 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT03866382 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05112601 | Map |
| MN | United Hospital | Saint Paul55102 | NCT04511013 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05112601 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05327686 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT03866382 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05112601 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT07166406 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05327686 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT04511013 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05112601 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT05327686 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT04511013 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT03866382 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05327686 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT03866382 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05112601 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT07166406 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT05327686 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT04511013 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT03866382 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT04511013 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT04511013 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT04511013 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT07383441 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT07383441 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT03866382 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT07383441 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT07383441 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT07383441 | Map |
| MO | Saint Louis Cancer and Breast Institute-Ballwin | Ballwin63011 | NCT04511013 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT04511013 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT04511013 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05327686 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04511013 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT03866382 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT07383441 | Map |
| MO | Southeast Cancer Center | Cape Girardeau63703 | NCT04511013 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05896839 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT03816345 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT03866382 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT07166406 | Map |
| MO | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia65212 | NCT05327686 | Map |
| MO | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia65212 | NCT05112601 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05896839 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT03816345 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT03866382 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT07166406 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04511013 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT03866382 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT07383441 | Map |
| MO | Capital Region Southwest Campus | Jefferson City65109 | NCT04511013 | Map |
| MO | Freeman Health System | Joplin64804 | NCT04511013 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT04511013 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT03816345 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT03866382 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT03816345 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT03816345 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT03866382 | Map |
| MO | University of Kansas Cancer Center at North Kansas City Hospital | North Kansas City64116 | NCT03816345 | Map |
| MO | Delbert Day Cancer Institute at PCRMC | Rolla65401 | NCT04511013 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT04511013 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT04511013 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04511013 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT03866382 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT07383441 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT04511013 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05327686 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT04511013 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05327686 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04511013 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT03866382 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05327686 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04511013 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05904080 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT03866382 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04511013 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT03866382 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT07383441 | Map |
| MO | Saint Louis Cancer and Breast Institute-South City | St Louis63109 | NCT04511013 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05896839 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT03816345 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT03866382 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT07166406 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05896839 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT03816345 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT03866382 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT07166406 | Map |
| MO | Washington University | St Louis63110 | NCT05533697 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05896839 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT03816345 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT03866382 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05112601 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06968988 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07166406 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07293351 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04511013 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT03866382 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT07383441 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT03866382 | Map |
| MO | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills63127 | NCT04511013 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT04511013 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT04511013 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05904080 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT03866382 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05112601 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT04511013 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05904080 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT03866382 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05112601 | Map |
| MT | Intermountain Health West End Clinic | Billings59106 | NCT05112601 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT05112601 | Map |
| MT | Bozeman Deaconess Hospital | Bozeman59715 | NCT04511013 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05904080 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT03866382 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05112601 | Map |
| MT | Benefis Healthcare- Sletten Cancer Institute | Great Falls59405 | NCT04511013 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05904080 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT03866382 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05112601 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT04511013 | Map |
| MT | Kalispell Regional Medical Center | Kalispell59901 | NCT04511013 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05904080 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT03866382 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05112601 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05904080 | Map |
| MT | Community Medical Center | Missoula59804 | NCT03866382 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05112601 | Map |
| MT | Community Medical Hospital | Missoula59804 | NCT04511013 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT04511013 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT05647265 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05327686 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT03866382 | Map |
| NE | Cancer Partners of Nebraska - Pine Lake | Lincoln68516 | NCT04511013 | Map |
| NE | Southeast Nebraska Cancer Center - 68th Street Place | Lincoln68516 | NCT04511013 | Map |
| NE | Exelixis Clinical Site #2 | Omaha68130 | NCT05176483 | Map |
| NE | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha68114 | NCT05904080 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05327686 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT03866382 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT05904080 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT05112601 | Map |
| NE | Research Site | Omaha68124 | NCT05536141 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT02693535 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05327686 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03866382 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06743126 | Map |
| NV | Carson Tahoe Regional Medical Center | Carson City89703 | NCT05647265 | Map |
| NV | Cancer and Blood Specialists-Henderson | Henderson89052 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Henderson | Henderson89052 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Horizon Ridge | Henderson89052 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Southeast Henderson | Henderson89074 | NCT05647265 | Map |
| NV | Las Vegas Urology - Green Valley | Henderson89074 | NCT05647265 | Map |
| NV | Las Vegas Urology - Pebble | Henderson89074 | NCT05647265 | Map |
| NV | Oncology Las Vegas - Henderson | Henderson89074 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Green Valley | Henderson89074 | NCT05647265 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas89169 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas89128 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas89144 | NCT05647265 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas89144 | NCT05647265 | Map |
| NV | Exelixis Clinical Site #55 | Las Vegas89052 | NCT05176483 | Map |
| NV | Hope Cancer Care of Nevada | Las Vegas89103 | NCT05647265 | Map |
| NV | Las Vegas Prostate Cancer Center | Las Vegas89113 | NCT05647265 | Map |
| NV | Las Vegas Urology - Cathedral Rock | Las Vegas89128 | NCT05647265 | Map |
| NV | Las Vegas Urology - Pecos | Las Vegas89074 | NCT05647265 | Map |
| NV | Las Vegas Urology - Smoke Ranch | Las Vegas89128 | NCT05647265 | Map |
| NV | Las Vegas Urology - Sunset | Las Vegas89113 | NCT05647265 | Map |
| NV | Oncology Las Vegas - Tenaya | Las Vegas89128 | NCT05647265 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05647265 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT03866382 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05647265 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT03866382 | Map |
| NV | OptumCare Cancer Care at MountainView | Las Vegas89128 | NCT05647265 | Map |
| NV | Radiation Oncology Centers of Nevada Central | Las Vegas89106 | NCT05647265 | Map |
| NV | Radiation Oncology Centers of Nevada Southeast | Las Vegas89119 | NCT05647265 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT05647265 | Map |
| NV | Sunrise Hospital and Medical Center | Las Vegas89109 | NCT05647265 | Map |
| NV | University Cancer Center | Las Vegas89169 | NCT05647265 | Map |
| NV | University Medical Center of Southern Nevada | Las Vegas89102 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Central | Las Vegas89106 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Northwest | Las Vegas89128 | NCT05647265 | Map |
| NV | Urology Specialists of Nevada - Southwest | Las Vegas89113 | NCT05647265 | Map |
| NV | Women's Cancer Center of Nevada | Las Vegas89106 | NCT05112601 | Map |
| NV | Hope Cancer Care of Nevada-Pahrump | Pahrump89048 | NCT05647265 | Map |
| NV | Radiation Oncology Associates | Reno89509 | NCT05647265 | Map |
| NV | Renown Health Medical Oncology | Reno89502 | NCT07227012 | Map |
| NV | Renown Office of Clinical Research | Reno89502 | NCT07227012 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT05647265 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT07227012 | Map |
| NV | Saint Mary's Regional Medical Center | Reno89503 | NCT05647265 | Map |
| NH | NH Oncology - Hematology, PA | Concord03103 | NCT02693535 | Map |
| NH | Dartmouth Hitchcock | Lebanon03756 | NCT06362369 | Map |
| NH | Solinsky Center for Cancer Care | Manchester03103 | NCT02693535 | Map |
| NH | New England Cancer Specialist | Portsmouth03801 | NCT02693535 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05327686 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05904080 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT03866382 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge07920 | NCT06594991 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge07920 | NCT07532902 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT05327686 | Map |
| NJ | Exelixis Clinical Site #88 | East Brunswick08816 | NCT05176483 | Map |
| NJ | Exelixis Clinical Site #105 | Hackensack07601 | NCT05176483 | Map |
| NJ | Hackensack Meridian Health (Data Collection Only) | Hackensack07601 | NCT06594991 | Map |
| NJ | John Theurer Cancer Center | Hackensack07601 | NCT05533697 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601-2191 | NCT07291076 | Map |
| NJ | John Theurer Cancer Center Site Number : 8400001 | Hackensack07601 | NCT05584670 | Map |
| NJ | John Theurer Cancer Center, Hackensack Meridian Health | Hackensack07410 | NCT05715229 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05327686 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05904080 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT03866382 | Map |
| NJ | Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown07748 | NCT06594991 | Map |
| NJ | Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown07748 | NCT07532902 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05327686 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05904080 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT03866382 | Map |
| NJ | Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale07645 | NCT07532902 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06594991 | Map |
| NJ | Atlantic Health System/Morristown Medical Center | Morristown07960 | NCT06743126 | Map |
| NJ | Cooper CyberKnife Center | Mount Laurel08054 | NCT05327686 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT03816345 | Map |
| NM | Lovelace Medical Center - Saint Joseph Square | Albuquerque87102 | NCT02693535 | Map |
| NM | Lovelace Medical Center-Saint Joseph Square | Albuquerque87102 | NCT05327686 | Map |
| NM | Lovelace Radiation Oncology | Albuquerque87109 | NCT05327686 | Map |
| NM | Presbyterian Kaseman Hospital | Albuquerque87110 | NCT02693535 | Map |
| NM | The University of New Mexico Comprehensive Cancer Center | Albuquerque87131 | NCT02693535 | Map |
| NM | University of New Mexico | Albuquerque87106 | NCT06624644 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05112601 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT07166406 | Map |
| NM | Memorial Medical Center | Las Cruces88011 | NCT02693535 | Map |
| NM | Presbyterian Rust Medical Center | Rio Rancho87124 | NCT02693535 | Map |
| NY | Northwell Health Imbert Cancer Center | Bay Shore11706 | NCT05327686 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT03899155 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05904080 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) | Commack11725 | NCT07532902 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06594991 | Map |
| NY | Memorial Sloan Kettering Westchester | East White Plains10604 | NCT05327686 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT05327686 | Map |
| NY | Northwell Health Cancer Institute at Huntington | Greenlawn11740 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05384496 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05904080 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT06594991 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT07532902 | Map |
| NY | Northwell Health Monter Cancer Center | Lake Success11042 | NCT02693535 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT05327686 | Map |
| NY | NYU Langone Hematology Oncology Associates-Mineola | Mineola11501 | NCT03899155 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05896839 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT03816345 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT03866382 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT02693535 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT05327686 | Map |
| NY | Cohen Children's Medical Center | New Hyde Park11040 | NCT02693535 | Map |
| NY | Exelixis Clinical Site #6 | New York10065 | NCT05176483 | Map |
| NY | Exelixis Clinical Site #60 | New York10032 | NCT05176483 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT05188118 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05327686 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05896839 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT03816345 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT06743126 | Map |
| NY | Lenox Hill Hospital | New York10075 | NCT05327686 | Map |
| NY | Manhattan Eye Ear and Throat Hospital | New York10065 | NCT05327686 | Map |
| NY | Manhattan Eye, Ear, and Throat Hospital | New York10065 | NCT02693535 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05384496 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04665206 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05904080 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06581406 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06743126 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics | New York10065 | NCT05533697 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06594991 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07532902 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT07166406 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT03816345 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT03866382 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT03816345 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT03866382 | Map |
| NY | NYU Langone Health | New York10016 | NCT05428007 | Map |
| NY | NYU Langone Health | New York10016 | NCT07504796 | Map |
| NY | NYU Langone Health-Perlmutter Cancer Center | New York10016 | NCT05533697 | Map |
| NY | NYU Langone Medical Center-New York- 550 1st Ave - BRANY - PPDS- Site Number : 8400013 | New York10016-6402 | NCT05584670 | Map |
| NY | Research Site | New York10029 | NCT05536141 | Map |
| NY | Research Site | New York10065 | NCT05536141 | Map |
| NY | Staten Island University Hospital | New York10305 | NCT02693535 | Map |
| NY | Queens Cancer Center | Rego Park11374 | NCT02693535 | Map |
| NY | University of Rochester | Rochester14642 | NCT05112601 | Map |
| NY | University of Rochester | Rochester14642 | NCT06743126 | Map |
| NY | Phelps Hospital | Sleepy Hollow10591 | NCT02693535 | Map |
| NY | Phelps Memorial Hospital Center | Sleepy Hollow10591 | NCT05327686 | Map |
| NY | Exelixis Clinical Site #76 | Syracuse13210 | NCT05176483 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05112601 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT07166406 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT07166406 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05327686 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05904080 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT03866382 | Map |
| NY | Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale11553 | NCT07532902 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06594991 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05112601 | Map |
| NC | Duke Cancer Center Cary | Cary27518 | NCT05327686 | Map |
| NC | Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT02693535 | Map |
| NC | UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06743126 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05327686 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05904080 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT03866382 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT05327686 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT05327686 | Map |
| NC | Atrium Health's Levine Cancer Institute | Charlotte28277 | NCT02693535 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05327686 | Map |
| NC | Levine Cancer Institute-Ballantyne | Charlotte28277 | NCT05327686 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT05904080 | Map |
| NC | Wake Forest University at Clemmons | Clemmons27012 | NCT05327686 | Map |
| NC | Wake Forest University at Clemmons | Clemmons27012 | NCT04511013 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04511013 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT05327686 | Map |
| NC | Duke Cancer Center Southpoint | Durham27713 | NCT05647265 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05327686 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05647265 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05112601 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06581406 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06708949 | Map |
| NC | Exelixis Clinical Site #12 | Durham27710 | NCT05176483 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT05327686 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04511013 | Map |
| NC | Margaret R Pardee Memorial Hospital | Hendersonville28791 | NCT03866382 | Map |
| NC | Hayworth Cancer Center | High Point27262 | NCT05327686 | Map |
| NC | Novant Health Cancer Institute - Huntersville | Huntersville28078 | NCT05904080 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04511013 | Map |
| NC | Novant Health Cancer Institute - Matthews | Matthews28105 | NCT05904080 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT05327686 | Map |
| NC | Novant Health Cancer Institute - Mooresville | Mooresville28117 | NCT05904080 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT05327686 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT05647265 | Map |
| NC | Duke Women's Cancer Care Raleigh | Raleigh27607 | NCT05112601 | Map |
| NC | Wake Forest Baptist Health - Hematology Oncology - Statesville | Statesville28677 | NCT04511013 | Map |
| NC | Wake Forest Baptist Health - Wilkes Medical Center | Wilkesboro28659 | NCT05327686 | Map |
| NC | Wake Forest Baptist Health - Wilkes Medical Center | Wilkesboro28659 | NCT04511013 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05327686 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT04511013 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05327686 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05904080 | Map |
| ND | Sanford Health- Bismarck | Bismarck58501 | NCT02693535 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05112601 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05327686 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05904080 | Map |
| ND | Sanford Health- Fargo | Fargo58122 | NCT02693535 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05327686 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05904080 | Map |
| OH | UH Seidman Cancer Center at UH Avon Health Center | Avon44011 | NCT05327686 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT05327686 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT04511013 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT05112601 | Map |
| OH | Indu and Raj Soin Medical Center | Beavercreek45431 | NCT04511013 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT04511013 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT03866382 | Map |
| OH | Saint Elizabeth Boardman Hospital | Boardman44512 | NCT04511013 | Map |
| OH | Dayton Physicians LLC-Miami Valley South | Centerville45459 | NCT04511013 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05327686 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05112601 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT04511013 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT05112601 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT04511013 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT03866382 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT05112601 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT03899155 | Map |
| OH | Oncology Hematology Care Inc-Kenwood | Cincinnati45236 | NCT04511013 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT05327686 | Map |
| OH | University of Cincinnati Medical Center | Cincinnati45219 | NCT02693535 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05327686 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT04511013 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05112601 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT05361720 | Map |
| OH | Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland44111 | NCT05112601 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT05112601 | Map |
| OH | Cleveland Clinic, Taussig Cancer Institute | Cleveland44195 | NCT06743126 | Map |
| OH | Exelixis Clinical Site #10 | Cleveland44106 | NCT05176483 | Map |
| OH | Research Site | Cleveland44106 | NCT05536141 | Map |
| OH | Research Site | Cleveland44195 | NCT05536141 | Map |
| OH | University Hospitals Seidman Cancer Center | Cleveland44106 | NCT05361720 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT04511013 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT03866382 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT04511013 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT03866382 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT04511013 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT03866382 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT04511013 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT03866382 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT04511013 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT03866382 | Map |
| OH | Ohio State University | Columbus43210 | NCT06743126 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05327686 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04697576 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04511013 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03816345 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT03866382 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05112601 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT07166406 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT04511013 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT03866382 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT04511013 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT03866382 | Map |
| OH | The Ohio State University | Columbus43210 | NCT06581406 | Map |
| OH | The Ohio University | Columbus43210 | NCT03899155 | Map |
| OH | Dayton Physician LLC-Miami Valley Hospital North | Dayton45415 | NCT04511013 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT05327686 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05327686 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT05327686 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT04511013 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT03866382 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT04511013 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT03866382 | Map |
| OH | Columbus Oncology and Hematology Associates | Dublin43016 | NCT04511013 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT04511013 | Map |
| OH | Armes Family Cancer Center | Findlay45840 | NCT04511013 | Map |
| OH | Blanchard Valley Hospital | Findlay45840 | NCT04511013 | Map |
| OH | Orion Cancer Care | Findlay45840 | NCT04511013 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05327686 | Map |
| OH | Dayton Physicians LLC-Atrium | Franklin45005 | NCT04511013 | Map |
| OH | Central Ohio Breast and Endocrine Surgery | Gahanna43230 | NCT04511013 | Map |
| OH | Dayton Physicians LLC-Wayne | Greenville45331 | NCT04511013 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05327686 | Map |
| OH | Wayne Hospital | Greenville45331 | NCT04511013 | Map |
| OH | Mount Carmel Grove City Hospital | Grove City43123 | NCT04511013 | Map |
| OH | Zangmeister Center Grove City | Grove City43123 | NCT04511013 | Map |
| OH | Greater Dayton Cancer Center | Kettering45409 | NCT04511013 | Map |
| OH | Kettering Health | Kettering45429 | NCT02693535 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT04511013 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT03866382 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT04511013 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT03866382 | Map |
| OH | Saint Rita's Medical Center | Lima45801 | NCT04511013 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT04511013 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT03866382 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT04511013 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT03866382 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT04511013 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT03866382 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT03866382 | Map |
| OH | Hillcrest Hospital Cancer Center | Mayfield Heights44124 | NCT05112601 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT05327686 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT05112601 | Map |
| OH | UH Seidman Cancer Center at Southwest General Hospital | Middleburg Heights44130 | NCT04511013 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT04511013 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT03866382 | Map |
| OH | Mount Carmel New Albany Surgical Hospital | New Albany43054 | NCT04511013 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT04511013 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT03866382 | Map |
| OH | Newark Radiation Oncology | Newark43055 | NCT04511013 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT05327686 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT04511013 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT05112601 | Map |
| OH | Mercy Health Perrysburg Cancer Center | Perrysburg43551 | NCT04511013 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT04511013 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT03866382 | Map |
| OH | University Hospitals Portage Medical Center | Ravenna44266 | NCT05327686 | Map |
| OH | University Hospitals Portage Medical Center | Ravenna44266 | NCT04511013 | Map |
| OH | UH Seidman Cancer Center at Firelands Regional Medical Center | Sandusky44870 | NCT04511013 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT04511013 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT03866382 | Map |
| OH | Springfield Regional Medical Center | Springfield45505 | NCT04511013 | Map |
| OH | Mercy Health - Saint Anne Hospital | Toledo43623 | NCT04511013 | Map |
| OH | Saint Vincent Mercy Medical Center | Toledo43608 | NCT04511013 | Map |
| OH | Dayton Physicians LLC - Troy | Troy45373 | NCT04511013 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05327686 | Map |
| OH | University Hospitals Sharon Health Center | Wadsworth44281 | NCT04511013 | Map |
| OH | Saint Joseph Warren Hospital | Warren44484 | NCT04511013 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT05327686 | Map |
| OH | West Chester Hospital | West Chester45069 | NCT02693535 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT04511013 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT03866382 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT04511013 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT05112601 | Map |
| OH | Saint Elizabeth Youngstown Hospital | Youngstown44501 | NCT04511013 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT04511013 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT03866382 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT05904080 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT03866382 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT04511013 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05327686 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04511013 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05904080 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT03866382 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05112601 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT05327686 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT05112601 | Map |
| OR | Saint Alphonsus Medical Center-Baker City | Baker City97814 | NCT04511013 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT04511013 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05647265 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT04511013 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT05647265 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT07166406 | Map |
| OR | Providence Cancer Institute Clackamas Clinic | Clackamas97015 | NCT04511013 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT04511013 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT05647265 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT05647265 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04511013 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05647265 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT03866382 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT07166406 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT03866382 | Map |
| OR | Saint Alphonsus Medical Center-Ontario | Ontario97914 | NCT04511013 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04511013 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05647265 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT03866382 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT07166406 | Map |
| OR | Exelixis Clinical Site #51 | Portland97239 | NCT05176483 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05904080 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT03866382 | Map |
| OR | Providence Cancer Institute Franz Clinic | Portland97213 | NCT06743126 | Map |
| OR | Providence Health & Services | Portland97213 | NCT02693535 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04511013 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05647265 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT03866382 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05112601 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT07166406 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT07291076 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04511013 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05647265 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT03866382 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05112601 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT07166406 | Map |
| OR | Providence St. Vincent Medical Center | Portland97225 | NCT07291076 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT04511013 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT05647265 | Map |
| PA | Lehigh Valley Hospital - Cedar Crest | Allentown18103 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05327686 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT03866382 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT05327686 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT05112601 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05327686 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT03866382 | Map |
| PA | Lehigh Valley Hospital- Muhlenberg | Bethlehem18017 | NCT02693535 | Map |
| PA | UPMC Hillman Cancer Center at Butler Health System | Butler16001 | NCT05112601 | Map |
| PA | Carlisle Regional Cancer Center | Carlisle17015 | NCT05327686 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center - Passavant - Cranberry | Cranberry Township16066 | NCT05112601 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05327686 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT07166406 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT02693535 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT03866382 | Map |
| PA | Saint Vincent Hospital | Erie16544 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT03866382 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05112601 | Map |
| PA | UPMC Cancer Center at UPMC Horizon | Farrell16121 | NCT05327686 | Map |
| PA | UPMC Cancer Center at UPMC Horizon | Farrell16121 | NCT05112601 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05327686 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT03866382 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05112601 | Map |
| PA | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg17109 | NCT05327686 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT05327686 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT03866382 | Map |
| PA | Exelixis Clinical Site #104 | Hershey17033 | NCT05176483 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT05327686 | Map |
| PA | IRMC Cancer Center | Indiana15701 | NCT05327686 | Map |
| PA | IRMC Cancer Center | Indiana15701 | NCT05112601 | Map |
| PA | Jefferson Hospital | Jefferson Hills15025 | NCT05327686 | Map |
| PA | UPMC-Johnstown/John P. Murtha Regional Cancer Center | Johnstown15901 | NCT05112601 | Map |
| PA | Lancaster General Health | Lancaster17601 | NCT03899155 | Map |
| PA | Lancaster General Hospital | Lancaster17601 | NCT03646617 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT05327686 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT07166406 | Map |
| PA | UPMC Cancer Center at UPMC McKeesport | McKeesport15132 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05112601 | Map |
| PA | Forbes Hospital | Monroeville15146 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT03866382 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center in Coraopolis | Moon Township15108 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center - Part of Frick Hospital | Mount Pleasant15666 | NCT05112601 | Map |
| PA | Arnold Palmer Cancer Center Medical Oncology Norwin | N. Huntingdon15642 | NCT03866382 | — |
| PA | Arnold Palmer Cancer Center Medical Oncology Norwin | N. Huntingdon15642 | NCT05112601 | — |
| PA | UPMC Cancer Center-Natrona Heights | Natrona Heights15065 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center - New Castle | New Castle16105 | NCT05327686 | Map |
| PA | UPMC Hillman Cancer Center - New Castle | New Castle16105 | NCT05112601 | Map |
| PA | Abramson Cancer Center | Philadelphia19104 | NCT03646617 | Map |
| PA | Abramson Cancer Center at University of Pennsylvania | Philadelphia19104 | NCT04464759 | Map |
| PA | Exelixis Clinical Site #98 | Philadelphia19104 | NCT05176483 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT02693535 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05498792 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06743126 | Map |
| PA | Penn Medicine Abramson Cancer Center | Philadelphia19104 | NCT06708949 | Map |
| PA | Thomas Jeffersion University, Sidney Kimmel Cancer Center | Philadelphia19107 | NCT06743126 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06581406 | Map |
| PA | University of Pennsylvania, Abramson Cancer Center | Philadelphia19104 | NCT06743126 | Map |
| PA | University of Pennsylvania, Abramson Cancer Center | Philadelphia19104 | NCT06747845 | Map |
| PA | UPenn | Philadelphia19107 | NCT06624644 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT05327686 | Map |
| PA | Exelixis Clinical Site #24 | Pittsburgh15232 | NCT05176483 | Map |
| PA | Exelixis Clinical Site #32 | Pittsburgh15212 | NCT05176483 | Map |
| PA | Research Site | Pittsburgh15232 | NCT05536141 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05327686 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT04511013 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05896839 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT03816345 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT03866382 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05112601 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT06581406 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT06743126 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT05327686 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT05112601 | Map |
| PA | UPMC-Mercy Hospital | Pittsburgh15219 | NCT05112601 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05327686 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT03866382 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05112601 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT05327686 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT03866382 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT05112601 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT05327686 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT05112601 | Map |
| PA | UPMC-Shadyside Hospital | Pittsburgh15232 | NCT05327686 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT05327686 | Map |
| PA | Geisinger Cancer Services-Pottsville | Pottsville17901 | NCT05327686 | Map |
| PA | Community Medical Center | Scranton18510 | NCT05327686 | Map |
| PA | UPMC Cancer Center at UPMC Northwest | Seneca16346 | NCT05327686 | Map |
| PA | UPMC Cancer Center at UPMC Northwest | Seneca16346 | NCT05112601 | Map |
| PA | UPMC Cancer Center-Washington | Washington15301 | NCT05112601 | Map |
| PA | UPMC West Mifflin-Cancer Center Jefferson | West Mifflin15122 | NCT05112601 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05327686 | Map |
| PA | Wexford Health and Wellness Pavilion | Wexford15090 | NCT05327686 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05327686 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT07166406 | Map |
| PA | Divine Providence Hospital | Williamsport17754 | NCT05327686 | Map |
| PA | UPMC Memorial | York17408 | NCT05327686 | Map |
| RI | Brown University Health Cancer Institute | Providence02906 | NCT06362369 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT04933903 | Map |
| RI | Rhode Island Hospital Site Number : 8400004 | Providence02903 | NCT05584670 | Map |
| RI | Women and Infants Hospital | Providence02905 | NCT05112601 | Map |
| SC | SC Cancer Specialists at St. Joseph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | St. Joseph's/Candler Smith | Bluffton29910 | NCT02693535 | Map |
| SC | Summit Cancer Care at St. Josph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05327686 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05904080 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT03866382 | Map |
| SC | MUSC Hollings Cancer Center | Charleston29425 | NCT07293351 | Map |
| SC | Self Regional Healthcare | Greenwood29646 | NCT05327686 | Map |
| SC | South Carolina Cancer Specialists | Hilton Head Island29926 | NCT02693535 | Map |
| SC | Carolina Urologic Research Center, LLC | Myrtle Beach29572 | NCT07293351 | Map |
| SC | Exelixis Clinical Site #9 | Myrtle Beach29572 | NCT05176483 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06743126 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05327686 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05904080 | Map |
| SD | Sanford Cancer Center Oncology Clinic and Pharmacy | Sioux Falls57104 | NCT02693535 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05327686 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05904080 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT07383441 | Map |
| TN | The West Clinic, PLLC dba West Cancer Center | Germantown38138 | NCT06581406 | Map |
| TN | University of Tennessee Medical Center | Knoxville37920 | NCT06581406 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT07383441 | Map |
| TN | Exelixis Clinical Site #3 | Nashville37203 | NCT05176483 | Map |
| TN | Research Site | Nashville37203 | NCT05536141 | Map |
| TN | Research Site | Nashville37240 | NCT05536141 | Map |
| TN | Sara Cannon Research Institute Tennessee | Nashville37203 | NCT05533697 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT06581406 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06743126 | Map |
| TN | Tennesse Oncology | Nashville37203 | NCT03899155 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT07291076 | Map |
| TN | Tennessee Oncology - Nashville / Sarah Cannon Research Institute | Nashville37203 | NCT02693535 | Map |
| TN | Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic) | Nashville37232 | NCT06581406 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06047379 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06708949 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT07291076 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05361720 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05501665 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05904080 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT03866382 | Map |
| TN | Vanderbilt-Ingram Cancer Center | Nashville37232 | NCT07188896 | Map |
| TX | Exelixis Clinical Site #46 | Austin78705 | NCT05176483 | Map |
| TX | Baylor University | Dallas75246 | NCT06743126 | Map |
| TX | Baylor, Scott and White Research Institute | Dallas75246 | NCT06047379 | Map |
| TX | Exelixis Clinical Site #111 | Dallas75246 | NCT05176483 | Map |
| TX | Exelixis Clinical Site #89 | Dallas75246 | NCT05176483 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05327686 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05112601 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06708949 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06743126 | Map |
| TX | University of Texas, Southwestern Medical Center | Dallas75390 | NCT05361720 | Map |
| TX | UT Southwestern Medical Center | Dallas75390 | NCT06581406 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05327686 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05647265 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT03816345 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT03866382 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05327686 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05647265 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT03816345 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT03866382 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05112601 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05327686 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05647265 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT03816345 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT03866382 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05112601 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03816345 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05048212 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT04665206 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06362369 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07401875 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT06708949 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT02693535 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06743126 | Map |
| TX | The University Of Texas Md Anderson Cancer Center | Houston77030 | NCT06581406 | Map |
| TX | University of Texas MD Anderson Cancer Center Site Number : 8400005 | Houston77030-4000 | NCT05584670 | Map |
| TX | Exelixis Clinical Site #73 | Irving75063 | NCT05176483 | Map |
| TX | NEXT Oncology | Irving75039 | NCT07563738 | Map |
| TX | Exelixis Clinical Site #50 | Plano75075 | NCT05176483 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05327686 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05647265 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT03816345 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT03866382 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05112601 | Map |
| TX | NEXT Oncology | San Antonio78229 | NCT04665206 | Map |
| TX | Research Site | San Antonio78229 | NCT05536141 | Map |
| TX | Scott and White Memorial Hospital | Temple76508 | NCT05327686 | Map |
| TX | Exelixis Clinical Site #70 | Tyler75601 | NCT05176483 | Map |
| UT | Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center | Cedar City84720 | NCT02693535 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06365619 | Map |
| UT | Huntsman Cancer Institute at the University of Utah | Salt Lake City84112 | NCT03646617 | Map |
| UT | Huntsman Cancer Institute, University of Utah | Salt Lake City84112 | NCT06743126 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT04511013 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05896839 | Map |
| UT | Intermountain Healthcare | Salt Lake City84107 | NCT02693535 | Map |
| UT | Dixie Regional Medical Center-River Road Campus | St. George84770 | NCT02693535 | Map |
| VT | Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners05602 | NCT05327686 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05327686 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05327686 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT05327686 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT07166406 | Map |
| VA | Virginia Cancer Specialists, PC | Arlington22201 | NCT04665206 | Map |
| VA | Exelixis Clinical Site #66 | Charlottesville22903 | NCT05176483 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05112601 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT05327686 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT07166406 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22042 | NCT02693535 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05327686 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT07166406 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT07563738 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT07166406 | Map |
| VA | Inova Loudoun Hospital | Leesburg20176 | NCT07166406 | Map |
| VA | Bon Secours Saint Francis Medical Center | Midlothian23114 | NCT05327686 | Map |
| VA | Bon Secours Cancer Institute at Reynolds Crossing | Richmond23230 | NCT05327686 | Map |
| VA | Henrico Doctor's Hospital | Richmond23229 | NCT05112601 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05904080 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05904080 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT03816345 | Map |
| VA | Virginia Commonwealth University | Richmond23219 | NCT06743126 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT04511013 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT05647265 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT04511013 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT05647265 | Map |
| WA | Northwest Medical Specialties | Bonney Lake98391 | NCT02693535 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT04511013 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT05647265 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04511013 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05647265 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05112601 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT04511013 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT05647265 | Map |
| WA | Northwest Medical Specialties | Federal Way98003 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Gig Harbor98332 | NCT02693535 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04511013 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05647265 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05112601 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT04511013 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT05647265 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT03866382 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT04511013 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05647265 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT04511013 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT05647265 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT05647265 | Map |
| WA | Northwest Medical Specialties | Olympia98502 | NCT02693535 | Map |
| WA | Jefferson Healthcare | Port Townsend98368 | NCT04511013 | Map |
| WA | Northwest Medical Specialties | Puyallup98373 | NCT02693535 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05647265 | Map |
| WA | Valley Medical Center | Renton98055 | NCT03866382 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06581406 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06743126 | Map |
| WA | Fred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010 | Seattle98109-4405 | NCT05584670 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT02693535 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT04511013 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT05647265 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT04511013 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT05647265 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04511013 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05647265 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05112601 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT05327686 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT04511013 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT05647265 | Map |
| WA | Providence Regional Cancer System-Shelton | Shelton98584 | NCT04511013 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT05647265 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT05647265 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT05647265 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT06047379 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT04511013 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT05647265 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT04511013 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT05647265 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT05647265 | Map |
| WA | Providence Regional Cancer System-Yelm | Yelm98597 | NCT04511013 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT05327686 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT05904080 | Map |
| WV | Camden Clark Medical Center | Parkersburg26101 | NCT05904080 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT05327686 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT04511013 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05327686 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT03866382 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05112601 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT07166406 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05327686 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05112601 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT07166406 | Map |
| WI | Aurora Cancer Care - Burlington | Burlington53105 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT03866382 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05327686 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04511013 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05904080 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT03866382 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT07166406 | Map |
| WI | Mayo Clinic Health System-Eau Claire Clinic | Eau Claire54701 | NCT03866382 | Map |
| WI | Aurora Health Care - Germantown Health Center | Germantown53022 | NCT02693535 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT03866382 | Map |
| WI | Aurora Cancer Care - Grafton | Grafton53024 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT03866382 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT02693535 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT03866382 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05327686 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05327686 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT05327686 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT07166406 | Map |
| WI | Aurora Cancer Care - Kenosha South | Kenosha53142 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT03866382 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04511013 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792 | NCT04511013 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05327686 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05327686 | Map |
| WI | University Of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06581406 | Map |
| WI | Aurora Bay Area Medical Center | Marinette54143 | NCT02693535 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT03866382 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05327686 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04511013 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05904080 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT03866382 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT07166406 | Map |
| WI | Aspirus Medford Hospital | Medford54451 | NCT04511013 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT05327686 | Map |
| WI | Aurora Cancer Care Milwaukee | Milwaukee53209 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT03866382 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT03866382 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53223 | NCT02693535 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT03866382 | Map |
| WI | Aurora St. Luke's Medical Center | Milwaukee53215 | NCT02693535 | Map |
| WI | Aurora West Allis Medical Center | Milwaukee53227 | NCT02693535 | Map |
| WI | Exelixis Clinical Site #33 | Milwaukee53226 | NCT05176483 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05327686 | Map |
| WI | Marshfield Clinic-Minocqua Center | Minocqua54548 | NCT04511013 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05327686 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05904080 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT03866382 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05327686 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT03866382 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT07166406 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05327686 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT04511013 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT05327686 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05327686 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT03866382 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT07166406 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT03866382 | Map |
| WI | Aurora Cancer Care - Racine | Racine53406 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT03866382 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT05327686 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05327686 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT04511013 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05904080 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT03866382 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT07166406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05327686 | Map |
| WI | Vince Lombardi Cancer Center | Sheboygan53081 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT03866382 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT05327686 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT07166406 | Map |
| WI | Ascension Saint Michael's Hospital | Stevens Point54481 | NCT04511013 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT05327686 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05327686 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04511013 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05904080 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT03866382 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT07166406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05327686 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT02693535 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT03866382 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT05327686 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT07166406 | Map |
| WI | Vince Lombardi Cancer Clinic - Two Rivers | Two Rivers54241 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT03866382 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT03866382 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05327686 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT03866382 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT07166406 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT05327686 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT04511013 | Map |
| WI | Aurora Cancer Care - Milwaukee West | Wauwatosa53226 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT03866382 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT03866382 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT05327686 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05327686 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04511013 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05904080 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT03866382 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT07166406 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT05327686 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT04511013 | Map |
| WY | Cheyenne Regional Medical Center-West | Cheyenne82001 | NCT04511013 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT04511013 | Map |
| WY | Welch Cancer Center | Sheridan82801 | NCT04511013 | Map |
Ipilimumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | no longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 2 | 2 | 4 | 2 | 1 | 11 | ||||
| P1 | 19 | 26 | 90 | 40 | 10 | 1 | 4 | 8 | 198 | |
| P1/P2 | 20 | 17 | 49 | 23 | 8 | 1 | 4 | 122 | ||
| P2 | 52 | 65 | 137 | 47 | 14 | 1 | 5 | 23 | 344 | |
| P2/P3 | 2 | 3 | 3 | 2 | 1 | 11 | ||||
| P3 | 6 | 16 | 35 | 2 | 1 | 1 | 3 | 64 | ||
| P4 | 2 | 1 | 3 | 1 | 7 | |||||
| N/A | 5 | 4 | 19 | 1 | 2 | 3 | 34 |
Recruiting Ipilimumab clinical trials (120)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05732389 | RESET-RImmunotherapy in Patients With Early dMMR Rectal Cancer | P2 | Cancer of Rectum | 39 | Feb 2023 |
| NCT02498756 | Cytokine-induced Killer Study for Patients With Stage II Melanoma | P2 | Melanoma | 300 | Aug 2015 |
| NCT06999980 | Neo IRENIENeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | P2 | Cutaneous Melanoma | 494 | Feb 2026 |
| NCT06492421 | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | P2 | Lung Cancer | 90 | Jul 2024 |
| NCT06482801 | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | P2 | Liver Cancer | 90 | Jun 2024 |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | P1/P2 | Lung Cancer | 100 | Nov 2021 |
| NCT07403877 | TORCH-OPTIMANeoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer | P2 | Colorectal Cancer (MSI-H) | 114 | Feb 2026 |
| NCT06240143 | MARIANEIntradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | P1/P2 | Melanoma | 96 | Mar 2024 |
| NCT04248569 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | P1 | Fibrolamellar Hepatocellular Carcinoma (FLC) | 56 | Apr 2020 |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | P3 | Advanced Clear Cell Renal Cell Carcinoma | 718 | Jun 2026 |
| NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | P1 | Soft Tissue Sarcomas | 18 | Aug 2026 |
| NCT07230613 | NEOREM-NEO-1Neo-adjuvant Immunotherapy in Patients With Localized Melanoma | P2 | Cutaneous Melanoma, Stage III | 50 | Jan 2026 |
| NCT06492408 | Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. | P2 | Hepatic Cancer | 90 | Jul 2024 |
| NCT06483347 | Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT | P2 | Lung Cancer | 90 | Apr 2024 |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | P2 | Advanced Clear Cell Renal Cell Carcinoma | 18 | Apr 2026 |
| NCT03815890 | BELLINIPre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | P2 | Breast Cancer | 80 | Oct 2019 |
| NCT07338981 | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | P3 | Advanced Kidney Cancer | 142 | Apr 2026 |
| NCT06683755 | TRINITYPhase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | P1/P2 | Melanoma | 30 | May 2025 |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | P2 | Basal Cell Carcinoma | 57 | Nov 2018 |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | P2 | Endometrial Adenocarcinoma | 81 | Jun 2022 |
| NCT07355205 | FLINNFirst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | P2 | Non-small Cell Lung Cancer Stage IV | 26 | Jun 2026 |
| NCT06364631 | CARE1CARE1 Pragmatic Clinical Trial | P3 | Metastatic Kidney Cancer | 1,250 | Apr 2024 |
| NCT06794775 | SWE-NEOSWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma | P3 | Malignant Melanoma Stage III | 128 | Jul 2025 |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | P1 | Peripheral T Cell Lymphoma | 21 | Jan 2024 |
| NCT03017820 | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | P1 | B-Cell Non-Hodgkin Lymphoma | 99 | Apr 2017 |
| NCT03026140 | NICHENeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | P2 | Colon Carcinoma | 353 | Mar 2017 |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | P1/P2 | Advanced Solid Tumors | 361 | Sep 2022 |
| NCT07293351 | RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | P1/P2 | Advanced Renal Cell Carcinoma (RCC) | 254 | Mar 2026 |
| NCT06743126 | SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | P3 | Melanoma, Cutaneous Malignant | 360 | Jan 2025 |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | P2/P3 | Metastatic Uveal Melanoma | 280 | Dec 2024 |
| NCT07291076 | HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | P1/P2 | Hepatocellular Carcinoma (HCC) | 198 | Mar 2026 |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | P1/P2 | Locally Advanced Clear Cell Renal Cell Carcinoma | 55 | Aug 2025 |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | P1 | Metastatic Soft-tissue Sarcoma | 18 | Jan 2026 |
| NCT03138161 | SAINTSAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | P1/P2 | Advanced Soft Tissue Sarcoma | 250 | Apr 2017 |
| NCT07061379 | PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen | — | PROMs | 144 | Jul 2025 |
| NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | P4 | Metastatic Melanoma | 90 | Apr 2026 |
| NCT07587827 | ODI-2001-01Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | P1 | Metastatic Colorectal Cancer (CRC) | 77 | Nov 2026 |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | P2/P3 | Melanoma (Skin Cancer) | 135 | Aug 2025 |
| NCT07188896 | RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | Advanced Renal Cell Carcinoma (aRCC) | 120 | Apr 2026 |
| NCT06926790 | GALAXY 3Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) | P2 | Lung Cancer - Non Small Cell | 69 | Feb 2025 |
| NCT07430202 | FLCA DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | P1 | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | 27 | Aug 2026 |
| NCT06365619 | NeoRelapseNeoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | P2 | Melanoma | 25 | Jun 2026 |
| NCT05176483 | STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | P1 | Renal Cell Carcinoma (RCC) | 1,314 | Dec 2021 |
| NCT06889493 | NECSVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | P1 | Neuroendocrine Carcinoma | 36 | May 2025 |
| NCT06342037 | TONIC-3NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial | P2 | Metastatic Breast Cancer | 60 | Jun 2024 |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | P1/P2 | Solid Tumor, Adult | 434 | Mar 2021 |
| NCT06712927 | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | P2 | Melanoma | 60 | Aug 2025 |
| NCT07401875 | SHARKA Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) | P1 | Phase 1b | 35 | Mar 2026 |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | P2 | Melanoma Stage III | 29 | Sep 2020 |
| NCT07563738 | TEADCOA 2-part Phase 1/2 Open-label Trial on ODM-212 | P1/P2 | Mesothelioma | 229 | Mar 2026 |
| NCT03340129 | ABC-XAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | P2 | Melanoma Stage Iv | 218 | Aug 2019 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | Cancer | 1,500 | Aug 2019 |
| NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | P1 | Diffuse Pleural Mesothelioma | 60 | Apr 2026 |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | P1 | Uveal Melanoma | 15 | May 2026 |
| NCT07422753 | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC | P2 | Hepatocellular Carcinoma (HCC) | 36 | Mar 2026 |
| NCT05536141 | ARC-20A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | P1 | Clear Cell Renal Cell Carcinoma | 362 | Oct 2022 |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | P3 | Advanced Hepatocellular Carcinoma | 226 | Feb 2026 |
| NCT07233668 | IVE in mRCCImmediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC | N/A | Metastatic Renal Cell Carcinoma ( mRCC) | 172 | Dec 2025 |
| NCT06747845 | ParpVax2Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy | P2 | Pancreatic Adenocarcinoma Metastatic | 68 | May 2025 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | P2 | Pancreatic Cancer | 20 | Sep 2025 |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | P1/P2 | Advanced Cancer | 126 | Aug 2024 |
| NCT06031233 | MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | Oncology | 776 | Sep 2023 |
| NCT02693535 | TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | Lymphoma, Non-Hodgkin | 4,200 | Mar 2016 |
| NCT06708949 | RCCA Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | Renal Cell Carcinoma, Clear Cell | 15 | Mar 2025 |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | P2 | Melanoma Stage III | 90 | May 2024 |
| NCT07227012 | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. | P1/P2 | Carcinoma, Hepatocellular | 138 | Dec 2025 |
| NCT07147101 | HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | Advanced Hepatocellular Carcinoma (HCC) | 150 | Sep 2025 |
| NCT06490536 | The Sagittarius Trial | P3 | Colon Cancer Stage II | 700 | Oct 2024 |
| NCT07128680 | EXL01Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | P1 | Advanced Clear Cell Renal Cell Carcinoma | 33 | Mar 2026 |
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | P2 | BRAF V600E | 49 | Mar 2026 |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | P1/P2 | Unresectable Hepatocellular Carcinoma | 33 | Feb 2026 |
| NCT06514651 | MAQ-001 in Patients With Advanced Solid Tumors | P1 | Advanced Solid Tumor | 30 | Jun 2024 |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | P1/P2 | Solid Tumor | 542 | Nov 2022 |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | P2 | Metastatic Nasopharyngeal Carcinoma | 50 | Feb 2024 |
| NCT05327686 | SAMURAITesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | P2 | Metastatic Renal Cell Carcinoma | 240 | Feb 2023 |
| NCT03563729 | MEMBRAINSMelanoma Metastasized to the Brain and Steroids | P2 | Malignant Melanoma | 80 | Jun 2018 |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | P2 | HCC - Hepatocellular Carcinoma | 43 | Mar 2026 |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | P2 | Uterine Cervical Neoplasms | 112 | Aug 2022 |
| NCT07422779 | MAKImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | N/A | Metastatic Melanoma | 100 | Mar 2022 |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | P1 | Autoimmune Disease | 300 | Jul 2019 |
| NCT07487662 | ACTION-001TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk | P2 | Hepato Cellular Carcinoma (HCC) | 105 | Mar 2026 |
| NCT07394062 | ALCG-01Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) | — | Nonsmall Cell Lung Cancer, Stage IV | 400 | Feb 2026 |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | P2 | Melanoma | 105 | Feb 2023 |
| NCT07134842 | WinGlio-ipiA Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. | P1 | Glioblastoma | 16 | Jul 2025 |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | P2 | Metastatic Melanoma | 37 | Sep 2023 |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | P1 | Hepatocellular Carcinoma (HCC) | 15 | Apr 2026 |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | P2 | Advanced Acral Melanoma | 99 | Oct 2025 |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | P2 | Brain Metastases | 20 | Sep 2022 |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | P1 | Clinical Stage I Cutaneous Melanoma AJCC v8 | 36 | Oct 2021 |
| NCT03646617 | RadVaxIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | P2 | Metastatic Melanoma | 54 | Nov 2018 |
| NCT02925234 | DRUPThe Drug Rediscovery Protocol (DRUP Trial) | P2 | Cancer | 1,550 | Aug 2016 |
| NCT03690986 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | P1 | Squamous Cell Carcinoma of the Head and Neck | 50 | Nov 2018 |
| NCT03406247 | ADJORL1Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | P2 | Head and Neck Squamous Cell Carcinoma | 140 | Feb 2018 |
| NCT06364917 | DISCERNDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | P2 | Non Small Cell Lung Cancer | 24 | May 2025 |
| NCT06594991 | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | P2 | Advanced Melanoma | 88 | Sep 2024 |
| NCT05310643 | NIPIRESCUENivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | P2 | Metastatic Colorectal Cancer | 30 | May 2022 |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Early P1 | Locally Advanced or Metastatic Melanoma | 12 | Nov 2022 |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 35 | Aug 2020 |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | P1/P2 | Diffuse Astrocytoma, IDH-Mutant | 134 | Nov 2023 |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | P2 | Advanced Clear Cell Renal Cell Carcinoma | 54 | Dec 2022 |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | P2 | Acral Lentiginous Melanoma | 112 | Jan 2021 |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | P2 | Mucosal Melanoma | 20 | May 2022 |
| NCT05715229 | G360-IITImmune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | P2 | Carcinoma, Non-Small-Cell Lung | 108 | Sep 2023 |
| NCT05597800 | LUNGVIRNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | P2 | NSCLC Stage IV | 105 | Feb 2023 |
| NCT04996823 | Axitinib + Ipilimumab in Advanced Melanoma | P2 | Melanoma | 25 | Aug 2021 |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | P2 | Bladder Adenocarcinoma | 314 | May 2019 |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | P1/P2 | Lung Non-Small Cell Carcinoma | 25 | May 2023 |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | P1/P2 | Clinical Stage III Cutaneous Melanoma AJCC v8 | 16 | Jul 2024 |
| NCT03297606 | CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | P2 | Lymphoma, Non-Hodgkin | 720 | Mar 2018 |
| NCT04464759 | LIMITA Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | P1/P2 | Melanoma | 94 | Oct 2020 |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | P1 | Anatomic Stage I Breast Cancer AJCC v8 | 18 | Dec 2025 |
| NCT06353646 | XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer | N/A | Pancreatic Cancer | 28 | Mar 2024 |
| NCT05188118 | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Early P1 | Renal Cell Carcinoma | 20 | Feb 2023 |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | P2 | Pleural Biphasic Mesothelioma | 26 | Nov 2024 |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | P1 | Advanced Clear Cell Renal Cell Carcinoma | 28 | Jun 2024 |
| NCT04933903 | LOWBrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | P2 | Non Small Cell Lung Cancer | 25 | Oct 2021 |
| NCT03844256 | CRIMIA Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study | P1/P2 | Urinary Bladder Cancer | 50 | Jan 2019 |
| NCT06163820 | BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | P1/P2 | Melanoma Brain Metastases | 46 | May 2025 |
| NCT03707808 | myDAvIpNiIntratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab | P1/P2 | Solid Tumor | 18 | Jan 2018 |
| NCT04823403 | HIPANIVHepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | P1 | Hepatocellular Carcinoma | 27 | Nov 2020 |
Ipilimumab clinical trials by indication
Melanoma (94)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02498756 | — | P2 | not yet recruiting | Cytokine-induced Killer Study for Patients With Stage II Melanoma |
| NCT04196452 | DMTR | N/A | active not recruiting | A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) |
| NCT06240143 | MARIANE | P1/P2 | recruiting | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma |
| NCT06683755 | TRINITY | P1/P2 | not yet recruiting | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) |
| NCT06365619 | NeoRelapse | P2 | recruiting | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma |
| NCT03999749 | — | P2 | active not recruiting | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma |
| NCT06712927 | — | P2 | recruiting | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases |
| NCT02374242 | ABC | P2 | active not recruiting | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases |
| + 86 more, see All trials below. | ||||
Metastatic Melanoma (39)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07504796 | — | P4 | recruiting | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab |
| NCT07422779 | MAK | N/A | recruiting | Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia |
| NCT05779423 | — | P2 | recruiting | Cryoablation+Ipilimumab+Nivolumab in Melanoma |
| NCT03646617 | RadVax | P2 | recruiting | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma |
| NCT03122522 | — | P2 | active not recruiting | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy |
| NCT03645928 | — | P2 | terminated | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors |
| NCT01701674 | — | N/A | completed | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts |
| NCT05704933 | — | Early P1 | completed | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases |
| + 31 more, see All trials below. | ||||
Renal Cell Carcinoma (16)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05148546 | NESCIO | P2 | active not recruiting | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer |
| NCT03873402 | — | P3 | active not recruiting | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer |
| NCT03937219 | COSMIC-313 | P3 | active not recruiting | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma |
| NCT05188118 | — | Early P1 | recruiting | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma |
| NCT05501054 | — | P1/P2 | active not recruiting | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. |
| NCT03141177 | CheckMate 9ER | P3 | active not recruiting | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma |
| NCT04074967 | — | P1/P2 | active not recruiting | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab |
| NCT03297593 | — | P2 | completed | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma |
| + 8 more, see All trials below. | ||||
Prostate Cancer (15)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03061539 | — | P2 | active not recruiting | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature |
| NCT01688492 | — | P1/P2 | active not recruiting | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer |
| NCT02985957 | CheckMate 650 | P2 | completed | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) |
| NCT02601014 | STARVE-PC | P2 | completed | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 |
| NCT01804465 | CTLA-4 | P2 | completed | Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer |
| NCT02113657 | — | Early P1 | completed | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer |
| NCT02423928 | CryoIT | P1 | completed | Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer |
| NCT01530984 | — | P2 | withdrawn | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer |
| + 7 more, see All trials below. | ||||
Malignant Melanoma (14)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03563729 | MEMBRAINS | P2 | recruiting | Melanoma Metastasized to the Brain and Steroids |
| NCT02068196 | Ipi4 | P4 | active not recruiting | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. |
| NCT04223648 | MEDI4736 | Early P1 | withdrawn | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma |
| NCT04382664 | — | P2 | completed | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma |
| NCT02523313 | — | P2 | completed | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED |
| NCT02275416 | — | P1/P2 | completed | Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma |
| NCT01024231 | MDX-1106 | P1 | completed | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma |
| NCT02272855 | — | P2 | completed | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma |
| + 6 more, see All trials below. | ||||
Advanced Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06362369 | — | P1/P2 | recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy |
| NCT03459222 | — | P1/P2 | completed | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread |
| NCT03369223 | — | P1/P2 | completed | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors |
| NCT03110107 | — | P1/P2 | terminated | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors |
| NCT04270864 | PRIMO | P1 | terminated | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers |
| NCT03444753 | — | P1 | terminated | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed |
| NCT02996110 | FRACTION-RCC | P2 | completed | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma |
| NCT02658890 | — | P1/P2 | completed | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread |
| + 4 more, see All trials below. | ||||
Non-Small Cell Lung Cancer (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06946797 | CheckMate-1533 | P2 | active not recruiting | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| NCT02259621 | NA_00092076 | P2 | active not recruiting | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC |
| NCT07526961 | — | N/A | completed | Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland |
| NCT02477826 | CheckMate 227 | P3 | completed | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| NCT03215706 | CheckMate 9LA | P3 | completed | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC |
| NCT03001882 | CheckMate 592 | P2 | completed | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| NCT03953235 | — | P1/P2 | completed | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens |
| NCT05005273 | — | P2 | completed | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer |
| + 3 more, see All trials below. | ||||
Pancreatic Cancer (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06941857 | — | P2 | recruiting | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer |
| NCT06353646 | — | N/A | recruiting | XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer |
| NCT05721846 | CheckVAC | P1 | active not recruiting | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer |
| NCT04361162 | — | P2 | active not recruiting | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer |
| NCT05014776 | — | P2 | completed | Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer |
| NCT05116917 | INFLUENCE | P2 | terminated | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. |
| NCT03190265 | — | P2 | completed | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer |
| NCT04258150 | TRIPPLE-R | P2 | terminated | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer |
| + 3 more, see All trials below. | ||||
Non Small Cell Lung Cancer (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05012254 | NIVIPI-Brain | P2 | active not recruiting | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases |
| NCT06364917 | DISCERN | P2 | recruiting | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC |
| NCT04933903 | LOW | P2 | recruiting | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab |
| NCT03377023 | — | P1/P2 | active not recruiting | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer |
| NCT03520686 | — | P3 | terminated | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer |
| NCT04966676 | ATLAS | P2 | terminated | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer |
| NCT02998528 | CheckMate 816 | P3 | completed | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) |
| NCT04571632 | Luscid | P2 | unknown | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors |
| + 3 more, see All trials below. | ||||
Cancer (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03899155 | — | P2 | recruiting | Pan Tumor Rollover Study |
| NCT02925234 | DRUP | P2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
| NCT04300244 | NIPU | P2 | active not recruiting | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma |
| NCT03400332 | — | P1/P2 | completed | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers |
| NCT04319224 | JTX-2011 | P1/P2 | terminated | Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors |
| NCT03989362 | EMERGE | P2 | completed | Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer |
| NCT03251924 | — | P1/P2 | terminated | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors |
| NCT02467361 | — | P1 | completed | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers |
| + 3 more, see All trials below. | ||||
Advanced Melanoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04462406 | — | P2 | active not recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial |
| NCT06594991 | — | P2 | recruiting | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma |
| NCT01134614 | — | P2 | active not recruiting | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| NCT04495257 | RCC | P1 | completed | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) |
| NCT07079644 | — | N/A | completed | Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database |
| NCT04894994 | — | P2 | terminated | FLX475 in Combination With Ipilimumab in Advanced Melanoma |
| NCT01621490 | PD-1 | P1 | completed | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma |
| NCT02224768 | — | N/A | completed | YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey |
| + 2 more, see All trials below. | ||||
Solid Tumor (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05584670 | — | P1/P2 | recruiting | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors |
| NCT03707808 | myDAvIpNi | P1/P2 | recruiting | Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab |
| NCT05284214 | SALIENT | P2 | withdrawn | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors |
| NCT03647163 | — | P1/P2 | active not recruiting | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors |
| NCT03195478 | — | P1/P2 | completed | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors |
| NCT03865082 | ILLUMINATE-206 | P2 | active not recruiting | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) |
| NCT03013491 | PROCLAIM-CX-072 | P1/P2 | terminated | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas |
| NCT03993379 | PROCLAIM | P2 | terminated | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors |
| + 1 more, see All trials below. | ||||
Breast Cancer (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03815890 | BELLINI | P2 | recruiting | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO |
| NCT03546686 | — | P2 | active not recruiting | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer |
| NCT03789110 | NIMBUS | P2 | active not recruiting | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer |
| NCT04591431 | ROME | P2 | unknown | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy |
| NCT02833233 | — | N/A | completed | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer |
| NCT03818685 | BreastImmune03 | P2 | unknown | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease |
| NCT04132817 | — | P1 | completed | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread |
| NCT03409198 | ICON | P2 | completed | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer |
| + 1 more, see All trials below. | ||||
Mesothelioma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07563738 | TEADCO | P1/P2 | recruiting | A 2-part Phase 1/2 Open-label Trial on ODM-212 |
| NCT03907852 | TC-210 | P1/P2 | active not recruiting | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer |
| NCT03918252 | — | P2 | active not recruiting | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma |
| NCT04334759 | DREAM3R | P3 | completed | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma |
| NCT02899299 | CheckMate743 | P3 | completed | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients |
| NCT05041062 | — | P2 | completed | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma |
| NCT04840615 | — | P1 | terminated | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma |
| NCT02716272 | MAPS2 | P2 | completed | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients |
Glioblastoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07134842 | WinGlio-ipi | P1 | recruiting | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. |
| NCT04606316 | — | P1 | active not recruiting | Surgical Nivolumab And Ipilimumab For Recurrent GBM |
| NCT03233152 | GlitIpNi | P1/P2 | active not recruiting | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. |
| NCT04817254 | ICI | P2 | completed | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma |
| NCT05074992 | NeAT Glio | P2 | terminated | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma |
| NCT03422094 | — | P1 | terminated | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma |
| NCT03707457 | — | P1 | terminated | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma |
| NCT03460782 | — | N/A | no longer available | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas |
Lung Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06492421 | — | P2 | recruiting | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. |
| NCT05187338 | — | P1/P2 | recruiting | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors |
| NCT06483347 | — | P2 | recruiting | Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT |
| NCT03575793 | — | P1/P2 | completed | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer |
| NCT02869789 | — | P4 | completed | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers |
| NCT02538666 | CheckMate 451 | P3 | completed | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy |
| NCT03256136 | — | P2 | completed | Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC |
| NCT00527735 | NSCLC | P2 | completed | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) |
Hepatocellular Carcinoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04472767 | — | P2 | recruiting | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma |
| NCT04039607 | CheckMate 9DW | P3 | active not recruiting | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma |
| NCT04823403 | HIPANIV | P1 | recruiting | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma |
| NCT01658878 | CheckMate040 | P1/P2 | completed | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer |
| NCT05220722 | — | P1/P2 | terminated | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors |
| NCT03682276 | PRIME-HCC | P1/P2 | unknown | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma |
| NCT03222076 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer |
| NCT03203304 | SBRT | P1 | terminated | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer |
Uveal Melanoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07501117 | — | P1 | not yet recruiting | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma |
| NCT03070392 | — | P2 | completed | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma |
| NCT04463368 | SCANDIUM II | P1 | completed | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases |
| NCT02913417 | — | P1/P2 | unknown | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases |
| NCT03922880 | — | P1 | completed | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma |
| NCT02626962 | GEM1402 | P2 | completed | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma |
| NCT03408587 | CLEVER | P1 | completed | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) |
Clinical Stage III Cutaneous Melanoma AJCC v8 (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04940299 | — | P2 | active not recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma |
| NCT05896839 | — | P1/P2 | recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer |
| NCT02506153 | — | P3 | active not recruiting | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery |
| NCT02224781 | — | P3 | active not recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma |
| NCT03816332 | — | P1 | active not recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers |
| NCT04967196 | — | P1 | terminated | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma |
| NCT03033576 | — | P2 | completed | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma |
Advanced Clear Cell Renal Cell Carcinoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07383441 | — | P3 | recruiting | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
| NCT07510334 | — | P2 | recruiting | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
| NCT07000149 | eVOLVE-RCC02 | P3 | active not recruiting | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC |
| NCT07128680 | EXL01 | P1 | recruiting | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer |
| NCT05361720 | — | P2 | recruiting | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study |
| NCT06399419 | — | P1 | recruiting | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer |
Carcinoma, Non-Small-Cell Lung (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05715229 | G360-IIT | P2 | recruiting | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy |
| NCT05401786 | RAD-IO | P2 | active not recruiting | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC |
| NCT03083691 | BIOLUMA | P2 | completed | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer |
| NCT03302234 | NSCLC | P3 | completed | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) |
| NCT03262779 | — | P2 | completed | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. |
| NCT03663166 | NSCLC | P1/P2 | terminated | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) |
Advanced Malignant Solid Neoplasm (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04317105 | — | P1/P2 | active not recruiting | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN |
| NCT04021043 | BMS-986156 | P1/P2 | completed | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers |
| NCT02419495 | KPT-330 | P1 | terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies |
| NCT02408861 | — | P1 | terminated | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
| NCT01738139 | — | P1 | completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer |
| NCT03326258 | — | P1/P2 | withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery |
Non-small Cell Lung Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03285321 | NSCLC | P2 | completed | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) |
| NCT03573947 | TOP1705 | P2 | completed | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC |
| NCT03425331 | — | P2 | terminated | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC |
| NCT01454102 | BMS-936558 | P1 | completed | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) |
| NCT03509584 | — | P1 | terminated | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients |
| NCT01998126 | — | P1 | completed | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer |
Malignant Melanoma Stage III (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06794775 | SWE-NEO | P3 | recruiting | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma |
| NCT04949113 | NADINA | P3 | active not recruiting | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma |
| NCT02977052 | OpACIN-neo | P2 | unknown | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab |
| NCT04133948 | DONIMI | P1/P2 | completed | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma |
| NCT01302496 | TriMix-Ipi | P2 | completed | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma |
Melanoma (Skin) (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06377111 | — | P1 | active not recruiting | A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma |
| NCT01176474 | — | P1 | completed | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma |
| NCT03949153 | CRIRIN | P1/P2 | completed | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis |
| NCT00077532 | — | P2 | completed | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma |
| NCT00357461 | — | P2 | withdrawn | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma |
Melanoma Stage III (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04562129 | — | P2 | recruiting | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients |
| NCT06295159 | — | P2 | recruiting | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma |
| NCT04013854 | — | P2 | active not recruiting | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab |
| NCT04007588 | BMS-986205 | P2 | withdrawn | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma |
| NCT03153085 | HF10 | P2 | completed | A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma |
Clear Cell Renal Cell Carcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05536141 | ARC-20 | P1 | recruiting | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors |
| NCT03793166 | — | P3 | active not recruiting | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study |
| NCT02210117 | — | Early P1 | active not recruiting | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery |
| NCT06049576 | — | P1 | active not recruiting | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma |
| NCT03149159 | — | P2 | withdrawn | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab |
Advanced Renal Cell Carcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05928806 | ARCITECT | P2 | suspended | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial |
| NCT02231749 | — | P3 | completed | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) |
| NCT03117309 | — | P2 | completed | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma |
| NCT03829111 | CBM588 | P1 | completed | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer |
| NCT04203901 | — | P2 | terminated | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma |
Recurrent Melanoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01708941 | — | P2 | active not recruiting | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery |
| NCT02203604 | — | P2 | terminated | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery |
| NCT01970527 | — | P2 | terminated | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma |
| NCT01703507 | — | P1 | completed | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma |
| NCT00871481 | — | P1/P2 | completed | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma |
Hepatocellular Carcinoma (HCC) (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07291076 | HCC | P1/P2 | recruiting | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) |
| NCT07422753 | — | P2 | recruiting | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC |
| NCT07075120 | — | P1 | recruiting | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer |
| NCT03510871 | HCC | P2 | completed | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) |
Metastatic Renal Cell Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05327686 | SAMURAI | P2 | recruiting | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial |
| NCT04090710 | CYTOSHRINK | P2 | active not recruiting | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer |
| NCT03075423 | — | P2 | completed | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC |
| NCT03126331 | — | P2 | completed | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab |
Advanced Solid Tumors (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05533697 | — | P1/P2 | recruiting | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors |
| NCT05407675 | — | P1/P2 | completed | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors |
| NCT03461952 | NIMBLe | P2 | terminated | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) |
| NCT03525795 | — | P1 | completed | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors |
Urothelial Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05200988 | Indi-Blade | P2 | active not recruiting | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC |
| NCT03387761 | NABUCCO | P1 | completed | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy |
| NCT01524991 | — | P2 | completed | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma |
| NCT00362713 | — | P1 | completed | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection |
Gastric Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05144854 | — | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
| NCT02872116 | CheckMate649 | P3 | completed | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer |
| NCT03784040 | da VINci | P1 | unknown | Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. |
| NCT03409848 | INTEGA | P2 | completed | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma |
Squamous Cell Carcinoma of the Head and Neck (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03690986 | — | P1 | recruiting | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer |
| NCT02812524 | — | P1 | active not recruiting | Ipilimumab for Head and Neck Cancer Patients |
| NCT04290546 | — | P1 | completed | CIML NK Cell in Head & Neck Cancer |
| NCT04326257 | — | P2 | completed | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy |
Small Cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03670056 | — | P2 | active not recruiting | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy |
| NCT03043599 | — | P1/P2 | completed | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer |
| NCT03406715 | SCLC | P2 | terminated | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) |
| NCT03026166 | — | P1/P2 | terminated | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer |
Head and Neck Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02919683 | — | P2 | active not recruiting | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity |
| NCT03700905 | IMSTAR-HN | P3 | unknown | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy |
| NCT02741570 | CheckMate 651 | P3 | completed | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT02823574 | CheckMate 714 | P2 | completed | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Intraocular Melanoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00084656 | — | P2 | completed | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma |
| NCT00058279 | — | P1/P2 | completed | Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma |
| NCT00032045 | — | P2 | completed | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma |
| NCT00025181 | — | P1 | completed | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery |
Cutaneous Melanoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06999980 | Neo IRENIE | P2 | recruiting | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) |
| NCT03929029 | — | P1 | active not recruiting | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma |
| NCT02519322 | — | P2 | completed | Neoadjuvant and Adjuvant Checkpoint Blockade |
Colorectal Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04117087 | — | P1 | active not recruiting | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
| NCT06410534 | — | P2 | withdrawn | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer |
| NCT03377361 | CheckMate 9N9 | P1/P2 | completed | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread |
Metastatic Uveal Melanoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06581406 | — | P2/P3 | recruiting | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| NCT05987332 | — | P2/P3 | active not recruiting | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
| NCT01585194 | — | P2 | completed | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma |
Non-small Cell Lung Cancer (NSCLC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06487156 | FINN | N/A | active not recruiting | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT07215962 | — | N/A | active not recruiting | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% |
| NCT02221739 | NSCLC | P1/P2 | completed | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) |
Advanced Solid Tumor (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06514651 | — | P1 | recruiting | MAQ-001 in Patients With Advanced Solid Tumors |
| NCT05933265 | — | P1/P2 | active not recruiting | Study of LP-184 in Patients With Advanced Solid Tumors |
| NCT04855929 | ANV419-001 | P1 | completed | A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. |
Brain Metastases (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05048212 | — | P2 | recruiting | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases |
| NCT03458455 | TREATMENT | N/A | unknown | Improved Therapy Response Assessment in Metastatic Brain Tumors |
| NCT02460068 | NIBIT-M2 | P3 | unknown | A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis |
Metastatic Colorectal Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05310643 | NIPIRESCUE | P2 | recruiting | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC |
| NCT04008030 | CheckMate 8HW | P3 | active not recruiting | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) |
| NCT03832621 | MAYA | P2 | completed | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer |
Colorectal Cancer Metastatic (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04730544 | NIPISAFE | P2 | active not recruiting | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. |
| NCT04721301 | — | P1 | completed | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial |
| NCT03982121 | ISILI | P1 | withdrawn | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy |
Sarcoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03463408 | — | Early P1 | active not recruiting | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma |
| NCT04741438 | RAR-Immune | P3 | unknown | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype |
| NCT01445379 | — | P1 | completed | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer |
Recurrent Glioblastoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04003649 | — | P1 | active not recruiting | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM |
| NCT02017717 | CheckMate 143 | P3 | completed | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients |
| NCT03430791 | — | P2 | terminated | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma |
Merkel Cell Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03071406 | — | P2 | active not recruiting | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma |
| NCT03798639 | — | P1 | completed | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer |
| NCT01913691 | — | P2 | withdrawn | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma |
Metastatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03693014 | — | P2 | active not recruiting | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors |
| NCT03453892 | ST-ICI | N/A | completed | Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition |
| NCT03009058 | MODULATE | P1/P2 | terminated | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer |
Advanced Malignancies (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03233139 | — | P1 | active not recruiting | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies |
| NCT03126110 | — | P1/P2 | completed | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies |
| NCT03241173 | — | P1/P2 | completed | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies |
Various Advanced Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03143153 | CheckMate 648 | P3 | completed | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin |
| NCT02488759 | CheckMate358 | P1/P2 | completed | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
| NCT03130959 | CheckMate 908 | P2 | completed | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies |
Advanced Renal Cell Carcinoma (aRCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07188896 | RCC | P2 | recruiting | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) |
| NCT06345183 | — | N/A | completed | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients |
HCC - Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07560488 | — | P2 | recruiting | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma |
| NCT05665348 | TRIPLET | P2/P3 | completed | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy |
Cutaneous Melanoma, Stage III (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07230613 | NEOREM-NEO-1 | P2 | recruiting | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma |
| NCT03719131 | — | P2 | active not recruiting | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy |
Metastatic Soft-tissue Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06968988 | — | P1 | recruiting | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma |
| NCT04551430 | — | P2 | active not recruiting | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma |
Neuroendocrine Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06889493 | NEC | P1 | recruiting | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) |
| NCT03591731 | NIPINEC | P2 | completed | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) |
Lung Cancer - Non Small Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06926790 | GALAXY 3 | P2 | recruiting | Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) |
| NCT01471197 | — | P2 | terminated | Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer |
Liver Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06482801 | — | P2 | recruiting | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT |
| NCT02239900 | SBRT | P1 | completed | Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors |
Cancer of Rectum (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05732389 | RESET-R | P2 | recruiting | Immunotherapy in Patients With Early dMMR Rectal Cancer |
| NCT02948348 | — | P1/P2 | unknown | Study to Nivolumab Following Preoperative Chemoradiotherapy |
Clinical Stage IV Cutaneous Melanoma AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03873818 | — | P2 | completed | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain |
| NCT05341349 | — | P1 | terminated | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases |
Lung Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929041 | — | P2/P3 | suspended | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative |
| NCT03391869 | — | P3 | active not recruiting | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer |
Urothelial Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03036098 | CheckMate901 | P3 | active not recruiting | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer |
| NCT05219435 | VEXILLUM | P2 | completed | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer |
Mucosal Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05384496 | — | P2 | recruiting | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma |
| NCT03241186 | — | P2 | active not recruiting | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma |
Prostatic Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05150236 | ANZUP2001 | P2 | unknown | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC |
| NCT02506114 | — | P2 | terminated | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer |
Adult Solid Tumor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04892043 | — | P1 | terminated | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors |
| NCT04084951 | — | P1 | completed | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors |
Metastatic Pancreatic Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04787991 | REVOLUTION | P1 | completed | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma |
| NCT01896869 | — | P2 | completed | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer |
Metastatic Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04611126 | — | P1/P2 | terminated | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer |
| NCT03287674 | — | P1/P2 | completed | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer |
Solid Tumor, Adult (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665206 | — | P1/P2 | recruiting | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors |
| NCT03728179 | RACIN | P1 | completed | RACIN in Patients With Advanced TIL-negative Solid Tumors |
Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03739710 | NSCLC | P2 | completed | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) |
| NCT06790303 | NSCLC | P2 | terminated | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2 |
Acral Lentiginous Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04511013 | — | P2 | recruiting | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases |
| NCT02978443 | — | P2 | terminated | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab |
Gliosarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04396860 | — | P2/P3 | completed | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma |
| NCT02311920 | — | P1 | completed | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma |
Pancreatic Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03816358 | — | P1 | active not recruiting | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer |
| NCT03404960 | Parpvax | P1/P2 | completed | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy |
Soft Tissue Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04118166 | — | P2 | completed | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma |
| NCT02982486 | — | P2 | unknown | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma |
Melanoma Stage Iv (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03340129 | ABC-X | P2 | recruiting | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
| NCT03161756 | CHARLI | P1/P2 | unknown | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma |
Kidney Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02950766 | — | P1 | active not recruiting | NeoVax Plus Ipilimumab in Renal Cell Carcinoma |
| NCT00057889 | — | P2 | completed | Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer |
Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03502733 | — | P1 | active not recruiting | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma |
| NCT00047164 | — | P1 | completed | Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy |
Metastatic Malignant Neoplasm in the Liver (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03068624 | — | P1 | unknown | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma |
| NCT03472586 | — | P2 | completed | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver |
Bladder Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03520491 | — | P2 | active not recruiting | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy |
| NCT02553642 | CA209-260 | P2 | completed | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) |
Lymphoma, Non-Hodgkin (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02693535 | TAPUR | P2 | recruiting | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
| NCT03297606 | CAPTUR | P2 | recruiting | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) |
Carcinoma, Renal Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03138512 | CheckMate 914 | P3 | completed | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney |
| NCT02917772 | TITAN-RCC | P2 | completed | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma |
B-Cell Non-Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03017820 | — | P1 | recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma |
| NCT01919619 | — | P2 | completed | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies |
Gastrointestinal Stromal Tumor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02880020 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery |
| NCT01643278 | — | P1 | completed | Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic |
Advanced Cancers (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02668770 | — | P1 | terminated | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies |
| NCT01750983 | — | P1 | completed | Ipilimumab and Lenalidomide in Advanced Cancer |
Recurrent Squamous Cell Lung Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02785952 | — | P3 | active not recruiting | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
| NCT02154490 | — | N/A | completed | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
Unresectable Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01927419 | CheckMate 069 | P2 | completed | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma |
| NCT02115243 | — | P1 | completed | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma |
Unresectable or Metastatic Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01844505 | — | P3 | completed | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) |
| NCT01810016 | — | P1 | terminated | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma |
Cervical Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01693783 | — | P2 | completed | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer |
| NCT01711515 | — | P1 | completed | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00039091 | — | P1 | terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer |
| NCT00060372 | — | P1 | completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
Metastatic Colorectal Cancer (CRC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07587827 | ODI-2001-01 | P1 | not yet recruiting | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer |
Soft Tissue Sarcomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07444619 | — | P1 | not yet recruiting | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas |
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07430202 | FLC | P1 | not yet recruiting | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) |
Advanced Kidney Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07338981 | — | P3 | not yet recruiting | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. |
Diffuse Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07532902 | — | P1 | recruiting | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer |
Non-small Cell Lung Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07355205 | FLINN | P2 | not yet recruiting | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
Advanced Renal Cell Carcinoma (RCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07293351 | RCC | P1/P2 | recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) |
Phase 1b (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07401875 | SHARK | P1 | recruiting | A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) |
Hepato Cellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07487662 | ACTION-001 | P2 | not yet recruiting | TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk |
BRAF V600E (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07506109 | — | P2 | recruiting | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer |
Unresectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07482059 | — | P1/P2 | recruiting | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma |
Advanced Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07166406 | — | P3 | recruiting | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial |
Colorectal Cancer (MSI-H) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07403877 | TORCH-OPTIMA | P2 | not yet recruiting | Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer |
Nonsmall Cell Lung Cancer, Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07394062 | ALCG-01 | N/A | recruiting | Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) |
Anatomic Stage I Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06324240 | — | P1 | recruiting | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer |
Metastatic Renal Cell Carcinoma ( mRCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07233668 | IVE in mRCC | N/A | not yet recruiting | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC |
Carcinoma, Hepatocellular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07227012 | — | P1/P2 | recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. |
Advanced Acral Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155317 | — | P2 | recruiting | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial |
Advanced Hepatocellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07147101 | HCC-IM-1 | N/A | recruiting | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment |
Very High Risk Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06388369 | NEPI | P1/P2 | terminated | Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer |
Locally Advanced Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06866262 | — | P1/P2 | recruiting | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial |
Melanoma (Skin Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06624644 | — | P2/P3 | recruiting | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma |
PROMs (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07061379 | PROMOTING | N/A | recruiting | Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen |
Melanoma Brain Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06163820 | BETTER | P1/P2 | recruiting | Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases |
Pancreatic Adenocarcinoma Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06747845 | ParpVax2 | P2 | recruiting | Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy |
Renal Cell Carcinoma, Clear Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06708949 | RCC | P2 | recruiting | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) |
Melanoma, Cutaneous Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06743126 | SUPRAME | P3 | recruiting | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma |
Melanoma Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06784648 | — | P1/P2 | active not recruiting | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma |
Diffuse Hemispheric Glioma, H3 G34-Mutant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05457959 | — | P1 | withdrawn | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant |
Pleural Biphasic Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05647265 | — | P2 | recruiting | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma |
Metastatic Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07024862 | — | N/A | active not recruiting | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy |
Colon Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06490536 | — | P3 | recruiting | The Sagittarius Trial |
Hepatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06492408 | — | P2 | recruiting | Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. |
Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06342037 | TONIC-3 | P2 | recruiting | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial |
Metastatic Kidney Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06364631 | CARE1 | P3 | recruiting | CARE1 Pragmatic Clinical Trial |
ICB-refractory Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06250335 | ICB | P2 | active not recruiting | Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients |
Metastatic Nasopharyngeal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05904080 | — | P2 | recruiting | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer |
Peripheral T Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06508463 | — | P1 | recruiting | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma |
Healthy Male Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06159101 | — | P1 | unknown | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects |
Unresectable Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06097728 | eVOLVE-Meso | P3 | active not recruiting | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma |
Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05504642 | CERAD-IMMUNE | P2 | withdrawn | Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients |
Diffuse Astrocytoma, IDH-Mutant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06047379 | — | P1/P2 | recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis |
Locally Advanced Extraskeletal Myxoid Chondrosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05836571 | — | P2 | active not recruiting | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma |
IDH1-mutant Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05921760 | — | P1/P2 | terminated | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma |
Oncology (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06031233 | MINUTE | P4 | recruiting | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie |
Atypical Teratoid Rhabdoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05407441 | — | P1/P2 | active not recruiting | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors |
Lung Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05501665 | — | P1/P2 | recruiting | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer |
NSCLC Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05597800 | LUNGVIR | P2 | not yet recruiting | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome |
BCLC Stage B Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05199285 | — | P2 | terminated | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab |
Gastroenteropancreatic Neuroendocrine Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05262556 | — | P1 | active not recruiting | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas |
Locally Advanced or Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05498792 | — | Early P1 | recruiting | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma |
Leptomeningeal Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05598853 | IT-IO | P1 | active not recruiting | Intrathecal Double Checkpoint Inhibition |
Uterine Cervical Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05492123 | — | P2 | recruiting | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer |
Melanoma, Ocular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05169957 | HAMMER I | P1 | completed | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) |
Myeloproliferative Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05444530 | — | P1 | completed | A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms |
Hematopoietic and Lymphoid Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04781855 | — | P1 | withdrawn | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation |
Refractory Cutaneous Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05200143 | — | P2 | terminated | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma |
Endometrial Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05112601 | — | P2 | recruiting | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |
Colonic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05456165 | — | P2 | withdrawn | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer |
Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05144529 | TOP2101 | P2 | terminated | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC |
Osteosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05302921 | — | P2 | completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors |
Colorectal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05141721 | — | P2/P3 | active not recruiting | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer |
Locally Advanced Rectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04751370 | — | P2 | active not recruiting | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer |
Metastatic Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04840589 | — | P1 | suspended | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors |
Mesothelioma, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05136677 | CheckMate 6DW | P2 | completed | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants |
Stage IV Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05088889 | — | P1 | unknown | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer |
Renal Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05215470 | CLARA | P2 | active not recruiting | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy |
Renal Cell Carcinoma (RCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05176483 | STELLAR-002 | P1 | recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors |
Clinical Stage I Cutaneous Melanoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04697576 | — | P1 | recruiting | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma |
Advanced Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04969887 | MOST-CIRCUIT | P2 | active not recruiting | Combination Immunotherapy in Rare Cancers Under InvesTigation |
Metastatic Uveal Melanoma in the Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04935229 | PERIO | P1 | terminated | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma |
Advanced or Metastatic Solid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04887870 | — | P2/P3 | completed | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study |
Nerve Sheath Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04465643 | — | P1 | completed | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor |
Metastatic Prostate Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04709276 | CHAMP | P2 | active not recruiting | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer |
Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04938232 | — | P2 | active not recruiting | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04868760 | — | P1 | completed | A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male Volunteers |
Metastatic Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04863885 | — | P1/P2 | active not recruiting | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients |
Carcinoma, Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04151563 | CheckMate 79X | P1/P2 | withdrawn | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy |
Advance Solid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04850755 | — | P1 | completed | A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies |
Carcinosarcoma of Ovary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04149275 | — | P2 | withdrawn | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma |
Constitutional Mismatch Repair Deficiency Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04500548 | — | P1 | withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study |
Prostatic Neoplasms, Castration-Resistant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04717154 | INSPIRE | P2 | completed | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer |
Astrocytoma, IDH-Mutant, Grade 4 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04145115 | — | P2 | active not recruiting | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden |
Kidney Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04513522 | CheckMate 7C9 | P4 | completed | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India |
Undifferentiated Pleomorphic Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04480502 | ENVASARC | P2 | unknown | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma |
Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04610658 | — | P1 | terminated | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC |
Papillary Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04413123 | — | P2 | active not recruiting | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC |
Brain Metastases, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04434560 | — | P2 | terminated | Neoadjuvant Immunotherapy in Brain Metastases |
Metastatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04315155 | BENEFIT | P1 | withdrawn | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation |
Metastatic Microsatellite Stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04575922 | — | P2 | unknown | Nivolumab+Ipilimumab+RT in MSS mCRC |
Cancer, Hepatocellular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04340193 | CheckMate 74W | P3 | completed | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer |
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04141644 | Osi+Ipi | P1 | active not recruiting | Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC |
Aggressive Variant Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04388852 | — | P1 | active not recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers |
Malignant Rhabdoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04416568 | — | P2 | active not recruiting | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers |
Cutaneous Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04620200 | MATISSE | P2 | completed | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery |
Clear-Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04518046 | — | P1 | completed | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies |
Metastatic Large Cell Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04079712 | — | P2 | active not recruiting | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors |
Cervix Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04256213 | COLIBRI | N/A | completed | COL Immunotherapy Before Radiochimio + Ipilimumab |
Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04311710 | CheckMate 76U | P1 | terminated | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types |
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04247165 | LAPTOP | P1/P2 | completed | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. |
Rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04124601 | CHINOREC | P2 | completed | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer |
Advanced Colon Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04362839 | — | P1 | completed | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer |
Fibrolamellar Hepatocellular Carcinoma (FLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04248569 | — | P1 | recruiting | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03878524 | SMMART | P1 | terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
Differentiated Thyroid Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03914300 | — | P2 | active not recruiting | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer |
Neuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04239040 | — | P1 | terminated | GVAX Plus Checkpoint Blockade in Neuroblastoma |
Relapsed/Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04635735 | — | P1/P2 | terminated | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma |
Head and Neck Squamous Cell Carcinoma (HNSCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04080804 | — | P2 | active not recruiting | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer |
Cancer of Unknown Primary Site (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04131621 | CheCUP | P2 | unknown | Nivolumab/Ipilimumab in Second Line CUP-syndrome |
Uveal Melanoma, Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04283890 | CHOPIN | P1/P2 | active not recruiting | PHP and Immunotherapy in Metastasized UM |
Prostate Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05655715 | CheckPRO | P2 | completed | Checkpoint Inhibitors and SBRT for MCRPC |
Localized Oesogastric Adenocarcimona (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04006262 | NEONIPIGA | P2 | active not recruiting | Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. |
Melanoma With Brain Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03903640 | — | P2 | terminated | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis |
Non-Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04026412 | CheckMate73L | P3 | completed | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery |
ALK Gene Rearrangement (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04013542 | — | P1 | active not recruiting | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer |
Advanced NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04043195 | NSCLC | P1/P2 | active not recruiting | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC |
Pituitary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04042753 | — | P2 | completed | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors |
Basal Cell Nevus Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03767439 | — | P2 | withdrawn | Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome |
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03799445 | — | P2 | terminated | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma |
Gastric and Esophagogastric Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03443856 | VESTIGE | P2 | active not recruiting | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence |
Autoimmune Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03816345 | — | P1 | recruiting | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO |
Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03912064 | — | P1 | active not recruiting | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT |
Anatomic Stage 0 Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04185311 | — | P1 | terminated | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted |
Grade 2 Meningioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03604978 | — | P1/P2 | active not recruiting | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma |
Bladder Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03866382 | — | P2 | recruiting | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03604991 | — | P2/P3 | suspended | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery |
Melanoma (Excluding Uveal Melanoma) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03752398 | DUET-3 | P1 | completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) |
Breast Neoplasm Female (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03650894 | HER | P2 | active not recruiting | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients |
Advanced Solid Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03956680 | — | P1 | completed | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers |
Acute Myeloid Leukemia and Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02846376 | CPIT-002 | P1 | terminated | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant |
Mucinous Adenocarcinoma of the Colon (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03693846 | — | P2 | terminated | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors |
Metastatic Hormone-sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03879122 | — | P2/P3 | unknown | A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer |
Inoperable œsophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03437200 | CRUCIAL | P2 | terminated | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer |
Metastatic Malignant Neoplasm in the Bone (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03749460 | — | P1/P2 | completed | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers |
Urinary Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03844256 | CRIMI | P1/P2 | recruiting | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study |
Clinical Stage 0 Gastric Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03776487 | — | P2 | active not recruiting | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer |
Stage III Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03477864 | — | P1 | withdrawn | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer |
Colorectal Neoplasms Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03507699 | — | P1 | completed | Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer |
Metastatic Castration Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03570619 | IMPACT | P2 | completed | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations |
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03769155 | — | P1 | active not recruiting | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma |
Basal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03521830 | — | P2 | recruiting | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma |
Adenocarcinoma of the Stomach (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03647969 | — | P2 | completed | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer |
Pan Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03668119 | CheckMate 848 | P2 | completed | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) |
Unresectable Stage III Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03235245 | EBIN | P2 | active not recruiting | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib |
Advanced Metastatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03651271 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer |
Allogeneic Hematopoietic Stem Cell Transplantation Recipient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03600155 | — | P1 | completed | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome |
Malignant Peritoneal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03508570 | — | P1 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis |
Metastatic Hormone-Sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03532217 | — | P1 | completed | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer |
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03620123 | OPTIM | P2 | completed | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck |
Relapsed Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03305445 | — | P1 | completed | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL |
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03468985 | — | P2 | completed | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer |
Non-Small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03469960 | DICIPLE | P3 | completed | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03355976 | — | P2 | active not recruiting | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas |
Bone Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03449108 | TNBC | P2 | active not recruiting | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas |
Stage III Cutaneous Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03396952 | — | P2 | completed | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma |
Classic Kaposi Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03219671 | CKS | P2 | unknown | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03347123 | ECHO-208 | P1/P2 | terminated | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) |
Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03442569 | — | P2 | completed | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC |
Neuroendocrine Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03420521 | — | P2 | terminated | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors |
Newly Diagnosed High Grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03425292 | — | P1 | completed | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer |
Esophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03416244 | RAMONA | P2 | completed | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer |
Advanced Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03351361 | eNERGY | P3 | completed | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients |
Leptomeningeal Carcinomatosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02939300 | — | P2 | completed | Ipilimumab and Nivolumab in Leptomeningeal Metastases |
Breast Cancer Female (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03342417 | — | P2 | terminated | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients |
Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03406247 | ADJORL1 | P2 | recruiting | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma |
MGMT-unmethylated Glioblastoma (GBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03367715 | — | P2 | completed | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma |
Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03388632 | — | P1 | completed | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers |
Genitourinary Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03333616 | — | P2 | active not recruiting | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Colon Carcinoma Metastatic in the Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03373188 | — | P1 | completed | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer |
Kidney Medullary Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03274258 | — | P2 | terminated | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma |
Metastatic Cancer Colorectal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03350126 | NIPICOL | P2 | active not recruiting | iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab |
Cervical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03220009 | — | P2 | withdrawn | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03283046 | — | P1 | withdrawn | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma |
Renal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03203473 | — | P2 | active not recruiting | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) |
Recurrent B Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02879695 | — | P1 | active not recruiting | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia |
MSS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03271047 | MSS | P2 | completed | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation |
Non Small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03168464 | — | P1/P2 | terminated | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) |
Dedifferentiated Liposarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03307616 | — | P2 | active not recruiting | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery |
Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03246958 | — | P2 | completed | Nivolumab Plus Ipilimumab in Thyroid Cancer |
HER2/Neu Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02892734 | — | P2 | terminated | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer |
Squamous-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03823625 | SQUINT | P2 | unknown | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) |
Biliary Tract Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03101566 | — | P2 | completed | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer |
Stage IV Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03223155 | COSINR | P1 | active not recruiting | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer |
Previously Treated Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02890329 | — | P1 | active not recruiting | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia |
Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02923934 | — | P2 | completed | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers |
High Grade Serous Ovarian (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03245892 | — | P1 | completed | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer |
Transitional Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03219775 | TITAN-TCC | P2 | unknown | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma |
Stage I Lung Non-Small Cell Cancer AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03158129 | — | P2 | completed | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer |
Malignant Melanoma Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03166397 | — | P2 | unknown | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients |
Clear Cell Metastatic Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02960906 | BIONIKK | P2 | completed | A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer |
Salivary Gland Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03172624 | — | P2 | completed | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer |
Major Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03146650 | — | P2 | unknown | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer |
Larynx (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03162731 | — | Early P1 | completed | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer |
Microsatellite Stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03104439 | — | P2 | active not recruiting | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer |
Advanced Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03138161 | SAINT | P1/P2 | recruiting | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma |
Nasopharyngeal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03097939 | — | P2 | unknown | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma |
Colon Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03026140 | NICHE | P2 | recruiting | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer |
Non-Small-Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02864251 | CheckMate722 | P3 | completed | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy |
Kidney Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03065179 | RADVAX | P2 | completed | SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients |
Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03003637 | IMCISION | P1/P2 | completed | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma |
Cancer Treated With Immune-checkpoint Inhibitors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03963518 | SURROGATE-ICI | N/A | completed | Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI) |
Acinar Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02834013 | — | P2 | active not recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
Metastatic Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02977156 | ISI-JX | P1 | completed | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. |
Metastatic Malignant Neoplasm in the Brain (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02696993 | — | P1/P2 | active not recruiting | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer |
Stage III/IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02857569 | NIVIPIT | P1/P2 | completed | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma |
Broad Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02913313 | — | P1/P2 | completed | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors |
Metastatic Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02866383 | CheckPAC | P2 | completed | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients |
Advanced Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02935634 | FRACTION-GC | P2 | completed | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer |
Stage III Skin Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02437279 | OpACIN | P1 | unknown | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients |
Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02922764 | — | P1 | completed | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer |
Malignant Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03048474 | INITIATE | P2 | completed | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma |
Malignant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02829931 | — | P1 | completed | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas |
Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02681302 | CPIT001 | P1/P2 | terminated | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence |
Castration Levels of Testosterone (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02703623 | — | P2 | active not recruiting | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer |
Advanced/Metastatic Solid Tumors or Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02675439 | ADU-S100 | P1 | terminated | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas |
Stage IIIC Skin Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02941744 | ipniv | P1/P2 | completed | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases |
Meningiomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02648997 | — | P2 | active not recruiting | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma |
Non-Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02659059 | CheckMate 568 | P2 | completed | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer |
Anatomic Stage III Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02453620 | — | P1 | active not recruiting | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer |
Limited Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02046733 | STIMULI | P2 | completed | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease |
Stage III Cutaneous Melanoma AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02339571 | — | P2/P3 | active not recruiting | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma |
Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02530463 | — | P2 | active not recruiting | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome |
Locally Advanced Bone Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02500797 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery |
Recurrent Fallopian Tube Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02498600 | — | P2 | completed | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Bladder Small Cell Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02496208 | — | P1 | active not recruiting | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
Metastatic Leiomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02428192 | — | P2 | completed | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma |
Anal Canal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02314169 | — | P2 | active not recruiting | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer |
Unresectable Stage III or Stage IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02413827 | — | P1/P2 | terminated | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma |
Acute Bilineal Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02397720 | — | P2 | completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia |
Stage III or IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02200562 | — | P1 | terminated | Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma |
Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02279732 | — | P3 | completed | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02254772 | — | P1/P2 | completed | A Phase I/II Study of Intratumoral Injection of SD-101 |
Liver Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02107755 | — | P2 | completed | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma |
Solid Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02174172 | — | P1 | completed | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors |
Stage IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02054520 | — | P2 | terminated | Immunotherapy Study for Patients With Stage IV Melanoma |
In-transit Metastases Melanoma Stage IIIB and IIIC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02094391 | ILP+/-IPI | P2 | completed | Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma |
Microsatellite Unstable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02060188 | CheckMate142 | P2 | completed | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread |
Recurrent Classic Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01896999 | — | P1/P2 | active not recruiting | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
Non-small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02039674 | MK-3475 | P1/P2 | completed | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) |
Stage IIIC Cutaneous Melanoma AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01950390 | — | P2 | completed | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery |
Metastatic Castration Sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02020070 | — | P2 | active not recruiting | Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy |
A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01988077 | — | P2 | terminated | Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients |
Advanced or Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01928394 | — | P1/P2 | completed | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors |
Newly Diagnosed Melanoma Metastases in the Brain and Spine (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01950195 | — | P1 | terminated | SRS (Stereotactic Radiosurgery) Plus Ipilimumab |
BRAF V600E Mutation Present (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01940809 | — | P1 | terminated | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery |
Allogeneic Hematopoietic Stem Cell Transplant Recipient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01822509 | — | P1 | completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant |
Advanced or Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01783938 | — | P2 | completed | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) |
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01935921 | — | P1 | completed | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer |
Adult Nasal Type Extranodal NK/T-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01769222 | — | P1 | terminated | Ipilimumab and Local Radiation for Selected Solid Tumors |
Solid Tumours (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01767454 | — | P1 | completed | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma |
CANCER, NOS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01750580 | — | P1 | completed | Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor |
Ciliary Body and Choroid Melanoma, Medium/Large Size (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01730157 | — | Early P1 | terminated | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01757639 | — | P1 | completed | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia |
Untreated Stage III Melanoma or Stage IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01676649 | — | P2 | unknown | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma |
CD20 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01729806 | — | P1 | completed | Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma |
Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01715077 | — | N/A | completed | Study of Ipilimumab in the Immune System |
CANCER,NOS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01714739 | — | P1/P2 | completed | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors |
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01611558 | — | P2 | completed | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01592370 | — | P1/P2 | completed | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma |
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01585987 | — | P2 | completed | An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy |
Duct Cell Adenocarcinoma of the Pancreas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01473940 | — | P1 | completed | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery |
Adenocarcinoma of the Prostate (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01498978 | — | P2 | completed | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer |
Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01450761 | ED-SCLC | P3 | completed | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone |
Ocular Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01355120 | DeCOG | P2 | completed | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease |
Extensive Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01331525 | ICE | P2 | completed | The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer |
Melanoma of Unknown Primary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01274338 | — | P3 | active not recruiting | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery |
Malignant Melanoma, Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01363206 | GIPI | P2 | completed | Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma |
Lung Cancer - Non Small Cell Squamous (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01285609 | — | P3 | completed | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin |
Metastatic Malignant Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01654692 | NIBIT-M1 | P2 | completed | A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma |
Leukemia, Myeloid, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00732186 | — | P1 | withdrawn | Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia |
B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00586391 | CRETI-NH | P1 | active not recruiting | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL |
High Risk Stage III Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00636168 | — | P3 | completed | Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma |
Unresectable Stage III or IV Malignant Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00261365 | MDX-010 | P1/P2 | completed | Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) |
Synovial Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00140855 | — | P2 | terminated | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma |
Adult Grade III Lymphomatoid Granulomatosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00089076 | — | P1/P2 | terminated | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma |
Prostate Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00170157 | — | P2 | completed | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer |
Recurrent Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00064129 | — | P1 | completed | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer |
Ipilimumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MINUTE | NCT06031233 | P4 | recruiting | Oncology | 776 | — |
| Ipi4 | NCT02068196 | P4 | active not recruiting | Malignant Melanoma | 150 | PMID 30821848 |
| CheckMate 7C9 | NCT04513522 | P4 | completed | Kidney Neoplasms | 101 | — |
| CHECKMATE 920 | NCT02982954 | P4 | completed | Renal Cell Carcinoma | 211 | PMID 35210307 |
| PROCLIVITY02 | NCT01856023 | P4 | terminated | Metastatic Melanoma | 29 | — |
| eVOLVE-RCC02 | NCT07000149 | P3 | active not recruiting | Advanced Clear Cell Renal Cell Carcinoma | 1,116 | — |
| CARE1 | NCT06364631 | P3 | recruiting | Metastatic Kidney Cancer | 1,250 | — |
| SWE-NEO | NCT06794775 | P3 | recruiting | Malignant Melanoma Stage III | 128 | — |
| SUPRAME | NCT06743126 | P3 | recruiting | Melanoma, Cutaneous Malignant | 360 | — |
| NADINA | NCT04949113 | P3 | active not recruiting | Malignant Melanoma Stage III | 423 | PMID 37104746 |
| eVOLVE-Meso | NCT06097728 | P3 | active not recruiting | Unresectable Pleural Mesothelioma | 861 | — |
| COSMIC-313 | NCT03937219 | P3 | active not recruiting | Renal Cell Carcinoma | 855 | PMID 34550754 |
| CheckMate 9DW | NCT04039607 | P3 | active not recruiting | Hepatocellular Carcinoma | 732 | PMID 40349714 |
| CheckMate 8HW | NCT04008030 | P3 | active not recruiting | Metastatic Colorectal Cancer | 839 | PMID 39602630 |
| CheckMate901 | NCT03036098 | P3 | active not recruiting | Urothelial Cancer | 1,314 | PMID 37870949 |
| CheckMate 9ER | NCT03141177 | P3 | active not recruiting | Renal Cell Carcinoma | 701 | PMID 41617395 |
| DICIPLE | NCT03469960 | P3 | completed | Non-Small Cell Lung Cancer Metastatic | 265 | — |
| RAR-Immune | NCT04741438 | P3 | unknown | Sarcoma | 96 | — |
| DREAM3R | NCT04334759 | P3 | completed | Mesothelioma | 214 | PMID 33358660 |
| CheckMate 648 | NCT03143153 | P3 | completed | Various Advanced Cancer | 970 | PMID 37139963 |
| CheckMate 816 | NCT02998528 | P3 | completed | Non Small Cell Lung Cancer | 505 | PMID 40454642 |
| CheckMate73L | NCT04026412 | P3 | completed | Non-Small Cell Lung Cancer (NSCLC) | 925 | PMID 42129521 |
| CheckMate 227 | NCT02477826 | P3 | completed | Non-Small Cell Lung Cancer | 2,747 | PMID 31195357 |
| CheckMate 9LA | NCT03215706 | P3 | completed | Non-Small Cell Lung Cancer | 719 | PMID 39270380 |
| CheckMate 238 | NCT02388906 | P3 | completed | Melanoma | 906 | PMID 34663559 |
| CheckMate 143 | NCT02017717 | P3 | completed | Recurrent Glioblastoma | 529 | PMID 32691060 |
| CheckMate649 | NCT02872116 | P3 | completed | Gastric Cancer | 2,031 | PMID 37713657 |
| IMSTAR-HN | NCT03700905 | P3 | unknown | Head and Neck Cancer | 276 | PMID 27247226 |
| CheckMate 914 | NCT03138512 | P3 | completed | Carcinoma, Renal Cell | 1,641 | PMID 36774933 |
| TIL | NCT02278887 | P3 | completed | Metastatic Melanoma | 168 | PMID 40474841 |
| CheckMate 74W | NCT04340193 | P3 | completed | Cancer, Hepatocellular | 26 | — |
| CheckMate743 | NCT02899299 | P3 | completed | Mesothelioma | 605 | PMID 33206991 |
| CheckMate722 | NCT02864251 | P3 | completed | Non-Small-Cell Lung Carcinoma | 367 | PMID 38252907 |
| CheckMate 651 | NCT02741570 | P3 | completed | Head and Neck Cancer | 947 | PMID 33684371 |
| NSCLC | NCT03302234 | P3 | completed | Carcinoma, Non-Small-Cell Lung | 568 | PMID 33513313 |
| eNERGY | NCT03351361 | P3 | completed | Advanced Non Small Cell Lung Cancer | 217 | PMID 39486424 |
| CheckMate 451 | NCT02538666 | P3 | completed | Lung Cancer | 907 | PMID 33683919 |
| CheckMate 915 | NCT03068455 | P3 | completed | Melanoma | 1,844 | PMID 35512259 |
| CheckMate 401 | NCT02599402 | P3 | completed | Melanoma | 533 | PMID 37307514 |
| NIBIT-M2 | NCT02460068 | P3 | unknown | Brain Metastases | 168 | — |
| CheckMate 955 | NCT03048136 | P3 | withdrawn | Non-Small Cell Lung Cancer | 0 | — |
| MK-3475 | NCT01866319 | P3 | completed | Melanoma | 834 | PMID 28822576 |
| ED-SCLC | NCT01450761 | P3 | completed | Small Cell Lung Carcinoma | 1,351 | PMID 27458307 |
| RESET-R | NCT05732389 | P2 | recruiting | Cancer of Rectum | 39 | — |
| Neo IRENIE | NCT06999980 | P2 | recruiting | Cutaneous Melanoma | 494 | — |
| TORCH-OPTIMA | NCT07403877 | P2 | not yet recruiting | Colorectal Cancer (MSI-H) | 114 | — |
| NEOREM-NEO-1 | NCT07230613 | P2 | recruiting | Cutaneous Melanoma, Stage III | 50 | — |
| BELLINI | NCT03815890 | P2 | recruiting | Breast Cancer | 80 | PMID 39284953 |
| FLINN | NCT07355205 | P2 | not yet recruiting | Non-small Cell Lung Cancer Stage IV | 26 | — |
| NICHE | NCT03026140 | P2 | recruiting | Colon Carcinoma | 353 | PMID 34606846 |
| RCC | NCT07188896 | P2 | recruiting | Advanced Renal Cell Carcinoma (aRCC) | 120 | — |
| GALAXY 3 | NCT06926790 | P2 | recruiting | Lung Cancer - Non Small Cell | 69 | — |
| NeoRelapse | NCT06365619 | P2 | recruiting | Melanoma | 25 | PMID 29945191 |
| TONIC-3 | NCT06342037 | P2 | recruiting | Metastatic Breast Cancer | 60 | — |
| ABC-X | NCT03340129 | P2 | recruiting | Melanoma Stage Iv | 218 | PMID 33450821 |
| NESCIO | NCT05148546 | P2 | active not recruiting | Renal Cell Carcinoma | 69 | — |
| ParpVax2 | NCT06747845 | P2 | recruiting | Pancreatic Adenocarcinoma Metastatic | 68 | — |
| ICB | NCT06250335 | P2 | active not recruiting | ICB-refractory Melanoma | 4 | — |
| TAPUR | NCT02693535 | P2 | recruiting | Lymphoma, Non-Hodgkin | 4,200 | PMID 36753688 |
| ABC | NCT02374242 | P2 | active not recruiting | Melanoma | 76 | PMID 37132182 |
| RCC | NCT06708949 | P2 | recruiting | Renal Cell Carcinoma, Clear Cell | 15 | — |
| CheckMate-1533 | NCT06946797 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 76 | — |
| CHAMP | NCT04709276 | P2 | active not recruiting | Metastatic Prostate Neuroendocrine Carcinoma | 41 | — |
| SAMURAI | NCT05327686 | P2 | recruiting | Metastatic Renal Cell Carcinoma | 240 | — |
| MEMBRAINS | NCT03563729 | P2 | recruiting | Malignant Melanoma | 80 | — |
| NIPISAFE | NCT04730544 | P2 | active not recruiting | Colorectal Cancer Metastatic | 96 | — |
| ACTION-001 | NCT07487662 | P2 | not yet recruiting | Hepato Cellular Carcinoma (HCC) | 105 | PMID 41125112 |
| RadVax | NCT03646617 | P2 | recruiting | Metastatic Melanoma | 54 | — |
| DRUP | NCT02925234 | P2 | recruiting | Cancer | 1,550 | PMID 37424386 |
| NIVIPI-Brain | NCT05012254 | P2 | active not recruiting | Non Small Cell Lung Cancer | 71 | — |
| ADJORL1 | NCT03406247 | P2 | recruiting | Head and Neck Squamous Cell Carcinoma | 140 | — |
| ARCITECT | NCT05928806 | P2 | suspended | Advanced Renal Cell Carcinoma | 120 | — |
| NA_00092076 | NCT02259621 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 39 | PMID 31754049 |
| CheckMate 7UA | NCT04495010 | P2 | withdrawn | Melanoma | 0 | — |
| DISCERN | NCT06364917 | P2 | recruiting | Non Small Cell Lung Cancer | 24 | — |
| NIPIRESCUE | NCT05310643 | P2 | recruiting | Metastatic Colorectal Cancer | 30 | — |
| Indi-Blade | NCT05200988 | P2 | active not recruiting | Urothelial Carcinoma | 50 | PMID 37711193 |
| TNBC | NCT03449108 | P2 | active not recruiting | Bone Sarcoma | 30 | — |
| G360-IIT | NCT05715229 | P2 | recruiting | Carcinoma, Non-Small-Cell Lung | 108 | PMID 20514052 |
| LUNGVIR | NCT05597800 | P2 | not yet recruiting | NSCLC Stage IV | 105 | — |
| NIPU | NCT04300244 | P2 | active not recruiting | Cancer | 118 | PMID 39133306 |
| MOST-CIRCUIT | NCT04969887 | P2 | active not recruiting | Advanced Biliary Tract Cancer | 240 | PMID 40608313 |
| NIMBUS | NCT03789110 | P2 | active not recruiting | Breast Cancer | 30 | PMID 40360544 |
| EBIN | NCT03235245 | P2 | active not recruiting | Unresectable Stage III Melanoma | 271 | PMID 40449497 |
| CAPTUR | NCT03297606 | P2 | recruiting | Lymphoma, Non-Hodgkin | 720 | — |
| HER | NCT03650894 | P2 | active not recruiting | Breast Neoplasm Female | 30 | — |
| CLARA | NCT05215470 | P2 | active not recruiting | Renal Cancer Metastatic | 100 | — |
| LOW | NCT04933903 | P2 | recruiting | Non Small Cell Lung Cancer | 25 | — |
| CERAD-IMMUNE | NCT05504642 | P2 | withdrawn | Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases | 0 | — |
| RAD-IO | NCT05401786 | P2 | active not recruiting | Carcinoma, Non-Small-Cell Lung | 54 | — |
| VESTIGE | NCT03443856 | P2 | active not recruiting | Gastric and Esophagogastric Junction Adenocarcinoma | 197 | PMID 32083013 |
| CYTOSHRINK | NCT04090710 | P2 | active not recruiting | Metastatic Renal Cell Carcinoma | 66 | — |
| ICI | NCT04817254 | P2 | completed | Glioblastoma | 47 | — |
| PORTSIDE | NCT05926960 | P2 | terminated | Melanoma | 38 | — |
| NIPICOL | NCT03350126 | P2 | active not recruiting | Metastatic Cancer Colorectal | 57 | PMID 37269904 |
| INSPIRE | NCT04717154 | P2 | completed | Prostatic Neoplasms, Castration-Resistant | 69 | — |
| CheckMate 6DW | NCT05136677 | P2 | completed | Mesothelioma, Malignant | 102 | — |
| NEONIPIGA | NCT04006262 | P2 | active not recruiting | Localized Oesogastric Adenocarcimona | 32 | PMID 35969830 |
| SALIENT | NCT05284214 | P2 | withdrawn | Solid Tumor | 0 | — |
| VEXILLUM | NCT05219435 | P2 | completed | Urothelial Cancer | 25 | — |
| ROME | NCT04591431 | P2 | unknown | Breast Cancer | 400 | PMID 41963505 |
| OpACIN-neo | NCT02977052 | P2 | unknown | Malignant Melanoma Stage III | 186 | PMID 31160251 |
| PICASSO | NCT04988841 | P2 | completed | Melanoma | 70 | — |
| NIBIT-ML1 | NCT04250246 | P2 | unknown | Melanoma | 184 | PMID 24384533 |
| ATLAS | NCT04966676 | P2 | terminated | Non Small Cell Lung Cancer | 5 | — |
| MATISSE | NCT04620200 | P2 | completed | Cutaneous Squamous Cell Carcinoma | 50 | PMID 41062829 |
| CheckMate 650 | NCT02985957 | P2 | completed | Prostate Cancer | 351 | PMID 32916128 |
| ANZUP2001 | NCT05150236 | P2 | unknown | Prostatic Neoplasms | 93 | — |
| NIPINEC | NCT03591731 | P2 | completed | Neuroendocrine Carcinoma | 185 | PMID 41774886 |
| ENVASARC | NCT04480502 | P2 | unknown | Undifferentiated Pleomorphic Sarcoma | 207 | — |
| CheckMate142 | NCT02060188 | P2 | completed | Microsatellite Unstable Colorectal Cancer | 385 | PMID 28734759 |
| TOP2101 | NCT05144529 | P2 | terminated | Lung Cancer Metastatic | 19 | — |
| CheckPRO | NCT05655715 | P2 | completed | Prostate Cancer Metastatic | 90 | PMID 36717150 |
| HCC | NCT03510871 | P2 | completed | Hepatocellular Carcinoma (HCC) | 43 | PMID 40972843 |
| SECOMBIT | NCT02631447 | P2 | completed | Metastatic Melanoma | 251 | PMID 39315864 |
| NSCLC | NCT03739710 | P2 | completed | Neoplasms | 175 | — |
| BreastImmune03 | NCT03818685 | P2 | unknown | Breast Cancer | 95 | PMID 41314029 |
| CA209-260 | NCT02553642 | P2 | completed | Bladder Cancer | 81 | PMID 29489427 |
| IMPACT | NCT03570619 | P2 | completed | Metastatic Castration Resistant Prostate Cancer | 56 | — |
| CHINOREC | NCT04124601 | P2 | completed | Rectal Cancer | 80 | PMID 40844778 |
| NSCLC | NCT03285321 | P2 | completed | Non-small Cell Lung Cancer | 105 | PMID 38971369 |
| Luscid | NCT04571632 | P2 | unknown | Non Small Cell Lung Cancer | 36 | PMID 38954010 |
| BIOLUMA | NCT03083691 | P2 | completed | Carcinoma, Non-Small-Cell Lung | 90 | — |
| INFLUENCE | NCT05116917 | P2 | terminated | Pancreatic Cancer | 19 | — |
| CheckMate 848 | NCT03668119 | P2 | completed | Pan Tumor | 212 | PMID 39107131 |
| TOP1705 | NCT03573947 | P2 | completed | Non-small Cell Lung Cancer | 46 | — |
| NeAT Glio | NCT05074992 | P2 | terminated | Glioblastoma | 1 | — |
| CheckMate 592 | NCT03001882 | P2 | completed | Non-Small Cell Lung Cancer | 230 | — |
| TITAN-TCC | NCT03219775 | P2 | unknown | Transitional Cell Carcinoma | 169 | PMID 38722641 |
| CheCUP | NCT04131621 | P2 | unknown | Cancer of Unknown Primary Site | 194 | PMID 37875494 |
| UNISoN | NCT03177239 | P2 | unknown | Renal Cell Carcinoma | 85 | — |
| CheckPAC | NCT02866383 | P2 | completed | Metastatic Pancreatic Cancer | 160 | PMID 37744345 |
| TITAN-RCC | NCT02917772 | P2 | completed | Carcinoma, Renal Cell | 200 | PMID 37844597 |
| CRUCIAL | NCT03437200 | P2 | terminated | Inoperable œsophageal Cancer | 8 | — |
| CKS | NCT03219671 | P2 | unknown | Classic Kaposi Sarcoma | 20 | — |
| OPTIM | NCT03620123 | P2 | completed | Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 54 | — |
| SCLC | NCT03406715 | P2 | terminated | Small Cell Lung Cancer | 14 | — |
| ICON | NCT03409198 | P2 | completed | Breast Cancer | 82 | PMID 38242720 |
| FRACTION-GC | NCT02935634 | P2 | completed | Advanced Gastric Cancer | 190 | — |
| ILLUMINATE-206 | NCT03865082 | P2 | active not recruiting | Solid Tumor | 30 | — |
| CheckMate 714 | NCT02823574 | P2 | completed | Head and Neck Cancer | 425 | PMID 37022706 |
| EMERGE | NCT03989362 | P2 | completed | Cancer | 61 | — |
| CheckMate 568 | NCT02659059 | P2 | completed | Non-Small-Cell Lung Cancer | 324 | PMID 30785829 |
| INTEGA | NCT03409848 | P2 | completed | Gastric Cancer | 97 | PMID 32487035 |
| Zirconipi | NCT03313323 | P2 | unknown | Melanoma | 29 | — |
| NIMBLe | NCT03461952 | P2 | terminated | Advanced Solid Tumors | 4 | — |
| STIMULI | NCT02046733 | P2 | completed | Limited Stage Small Cell Lung Cancer | 222 | — |
| CheckMate 908 | NCT03130959 | P2 | completed | Various Advanced Cancer | 166 | PMID 36808285 |
| TRIPPLE-R | NCT04258150 | P2 | terminated | Pancreatic Cancer | 26 | PMID 36592507 |
| FRACTION-RCC | NCT02996110 | P2 | completed | Advanced Cancer | 182 | PMID 36328377 |
| RAMONA | NCT03416244 | P2 | completed | Esophageal Cancer | 66 | PMID 30871493 |
| STARVE-PC | NCT02601014 | P2 | completed | Prostate Cancer | 32 | PMID 33636027 |
| MAYA | NCT03832621 | P2 | completed | Metastatic Colorectal Cancer | 135 | PMID 35258987 |
| NSCLC | NCT06790303 | P2 | terminated | Neoplasms | 8 | — |
| GEM1402 | NCT02626962 | P2 | completed | Uveal Melanoma | 52 | PMID 33417511 |
| SQUINT | NCT03823625 | P2 | unknown | Squamous-Cell Lung Cancer | 112 | PMID 39836372 |
| CheckMate 069 | NCT01927419 | P2 | completed | Unresectable Melanoma | 142 | PMID 25891304 |
| MSS | NCT03271047 | P2 | completed | MSS | 75 | PMID 38600471 |
| BIONIKK | NCT02960906 | P2 | completed | Clear Cell Metastatic Renal Cell Carcinoma | 200 | PMID 35390339 |
| RADVAX | NCT03065179 | P2 | completed | Kidney Cancer Metastatic | 29 | — |
| CheckMate204 | NCT02320058 | P2 | completed | Melanoma | 119 | PMID 33880555 |
| CTLA-4 | NCT01804465 | P2 | completed | Prostate Cancer | 50 | PMID 33986125 |
| PROCLAIM | NCT03993379 | P2 | terminated | Solid Tumor | 3 | — |
| FRACTION-Lung | NCT02750514 | P2 | terminated | Advanced Cancer | 295 | — |
| INITIATE | NCT03048474 | P2 | completed | Malignant Pleural Mesothelioma | 36 | PMID 33166791 |
| BMS-986205 | NCT04007588 | P2 | withdrawn | Melanoma Stage III | 0 | — |
| MAPS2 | NCT02716272 | P2 | completed | Mesothelioma | 125 | PMID 30660609 |
| HF10 | NCT03153085 | P2 | completed | Melanoma Stage III | 28 | — |
| GRAY-B | NCT02115139 | P2 | completed | Melanoma | 58 | — |
| TOP1201 IPI | NCT01820754 | P2 | completed | Non Small Cell Lung Cancer | 24 | PMID 29258674 |
| SART | NCT01565837 | P2 | unknown | Melanoma | 50 | — |
| MDX-010 | NCT01323517 | P2 | completed | Melanoma | 26 | — |
| TriMix-Ipi | NCT01302496 | P2 | completed | Malignant Melanoma Stage III | 39 | PMID 32114500 |
| CTLA4 NY-ESO-1 | NCT01216696 | P2 | completed | Metastatic Melanoma | 25 | PMID 29306769 |
| ILP+/-IPI | NCT02094391 | P2 | completed | In-transit Metastases Melanoma Stage IIIB and IIIC | 4 | PMID 34132224 |
| IPI+RTS | NCT02662725 | P2 | completed | Melanoma | 73 | — |
| ICE | NCT01331525 | P2 | completed | Extensive Stage Small Cell Lung Cancer | 42 | — |
| GIPI | NCT01363206 | P2 | completed | Malignant Melanoma, Metastatic | 29 | PMID 32376721 |
| NIBIT-M1 | NCT01654692 | P2 | completed | Metastatic Malignant Melanoma | 86 | PMID 25538176 |
| DeCOG | NCT01355120 | P2 | completed | Ocular Melanoma | 171 | PMID 25761109 |
| NSCLC | NCT00527735 | P2 | completed | Lung Cancer | 334 | — |
| MDX-010 | NCT00289640 | P2 | completed | Melanoma | 210 | PMID 20004617 |
| BMS-734016 | NCT00135408 | P2 | completed | Malignant Melanoma | 115 | — |
Terminated and withdrawn Ipilimumab trials (153)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04929041suspendedTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
- NCT05457959withdrawnPeptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
- NCT04840589suspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
- NCT05928806suspendedAdvanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
- NCT04495010withdrawnNeoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- NCT03604991suspendedNivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
- NCT05504642withdrawnChemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
- NCT04151563withdrawnA Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- NCT03799445terminatedIpilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
- NCT06388369terminatedNeoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
- NCT03645928terminatedStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT05926960terminatedA Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- NCT03958383terminatedIT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
- NCT03274258terminatedPhase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
- NCT02668770terminatedIpilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
- NCT03520686terminatedNogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
- NCT05284214withdrawnSargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
- NCT04315155withdrawnEvaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
- NCT06410534withdrawnA Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
- NCT05199285terminatedA Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
- NCT04223648withdrawnProgrammed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
- NCT04781855withdrawnIpilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
- NCT04966676terminatedStudy of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
- NCT05921760terminatedIvosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
- NCT05909995terminatedInterventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
- NCT05144529terminatedA Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
- NCT02419495terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- NCT02408861terminatedNivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- NCT05220722terminatedPressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- NCT05200143terminatedStudy of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
- NCT04935229terminatedIntrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
- NCT05341349terminatedStereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
- NCT02681302terminatedCheck Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
- NCT04967196terminatedIpilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
- NCT03110107terminatedFirst-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- NCT04611126terminatedT-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
- NCT04239040terminatedGVAX Plus Checkpoint Blockade in Neuroblastoma
- NCT03552380terminatedStudy of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
- NCT04429321terminatedNivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
- NCT04060407withdrawnCD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
- NCT02846376terminatedSingle Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
- NCT04892043terminatedStudy of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
- NCT05116917terminatedImmunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
- NCT04203901terminatedDendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
- NCT04270864terminatedIntratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- NCT03978611terminatedA Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- NCT04899921terminatedTroriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
- NCT04185311terminatedIpilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
- NCT05074992terminatedA Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
- NCT04610658terminatedImmune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- NCT04635735terminatedStudy of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
- NCT04311710terminatedA Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
- NCT04319224terminatedVopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- NCT03126461withdrawnSAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
- NCT03437200terminatedCombination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
- NCT04655157terminatedSafety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
- NCT04894994terminatedFLX475 in Combination With Ipilimumab in Advanced Melanoma
- NCT05456165withdrawnStudy of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- NCT02978443terminatedA Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
- NCT04500548withdrawnTesting the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
- NCT03406715terminatedCombination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
- NCT03168464terminatedRadiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
- NCT01940809terminatedIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
- NCT03444753terminatedAn Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
- NCT03461952terminatedNivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
- NCT04840615terminatedIntratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
- NCT03251924terminatedA Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- NCT03425331terminatedBiomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
- NCT03420521terminatedNivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
- NCT04258150terminatedIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
- NCT04088500terminatedA Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
- NCT03903640terminatedOptune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
- NCT03663166terminatedRadiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
- NCT06790303terminatedPlatform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
- NCT03220009withdrawnNivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
- NCT04434560terminatedNeoadjuvant Immunotherapy in Brain Metastases
- NCT03445533terminatedA Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- NCT03693846terminatedNivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
- NCT03425461terminatedAnti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
- NCT04149275withdrawnCabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
- NCT03347123terminatedA Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- NCT03430791terminatedTrial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
- NCT02054520terminatedImmunotherapy Study for Patients With Stage IV Melanoma
- NCT03728465terminatedEvaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
- NCT03422094terminatedNeoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
- NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- NCT03526185terminatedA Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
- NCT03283046withdrawnStudy of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
- NCT03354962terminatedInduction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
- NCT03013491terminatedPROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- NCT03597282terminatedA Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
- NCT02675439terminatedSafety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
- NCT02097732terminatedIpilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
- NCT03707457terminatedBiomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
- NCT03724968terminatedNivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- NCT03993379terminatedPROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- NCT02506114terminatedNeoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
- NCT03767439withdrawnNivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
- NCT03982121withdrawnStudy of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
- NCT03297463withdrawnRadiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
- NCT02750514terminatedAn Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
- NCT02203604terminatedHigh-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
- NCT03565406terminatedA Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- NCT04007588withdrawnA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- NCT03091491terminatedStudy of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
- NCT03477864withdrawnStereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
- NCT03048136withdrawnA Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
- NCT02385669terminatedA Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
- NCT03026166terminatedA Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- NCT03509584terminatedPhase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
- NCT01970527terminatedPhase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
- NCT03342417terminatedCombination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
- NCT03203304terminatedStereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
- NCT02892734terminatedIpilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
- NCT02452281withdrawnPilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
- NCT01530984withdrawnIpilimumab and GMCSF Immunotherapy for Prostate Cancer
- NCT01988077terminatedClinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients
- NCT02723006terminatedStudy to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- NCT03326258withdrawnGlembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- NCT03149159withdrawnInvestigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
- NCT03009058terminatedStudy of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- NCT01377389terminatedIpilimumab + Androgen Depravation Therapy in Prostate Cancer
- NCT02736123withdrawnNeoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
- NCT02200562terminatedIpilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
- NCT01604889terminatedA Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
- NCT02210104withdrawnAdoptive Therapy Using Antigen-Specific CD4 T-Cells
- NCT02413827terminatedA Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
- NCT01696045terminatedPhase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
- NCT01409174terminatedIPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
- NCT01810016terminatedNY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
- NCT01984255terminatedA Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
- NCT01557114terminatedStudy of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
- NCT01730157terminatedRadioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
- NCT01838200terminatedPhase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
- NCT01856023terminatedHD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
- NCT01590082terminatedDoxycycline, Temozolomide and Ipilimumab in Melanoma
- NCT01769222terminatedIpilimumab and Local Radiation for Selected Solid Tumors
- NCT01689974terminatedPhase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
- NCT02009384terminatedIpilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
- NCT01689870withdrawnStudy of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
- NCT01709162terminatedStudy to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
- NCT01913691withdrawnStudy of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
- NCT01400451terminatedPh I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
- NCT01950195terminatedSRS (Stereotactic Radiosurgery) Plus Ipilimumab
- NCT01471197terminatedSafety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
- NCT00803374withdrawnCombination of Anti-CD137 & Ipilimumab in Patients With Melanoma
- NCT01510288terminatedPhase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
- NCT01409187withdrawnIPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
- NCT00732186withdrawnStudy of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
- NCT00089076terminatedMDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
- NCT00039091terminatedMonoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
- NCT00140855terminatedA Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
- NCT00357461withdrawnIpilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
All Ipilimumab trials (791)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05732389 | RESET-R | Immunotherapy in Patients With Early dMMR Rectal Cancer | P2 | recruiting | 39 | Odense University Hospital | Feb 2023 |
| NCT02498756 | Cytokine-induced Killer Study for Patients With Stage II Melanoma | P2 | not yet recruiting | 300 | The First People's Hospital of Changzhou | Aug 2015 | |
| NCT06999980 | Neo IRENIE | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | P2 | recruiting | 494 | Melanoma Institute Australia | Feb 2026 |
| NCT06492421 | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | P2 | recruiting | 90 | Second Affiliated Hospital of Guangzhou Medical University | Jul 2024 | |
| NCT06482801 | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | P2 | recruiting | 90 | Second Affiliated Hospital of Guangzhou Medical University | Jun 2024 | |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | P1/P2 | recruiting | 100 | Second Affiliated Hospital of Guangzhou Medical University | Nov 2021 | |
| NCT07403877 | TORCH-OPTIMA | Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer | P2 | not yet recruiting | 114 | Fudan University | Feb 2026 |
| NCT04196452 | DMTR | A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) | — | active not recruiting | 10 | Bristol-Myers Squibb | Aug 2019 |
| NCT06240143 | MARIANE | Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | P1/P2 | recruiting | 96 | The Netherlands Cancer Institute | Mar 2024 |
| NCT04248569 | DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | P1 | recruiting | 56 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Apr 2020 | |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | P3 | recruiting | 718 | SWOG Cancer Research Network | Jun 2026 | |
| NCT07444619 | A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | P1 | not yet recruiting | 18 | M.D. Anderson Cancer Center | Aug 2026 | |
| NCT07230613 | NEOREM-NEO-1 | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma | P2 | recruiting | 50 | UNICANCER | Jan 2026 |
| NCT06492408 | Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. | P2 | recruiting | 90 | Second Affiliated Hospital of Guangzhou Medical University | Jul 2024 | |
| NCT06483347 | Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT | P2 | recruiting | 90 | Second Affiliated Hospital of Guangzhou Medical University | Apr 2024 | |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | P2 | recruiting | 18 | Mayo Clinic | Apr 2026 | |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | P2/P3 | active not recruiting | 600 | National Cancer Institute (NCI) | Nov 2015 | |
| NCT03815890 | BELLINI | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | P2 | recruiting | 80 | The Netherlands Cancer Institute | Oct 2019 |
| NCT07338981 | The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. | P3 | not yet recruiting | 142 | Guliz Ozgun | Apr 2026 | |
| NCT03769155 | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma | P1 | active not recruiting | 41 | Emory University | Dec 2018 | |
| NCT06683755 | TRINITY | Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | P1/P2 | not yet recruiting | 30 | M.D. Anderson Cancer Center | May 2025 |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | P2 | recruiting | 57 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2018 | |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | P2 | recruiting | 81 | National Cancer Institute (NCI) | Jun 2022 | |
| NCT07000149 | eVOLVE-RCC02 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | P3 | active not recruiting | 1,116 | AstraZeneca | Jul 2025 |
| NCT07355205 | FLINN | First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | P2 | not yet recruiting | 26 | Washington University School of Medicine | Jun 2026 |
| NCT06364631 | CARE1 | CARE1 Pragmatic Clinical Trial | P3 | recruiting | 1,250 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2024 |
| NCT06794775 | SWE-NEO | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma | P3 | recruiting | 128 | Hildur Helgadottir | Jul 2025 |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | P1 | recruiting | 21 | Mayo Clinic | Jan 2024 | |
| NCT03017820 | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | P1 | recruiting | 99 | Mayo Clinic | Apr 2017 | |
| NCT03026140 | NICHE | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | P2 | recruiting | 353 | The Netherlands Cancer Institute | Mar 2017 |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | P1/P2 | recruiting | 361 | ModernaTX, Inc. | Sep 2022 | |
| NCT07293351 | RCC | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | P1/P2 | recruiting | 254 | Bristol-Myers Squibb | Mar 2026 |
| NCT06743126 | SUPRAME | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | P3 | recruiting | 360 | Immatics US, Inc. | Jan 2025 |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | P2/P3 | recruiting | 280 | Replimune, Inc. | Dec 2024 | |
| NCT07291076 | HCC | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | P1/P2 | recruiting | 198 | Bristol-Myers Squibb | Mar 2026 |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | P1/P2 | recruiting | 55 | University of Michigan Rogel Cancer Center | Aug 2025 | |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | P1 | recruiting | 18 | Washington University School of Medicine | Jan 2026 | |
| NCT03138161 | SAINT | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | P1/P2 | recruiting | 250 | Sarcoma Oncology Research Center, LLC | Apr 2017 |
| NCT07061379 | PROMOTING | Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen | — | recruiting | 144 | IRCCS San Raffaele | Jul 2025 |
| NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | P4 | recruiting | 90 | NYU Langone Health | Apr 2026 | |
| NCT07587827 | ODI-2001-01 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | P1 | not yet recruiting | 77 | Centre Georges Francois Leclerc | Nov 2026 |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | P2/P3 | recruiting | 135 | Linnaeus Therapeutics, Inc. | Aug 2025 | |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | P2/P3 | suspended | 427 | National Cancer Institute (NCI) | Oct 2022 | |
| NCT05457959 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | P1 | withdrawn | 0 | Jonsson Comprehensive Cancer Center | Dec 2024 | |
| NCT07188896 | RCC | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | recruiting | 120 | Brian Rini | Apr 2026 |
| NCT06926790 | GALAXY 3 | Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) | P2 | recruiting | 69 | The First Affiliated Hospital of Guangzhou Medical University | Feb 2025 |
| NCT06487156 | FINN | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | active not recruiting | 404 | Bristol-Myers Squibb | Oct 2023 |
| NCT04462406 | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | P2 | active not recruiting | 150 | ECOG-ACRIN Cancer Research Group | Feb 2021 | |
| NCT07430202 | FLC | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | P1 | not yet recruiting | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Aug 2026 |
| NCT06365619 | NeoRelapse | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | P2 | recruiting | 25 | University of Utah | Jun 2026 |
| NCT05176483 | STELLAR-002 | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | P1 | recruiting | 1,314 | Exelixis | Dec 2021 |
| NCT06889493 | NEC | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | P1 | recruiting | 36 | Peter Hosein, MD | May 2025 |
| NCT02950766 | NeoVax Plus Ipilimumab in Renal Cell Carcinoma | P1 | active not recruiting | 19 | Patrick Ott, MD, PhD | Mar 2019 | |
| NCT03999749 | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | P2 | active not recruiting | 71 | NYU Langone Health | Jun 2019 | |
| NCT06342037 | TONIC-3 | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial | P2 | recruiting | 60 | The Netherlands Cancer Institute | Jun 2024 |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | P1/P2 | recruiting | 434 | Vivace Therapeutics, Inc | Mar 2021 | |
| NCT06712927 | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | P2 | recruiting | 60 | Stanford University | Aug 2025 | |
| NCT04283890 | CHOPIN | PHP and Immunotherapy in Metastasized UM | P1/P2 | active not recruiting | 83 | Leiden University Medical Center | Dec 2019 |
| NCT07401875 | SHARK | A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) | P1 | recruiting | 35 | M.D. Anderson Cancer Center | Mar 2026 |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | P2 | recruiting | 29 | H. Lee Moffitt Cancer Center and Research Institute | Sep 2020 | |
| NCT07563738 | TEADCO | A 2-part Phase 1/2 Open-label Trial on ODM-212 | P1/P2 | recruiting | 229 | Orion Corporation, Orion Pharma | Mar 2026 |
| NCT03340129 | ABC-X | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | P2 | recruiting | 218 | Melanoma Institute Australia | Aug 2019 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | recruiting | 1,500 | Bristol-Myers Squibb | Aug 2019 | |
| NCT00586391 | CRETI-NH | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | P1 | active not recruiting | 14 | Baylor College of Medicine | Feb 2009 |
| NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | P1 | recruiting | 60 | Memorial Sloan Kettering Cancer Center | Apr 2026 | |
| NCT05148546 | NESCIO | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | P2 | active not recruiting | 69 | The Netherlands Cancer Institute | Apr 2022 |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | P1 | not yet recruiting | 15 | Inge Marie Svane | May 2026 | |
| NCT07422753 | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC | P2 | recruiting | 36 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Mar 2026 | |
| NCT05536141 | ARC-20 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | P1 | recruiting | 362 | Arcus Biosciences, Inc. | Oct 2022 |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | P3 | recruiting | 226 | NRG Oncology | Feb 2026 | |
| NCT07233668 | IVE in mRCC | Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC | N/A | not yet recruiting | 172 | Seoul National University Hospital | Dec 2025 |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | P1/P2 | active not recruiting | 49 | Susan Chi, MD | Aug 2023 | |
| NCT04551430 | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | P2 | active not recruiting | 105 | Washington University School of Medicine | Jan 2021 | |
| NCT06747845 | ParpVax2 | Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy | P2 | recruiting | 68 | Abramson Cancer Center at Penn Medicine | May 2025 |
| NCT06250335 | ICB | Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients | P2 | active not recruiting | 4 | M.D. Anderson Cancer Center | Mar 2024 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | P2 | recruiting | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2025 | |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | P1/P2 | recruiting | 126 | 7 Hills Pharma, LLC | Aug 2024 | |
| NCT06031233 | MINUTE | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | recruiting | 776 | Isala | Sep 2023 |
| NCT02693535 | TAPUR | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | recruiting | 4,200 | American Society of Clinical Oncology | Mar 2016 |
| NCT02374242 | ABC | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases | P2 | active not recruiting | 76 | Melanoma Institute Australia | Nov 2014 |
| NCT04949113 | NADINA | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | P3 | active not recruiting | 423 | The Netherlands Cancer Institute | Jul 2021 |
| NCT06708949 | RCC | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | P2 | recruiting | 15 | M.D. Anderson Cancer Center | Mar 2025 |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | P2 | recruiting | 90 | H. Lee Moffitt Cancer Center and Research Institute | May 2024 | |
| NCT06097728 | eVOLVE-Meso | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | P3 | active not recruiting | 861 | AstraZeneca | Nov 2023 |
| NCT03907852 | TC-210 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | P1/P2 | active not recruiting | 57 | TCR2 Therapeutics | Apr 2019 |
| NCT06946797 | CheckMate-1533 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | P2 | active not recruiting | 76 | Bristol-Myers Squibb | Sep 2025 |
| NCT07227012 | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. | P1/P2 | recruiting | 138 | Pfizer | Dec 2025 | |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | P1 | active not recruiting | 11 | Dana-Farber Cancer Institute | Nov 2020 | |
| NCT07147101 | HCC-IM-1 | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | recruiting | 150 | Fudan University | Sep 2025 |
| NCT06490536 | The Sagittarius Trial | P3 | recruiting | 700 | IFOM ETS - The AIRC Institute of Molecular Oncology | Oct 2024 | |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | P1 | suspended | 66 | National Cancer Institute (NCI) | Feb 2022 | |
| NCT04709276 | CHAMP | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer | P2 | active not recruiting | 41 | Andrew J. Armstrong, MD | Jun 2021 |
| NCT07128680 | EXL01 | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | P1 | recruiting | 33 | City of Hope Medical Center | Mar 2026 |
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | P2 | recruiting | 49 | Tianjin Medical University Cancer Institute and Hospital | Mar 2026 | |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | P1/P2 | recruiting | 33 | West China Hospital | Feb 2026 | |
| NCT06514651 | MAQ-001 in Patients With Advanced Solid Tumors | P1 | recruiting | 30 | MabQuest SA | Jun 2024 | |
| NCT03546686 | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | P2 | active not recruiting | 51 | University of Texas Southwestern Medical Center | Nov 2019 | |
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | P2 | active not recruiting | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Oct 2019 | |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | P1/P2 | recruiting | 542 | Sanofi | Nov 2022 | |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | P2 | recruiting | 50 | National Cancer Institute (NCI) | Feb 2024 | |
| NCT05327686 | SAMURAI | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | P2 | recruiting | 240 | NRG Oncology | Feb 2023 |
| NCT03563729 | MEMBRAINS | Melanoma Metastasized to the Brain and Steroids | P2 | recruiting | 80 | Inge Marie Svane | Jun 2018 |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | P2 | recruiting | 43 | Tianjin Medical University Cancer Institute and Hospital | Mar 2026 | |
| NCT04730544 | NIPISAFE | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | P2 | active not recruiting | 96 | GERCOR - Multidisciplinary Oncology Cooperative Group | May 2021 |
| NCT04141644 | Osi+Ipi | Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC | P1 | active not recruiting | 24 | University of Utah | Aug 2020 |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | P2 | recruiting | 112 | Hospital Israelita Albert Einstein | Aug 2022 | |
| NCT07422779 | MAK | Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | N/A | recruiting | 100 | Institute of Oncology Ljubljana | Mar 2022 |
| NCT02703623 | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | P2 | active not recruiting | 196 | M.D. Anderson Cancer Center | May 2016 | |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | P1 | recruiting | 300 | National Cancer Institute (NCI) | Jul 2019 | |
| NCT07487662 | ACTION-001 | TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk | P2 | not yet recruiting | 105 | Sun Yat-sen University | Mar 2026 |
| NCT07394062 | ALCG-01 | Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) | — | recruiting | 400 | Gazi University | Feb 2026 |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | P2 | recruiting | 105 | NYU Langone Health | Feb 2023 | |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | P3 | active not recruiting | 1,175 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | P2/P3 | active not recruiting | 420 | IDEAYA Biosciences | Oct 2023 | |
| NCT07134842 | WinGlio-ipi | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. | P1 | recruiting | 16 | University College, London | Jul 2025 |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | P2 | recruiting | 37 | Massachusetts General Hospital | Sep 2023 | |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | P1 | recruiting | 15 | University of Hawaii | Apr 2026 | |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | P2 | recruiting | 99 | Emory University | Oct 2025 | |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | P2 | recruiting | 20 | M.D. Anderson Cancer Center | Sep 2022 | |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | P1 | recruiting | 36 | Carlo Contreras | Oct 2021 | |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | P2 | active not recruiting | 35 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT04013542 | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | P1 | active not recruiting | 21 | M.D. Anderson Cancer Center | Sep 2019 | |
| NCT03646617 | RadVax | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | P2 | recruiting | 54 | Abramson Cancer Center at Penn Medicine | Nov 2018 |
| NCT03223155 | COSINR | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer | P1 | active not recruiting | 78 | University of Chicago | Sep 2017 |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | P1/P2 | active not recruiting | 80 | M.D. Anderson Cancer Center | Dec 2016 | |
| NCT02925234 | DRUP | The Drug Rediscovery Protocol (DRUP Trial) | P2 | recruiting | 1,550 | The Netherlands Cancer Institute | Aug 2016 |
| NCT05012254 | NIVIPI-Brain | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | P2 | active not recruiting | 71 | Fundación GECP | Nov 2021 |
| NCT03690986 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | P1 | recruiting | 50 | Emory University | Nov 2018 | |
| NCT03406247 | ADJORL1 | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | P2 | recruiting | 140 | Gustave Roussy, Cancer Campus, Grand Paris | Feb 2018 |
| NCT05928806 | ARCITECT | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | P2 | suspended | 120 | Michael B. Atkins, MD | Sep 2023 |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | P1/P2 | active not recruiting | 46 | H. Lee Moffitt Cancer Center and Research Institute | Apr 2021 | |
| NCT03307616 | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | P2 | active not recruiting | 32 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT02259621 | NA_00092076 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | P2 | active not recruiting | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2014 |
| NCT04495010 | CheckMate 7UA | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | P2 | withdrawn | 0 | Bristol-Myers Squibb | Mar 2021 |
| NCT06364917 | DISCERN | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | P2 | recruiting | 24 | University of Alabama at Birmingham | May 2025 |
| NCT06594991 | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | P2 | recruiting | 88 | Memorial Sloan Kettering Cancer Center | Sep 2024 | |
| NCT05310643 | NIPIRESCUE | Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | P2 | recruiting | 30 | GERCOR - Multidisciplinary Oncology Cooperative Group | May 2022 |
| NCT03233139 | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies | P1 | active not recruiting | 146 | Regeneron Pharmaceuticals | Jun 2017 | |
| NCT02530463 | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome | P2 | active not recruiting | 99 | M.D. Anderson Cancer Center | Sep 2015 | |
| NCT05200988 | Indi-Blade | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC | P2 | active not recruiting | 50 | The Netherlands Cancer Institute | Mar 2022 |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | Early P1 | recruiting | 12 | Fox Chase Cancer Center | Nov 2022 | |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | P2 | recruiting | 35 | University of California, Irvine | Aug 2020 | |
| NCT06377111 | A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma | P1 | active not recruiting | 12 | University Health Network, Toronto | Jun 2024 | |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | P1/P2 | recruiting | 134 | Neonc Technologies, Inc. | Nov 2023 | |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | P2 | recruiting | 54 | Vanderbilt-Ingram Cancer Center | Dec 2022 | |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | P2 | recruiting | 112 | SWOG Cancer Research Network | Jan 2021 | |
| NCT03061539 | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | P2 | active not recruiting | 380 | University College, London | Feb 2018 | |
| NCT04117087 | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | P1 | active not recruiting | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2020 | |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | P2 | active not recruiting | 798 | National Cancer Institute (NCI) | Jan 2017 | |
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | P2 | recruiting | 20 | Memorial Sloan Kettering Cancer Center | May 2022 | |
| NCT05144854 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | P3 | active not recruiting | 626 | Ono Pharmaceutical Co., Ltd. | Nov 2021 | |
| NCT04317105 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | P1/P2 | active not recruiting | 54 | National Cancer Institute (NCI) | Jul 2020 | |
| NCT03449108 | TNBC | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | P2 | active not recruiting | 30 | M.D. Anderson Cancer Center | Apr 2018 |
| NCT03104439 | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | P2 | active not recruiting | 84 | Massachusetts General Hospital | May 2017 | |
| NCT03122522 | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | P2 | active not recruiting | 70 | Memorial Sloan Kettering Cancer Center | Apr 2017 | |
| NCT05715229 | G360-IIT | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | P2 | recruiting | 108 | Hackensack Meridian Health | Sep 2023 |
| NCT02785952 | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | P3 | active not recruiting | 275 | SWOG Cancer Research Network | Dec 2015 | |
| NCT05141721 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | P2/P3 | active not recruiting | 700 | Seattle Project Corporation | Feb 2022 | |
| NCT03391869 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | P3 | active not recruiting | 339 | M.D. Anderson Cancer Center | Dec 2017 | |
| NCT05597800 | LUNGVIR | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | P2 | not yet recruiting | 105 | Universita di Verona | Feb 2023 |
| NCT04996823 | Axitinib + Ipilimumab in Advanced Melanoma | P2 | recruiting | 25 | H. Lee Moffitt Cancer Center and Research Institute | Aug 2021 | |
| NCT02314169 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | P2 | active not recruiting | 143 | National Cancer Institute (NCI) | May 2015 | |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | P1/P2 | active not recruiting | 38 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT01134614 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | P2 | active not recruiting | 245 | National Cancer Institute (NCI) | Dec 2010 | |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | P2 | active not recruiting | 88 | National Cancer Institute (NCI) | Jan 2013 | |
| NCT04300244 | NIPU | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | P2 | active not recruiting | 118 | Åslaug Helland | May 2020 |
| NCT05289193 | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | P2 | active not recruiting | 28 | Memorial Sloan Kettering Cancer Center | Mar 2022 | |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | P3 | active not recruiting | 437 | Bristol-Myers Squibb | Jun 2019 | |
| NCT04969887 | MOST-CIRCUIT | Combination Immunotherapy in Rare Cancers Under InvesTigation | P2 | active not recruiting | 240 | Olivia Newton-John Cancer Research Institute | Aug 2021 |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | P2 | recruiting | 314 | National Cancer Institute (NCI) | May 2019 | |
| NCT03789110 | NIMBUS | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | P2 | active not recruiting | 30 | Dana-Farber Cancer Institute | Mar 2019 |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | P3 | active not recruiting | 1,673 | National Cancer Institute (NCI) | Jun 2011 | |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | P1/P2 | recruiting | 25 | Vanderbilt-Ingram Cancer Center | May 2023 | |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | P1/P2 | recruiting | 16 | National Cancer Institute (NCI) | Jul 2024 | |
| NCT03816358 | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | P1 | active not recruiting | 74 | National Cancer Institute (NCI) | Dec 2019 | |
| NCT03937219 | COSMIC-313 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | P3 | active not recruiting | 855 | Exelixis | Jun 2019 |
| NCT03235245 | EBIN | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | P2 | active not recruiting | 271 | European Organisation for Research and Treatment of Cancer - EORTC | Oct 2018 |
| NCT03520491 | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | P2 | active not recruiting | 52 | Memorial Sloan Kettering Cancer Center | Apr 2018 | |
| NCT03297606 | CAPTUR | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | P2 | recruiting | 720 | Canadian Cancer Trials Group | Mar 2018 |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | P3 | active not recruiting | 1,301 | National Cancer Institute (NCI) | Nov 2015 | |
| NCT04464759 | LIMIT | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | P1/P2 | recruiting | 94 | Ravi Amaravadi, MD | Oct 2020 |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | P1 | recruiting | 18 | Emory University | Dec 2025 | |
| NCT06353646 | XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer | N/A | recruiting | 28 | Wu Wenming | Mar 2024 | |
| NCT05721846 | CheckVAC | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer | P1 | active not recruiting | 20 | Inna Chen, MD | May 2023 |
| NCT05188118 | Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Early P1 | recruiting | 20 | Icahn School of Medicine at Mount Sinai | Feb 2023 | |
| NCT04751370 | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | P2 | active not recruiting | 31 | National Cancer Institute (NCI) | Feb 2022 | |
| NCT04606316 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | P1 | active not recruiting | 63 | Patrick Wen, MD | Feb 2021 | |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | P2 | active not recruiting | 37 | National Cancer Institute (NCI) | Dec 2020 | |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | P1 | active not recruiting | 65 | M.D. Anderson Cancer Center | Aug 2020 | |
| NCT04091750 | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | P2 | active not recruiting | 14 | Georgetown University | Mar 2020 | |
| NCT04043195 | NSCLC | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | P1/P2 | active not recruiting | 30 | Hatim Husain | Aug 2019 |
| NCT03912064 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | P1 | active not recruiting | 25 | Dana-Farber Cancer Institute | Jul 2019 | |
| NCT03604991 | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery | P2/P3 | suspended | 278 | National Cancer Institute (NCI) | May 2019 | |
| NCT03650894 | HER | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | P2 | active not recruiting | 30 | Providence Health & Services | Apr 2019 |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | P2 | active not recruiting | 100 | Dana-Farber Cancer Institute | Dec 2017 | |
| NCT02919683 | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | P2 | active not recruiting | 30 | Dana-Farber Cancer Institute | Nov 2016 | |
| NCT02812524 | Ipilimumab for Head and Neck Cancer Patients | P1 | active not recruiting | 18 | Providence Health & Services | Nov 2016 | |
| NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | Early P1 | active not recruiting | 104 | M.D. Anderson Cancer Center | Nov 2014 | |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | P1/P2 | active not recruiting | 146 | National Cancer Institute (NCI) | Mar 2014 | |
| NCT02068196 | Ipi4 | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. | P4 | active not recruiting | 150 | Oslo University Hospital | Jan 2014 |
| NCT02020070 | Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy | P2 | active not recruiting | 16 | Memorial Sloan Kettering Cancer Center | Dec 2013 | |
| NCT03776487 | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | P2 | active not recruiting | 32 | M.D. Anderson Cancer Center | Jan 2019 | |
| NCT04413123 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | P2 | active not recruiting | 60 | Bradley A. McGregor, MD | Nov 2020 | |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | P3 | active not recruiting | 267 | National Cancer Institute (NCI) | Sep 2015 | |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | P2 | active not recruiting | 11 | National Cancer Institute (NCI) | Feb 2020 | |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | P2 | recruiting | 26 | Alliance for Clinical Trials in Oncology | Nov 2024 | |
| NCT05215470 | CLARA | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | P2 | active not recruiting | 100 | Hospital das Clínicas de Ribeirão Preto | Jan 2022 |
| NCT03233152 | GlitIpNi | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. | P1/P2 | active not recruiting | 110 | Universitair Ziekenhuis Brussel | Nov 2016 |
| NCT05501054 | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | P1/P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Feb 2023 | |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | P2 | active not recruiting | 30 | Massachusetts General Hospital | May 2020 | |
| NCT03693014 | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | P2 | active not recruiting | 69 | Memorial Sloan Kettering Cancer Center | Oct 2018 | |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | P1 | recruiting | 28 | Osel, Inc. | Jun 2024 | |
| NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | P2 | active not recruiting | 80 | Dan Zandberg | Dec 2019 | |
| NCT04933903 | LOW | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | P2 | recruiting | 25 | Brown University | Oct 2021 |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | P2 | active not recruiting | 46 | Brown University | Apr 2018 | |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | P1 | active not recruiting | 152 | National Cancer Institute (NCI) | Jul 2015 | |
| NCT01688492 | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | P1/P2 | active not recruiting | 54 | Memorial Sloan Kettering Cancer Center | Sep 2012 | |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | P1 | active not recruiting | 20 | City of Hope Medical Center | Dec 2019 | |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | P1 | active not recruiting | 12 | National Cancer Institute (NCI) | Nov 2019 | |
| NCT03071406 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | P2 | active not recruiting | 50 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2017 | |
| NCT02453620 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | P1 | active not recruiting | 57 | National Cancer Institute (NCI) | Feb 2016 | |
| NCT04013854 | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | P2 | active not recruiting | 67 | Abramson Cancer Center at Penn Medicine | Jan 2020 | |
| NCT03377023 | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | P1/P2 | active not recruiting | 66 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2018 | |
| NCT04079712 | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | P2 | active not recruiting | 17 | National Cancer Institute (NCI) | Aug 2020 | |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | P1 | active not recruiting | 54 | National Cancer Institute (NCI) | Sep 2017 | |
| NCT04938232 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | P2 | active not recruiting | 13 | Dana-Farber Cancer Institute | Jun 2021 | |
| NCT03463408 | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | Early P1 | active not recruiting | 14 | University of Rochester | Jul 2018 | |
| NCT05504642 | CERAD-IMMUNE | Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients | P2 | withdrawn | 0 | Universitätsklinikum Köln | Nov 2023 |
| NCT03844256 | CRIMI | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study | P1/P2 | recruiting | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Jan 2019 |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | P1/P2 | active not recruiting | 64 | Lantern Pharma Inc. | Jun 2023 | |
| NCT02879695 | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | P1 | active not recruiting | 28 | National Cancer Institute (NCI) | Oct 2017 | |
| NCT04039607 | CheckMate 9DW | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | P3 | active not recruiting | 732 | Bristol-Myers Squibb | Sep 2019 |
| NCT03502733 | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | P1 | active not recruiting | 64 | National Cancer Institute (NCI) | Aug 2018 | |
| NCT05401786 | RAD-IO | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | P2 | active not recruiting | 54 | The Netherlands Cancer Institute | Jan 2023 |
| NCT05262556 | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas | P1 | active not recruiting | 15 | Amr Mohamed MD | Dec 2022 | |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | P2 | active not recruiting | 45 | Dana-Farber Cancer Institute | Aug 2020 | |
| NCT03443856 | VESTIGE | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence | P2 | active not recruiting | 197 | European Organisation for Research and Treatment of Cancer - EORTC | Jul 2019 |
| NCT03719131 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | P2 | active not recruiting | 15 | Emory University | Jun 2019 | |
| NCT02743819 | Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma | P2 | active not recruiting | 70 | University of Chicago | Jun 2016 | |
| NCT03203473 | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | P2 | active not recruiting | 85 | Toni Choueiri, MD | Oct 2017 | |
| NCT06049576 | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | P1 | active not recruiting | 31 | City of Hope Medical Center | Oct 2023 | |
| NCT04008030 | CheckMate 8HW | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | P3 | active not recruiting | 839 | Bristol-Myers Squibb | Aug 2019 |
| NCT04042753 | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | P2 | completed | 10 | Memorial Sloan Kettering Cancer Center | Jul 2019 | |
| NCT03166397 | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | P2 | unknown | 30 | Sheba Medical Center | Jun 2017 | |
| NCT02648997 | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | P2 | active not recruiting | 40 | Dana-Farber Cancer Institute | Mar 2016 | |
| NCT01676649 | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | P2 | unknown | 30 | Jewish General Hospital | Nov 2012 | |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | P2 | active not recruiting | 66 | National Cancer Institute LAO | Oct 2023 | |
| NCT03036098 | CheckMate901 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | P3 | active not recruiting | 1,314 | Bristol-Myers Squibb | Mar 2017 |
| NCT04151563 | CheckMate 79X | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | P1/P2 | withdrawn | 0 | Bristol-Myers Squibb | Apr 2021 |
| NCT04090710 | CYTOSHRINK | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | P2 | active not recruiting | 66 | Ontario Clinical Oncology Group (OCOG) | Jan 2020 |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | P2 | terminated | 37 | M.D. Anderson Cancer Center | Jul 2019 | |
| NCT04817254 | ICI | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | P2 | completed | 47 | National Cancer Institute (NCI) | Dec 2021 |
| NCT06388369 | NEPI | Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer | P1/P2 | terminated | 1 | University Hospital, Essen | Aug 2025 |
| NCT04495257 | RCC | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | P1 | completed | 26 | Yale University | Sep 2020 |
| NCT07215962 | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% | — | active not recruiting | 300 | Bristol-Myers Squibb | Nov 2024 | |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | P2 | terminated | 225 | Iovance Biotherapeutics, Inc. | May 2019 | |
| NCT05926960 | PORTSIDE | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | P2 | terminated | 38 | Pfizer | Jun 2023 |
| NCT06163820 | BETTER | Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | P1/P2 | recruiting | 46 | Melanoma and Skin Cancer Trials Limited | May 2025 |
| NCT07526961 | Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland | — | completed | 240 | Bristol-Myers Squibb | Dec 2025 | |
| NCT03141177 | CheckMate 9ER | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | P3 | active not recruiting | 701 | Bristol-Myers Squibb | Jul 2017 |
| NCT05598853 | IT-IO | Intrathecal Double Checkpoint Inhibition | P1 | active not recruiting | 26 | University of Zurich | Nov 2022 |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | P1/P2 | active not recruiting | 70 | Dan Zandberg | Jun 2020 | |
| NCT03670056 | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | P2 | active not recruiting | 25 | Yale University | Dec 2018 | |
| NCT03350126 | NIPICOL | iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab | P2 | active not recruiting | 57 | GERCOR - Multidisciplinary Oncology Cooperative Group | Dec 2017 |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | P1/P2 | active not recruiting | 35 | BioInvent International AB | Dec 2024 | |
| NCT03707808 | myDAvIpNi | Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab | P1/P2 | recruiting | 18 | Universitair Ziekenhuis Brussel | Jan 2018 |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | P2/P3 | completed | 159 | National Cancer Institute (NCI) | Sep 2020 | |
| NCT04717154 | INSPIRE | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | P2 | completed | 69 | Radboud University Medical Center | Jan 2021 |
| NCT04362839 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | P1 | completed | 39 | City of Hope Medical Center | May 2020 | |
| NCT03958383 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | P1/P2 | terminated | 8 | University of Wisconsin, Madison | Jan 2020 | |
| NCT03400332 | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | P1/P2 | completed | 281 | Bristol-Myers Squibb | Feb 2018 | |
| NCT03245892 | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | P1 | completed | 27 | Memorial Sloan Kettering Cancer Center | Aug 2017 | |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | P2 | terminated | 10 | M.D. Anderson Cancer Center | Dec 2017 | |
| NCT05136677 | CheckMate 6DW | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants | P2 | completed | 102 | Bristol-Myers Squibb | Jan 2022 |
| NCT07091695 | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | — | completed | 100 | Bristol-Myers Squibb | May 2025 | |
| NCT02668770 | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | P1 | terminated | 28 | M.D. Anderson Cancer Center | May 2016 | |
| NCT04006262 | NEONIPIGA | Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | P2 | active not recruiting | 32 | GERCOR - Multidisciplinary Oncology Cooperative Group | Oct 2019 |
| NCT03469960 | DICIPLE | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | P3 | completed | 265 | Intergroupe Francophone de Cancerologie Thoracique | May 2018 |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | P3 | terminated | 102 | ImmunityBio, Inc. | May 2018 | |
| NCT05284214 | SALIENT | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors | P2 | withdrawn | 0 | Partner Therapeutics, Inc. | Jan 2024 |
| NCT04315155 | BENEFIT | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation | P1 | withdrawn | 0 | University of Utah | Oct 2020 |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | P1/P2 | active not recruiting | 33 | Vyriad, Inc. | Apr 2019 | |
| NCT04887870 | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study | P2/P3 | completed | 52 | Mirati Therapeutics Inc. | Jun 2021 | |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | P2 | completed | 378 | Immunocore Ltd | Oct 2017 | |
| NCT06410534 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Sep 2025 | |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | P2 | terminated | 15 | Academic and Community Cancer Research United | Jan 2023 | |
| NCT04741438 | RAR-Immune | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype | P3 | unknown | 96 | Centre Leon Berard | Mar 2021 |
| NCT03873818 | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | P2 | completed | 24 | M.D. Anderson Cancer Center | Feb 2019 | |
| NCT01701674 | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | N/A | completed | 13 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2012 | |
| NCT03146650 | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | P2 | unknown | 25 | Northwestern University | May 2017 | |
| NCT04787991 | REVOLUTION | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | P1 | completed | 45 | Cancer Insight, LLC | Aug 2021 |
| NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | P1 | unknown | 34 | M.D. Anderson Cancer Center | Sep 2017 | |
| NCT04465643 | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | P1 | completed | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2021 | |
| NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | P2 | completed | 100 | National Cancer Institute (NCI) | Aug 2015 | |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | P1/P2 | completed | 68 | Bristol-Myers Squibb | Aug 2022 | |
| NCT05219435 | VEXILLUM | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | P2 | completed | 25 | Spanish Oncology Genito-Urinary Group | Jul 2022 |
| NCT04107168 | Microbiome Immunotherapy Toxicity and Response Evaluation | — | unknown | 1,800 | CCTU- Cancer Theme | Jul 2020 | |
| NCT07024862 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | — | active not recruiting | 100 | Bristol-Myers Squibb | Oct 2024 | |
| NCT04334759 | DREAM3R | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | P3 | completed | 214 | PrECOG, LLC. | Feb 2021 |
| NCT04591431 | ROME | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | P2 | unknown | 400 | Fondazione per la Medicina Personalizzata | Oct 2020 |
| NCT02977052 | OpACIN-neo | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | P2 | unknown | 186 | The Netherlands Cancer Institute | Nov 2016 |
| NCT02437279 | OpACIN | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients | P1 | unknown | 20 | The Netherlands Cancer Institute | Nov 2016 |
| NCT05444530 | A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | P1 | completed | 14 | Janssen Research & Development, LLC | Jul 2022 | |
| NCT05014776 | Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | P2 | completed | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Aug 2022 | |
| NCT05665348 | TRIPLET | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy | P2/P3 | completed | 229 | Federation Francophone de Cancerologie Digestive | Mar 2023 |
| NCT03388632 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | P1 | completed | 31 | National Cancer Institute (NCI) | Feb 2018 | |
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | P2 | completed | 74 | Swiss Cancer Institute | Dec 2017 | |
| NCT04988841 | PICASSO | Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma | P2 | completed | 70 | Assistance Publique - Hôpitaux de Paris | Jan 2022 |
| NCT04021043 | BMS-986156 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | P1/P2 | completed | 51 | M.D. Anderson Cancer Center | Aug 2019 |
| NCT07079644 | Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database | — | completed | 678 | Bristol-Myers Squibb | Nov 2024 | |
| NCT04250246 | NIBIT-ML1 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | P2 | unknown | 184 | Italian Network for Tumor Biotherapy Foundation | Mar 2020 |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | P3 | completed | 1,096 | Bristol-Myers Squibb | Oct 2014 | |
| NCT04850755 | A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies | P1 | completed | 11 | National University Hospital, Singapore | Mar 2021 | |
| NCT04223648 | MEDI4736 | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma | Early P1 | withdrawn | 0 | Yale University | Aug 2020 |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Jul 2022 | |
| NCT04966676 | ATLAS | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer | P2 | terminated | 5 | University Health Network, Toronto | Jan 2022 |
| NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | P1/P2 | completed | 229 | Bristol-Myers Squibb | May 2018 | |
| NCT01950390 | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | P2 | completed | 169 | National Cancer Institute (NCI) | Jan 2014 | |
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | P2 | completed | 164 | Michael B. Atkins, MD | Apr 2017 | |
| NCT02922764 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | P1 | completed | 146 | Inspirna, Inc. | Nov 2016 | |
| NCT03143153 | CheckMate 648 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin | P3 | completed | 970 | Bristol-Myers Squibb | Jun 2017 |
| NCT04620200 | MATISSE | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery | P2 | completed | 50 | The Netherlands Cancer Institute | Aug 2020 |
| NCT03387761 | NABUCCO | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | P1 | completed | 54 | The Netherlands Cancer Institute | Jan 2018 |
| NCT02985957 | CheckMate 650 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | P2 | completed | 351 | Bristol-Myers Squibb | Mar 2017 |
| NCT05150236 | ANZUP2001 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | P2 | unknown | 93 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Apr 2022 |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | P2 | unknown | 35 | European Institute of Oncology | Mar 2019 | |
| NCT03879122 | A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer | P2/P3 | unknown | 135 | Spanish Oncology Genito-Urinary Group | Feb 2019 | |
| NCT03472586 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | P2 | completed | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | May 2018 | |
| NCT03097939 | Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | P2 | unknown | 113 | National Cancer Centre, Singapore | Mar 2017 | |
| NCT03458455 | TREATMENT | Improved Therapy Response Assessment in Metastatic Brain Tumors | — | unknown | 200 | Oslo University Hospital | Mar 2013 |
| NCT03172624 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | P2 | completed | 64 | Memorial Sloan Kettering Cancer Center | May 2017 | |
| NCT04290546 | CIML NK Cell in Head & Neck Cancer | P1 | completed | 11 | Dana-Farber Cancer Institute | Jul 2020 | |
| NCT03591731 | NIPINEC | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | P2 | completed | 185 | Intergroupe Francophone de Cancerologie Thoracique | Jan 2019 |
| NCT02998528 | CheckMate 816 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 505 | Bristol-Myers Squibb | Mar 2017 |
| NCT04247165 | LAPTOP | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. | P1/P2 | completed | 55 | Herlev Hospital | Jun 2020 |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | P1 | completed | 29 | M.D. Anderson Cancer Center | Oct 2018 | |
| NCT03442569 | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | P2 | completed | 56 | UNC Lineberger Comprehensive Cancer Center | Mar 2018 | |
| NCT04823403 | HIPANIV | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma | P1 | recruiting | 27 | Gustave Roussy, Cancer Campus, Grand Paris | Nov 2020 |
| NCT04133948 | DONIMI | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma | P1/P2 | completed | 44 | The Netherlands Cancer Institute | Jan 2020 |
| NCT04026412 | CheckMate73L | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery | P3 | completed | 925 | Bristol-Myers Squibb | Oct 2019 |
| NCT05921760 | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | P1/P2 | terminated | 7 | Servier Bio-Innovation LLC | Oct 2023 | |
| NCT01928394 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | P1/P2 | completed | 1,163 | Bristol-Myers Squibb | Oct 2013 | |
| NCT03158129 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | P2 | completed | 101 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT01658878 | CheckMate040 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | P1/P2 | completed | 657 | Bristol-Myers Squibb | Oct 2012 |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | P1 | terminated | 8 | Incyte Corporation | Aug 2023 | |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | P1 | completed | 26 | M.D. Anderson Cancer Center | Sep 2018 | |
| NCT03369223 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | P1/P2 | completed | 356 | Bristol-Myers Squibb | Dec 2017 | |
| NCT03377361 | CheckMate 9N9 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | P1/P2 | completed | 325 | Bristol-Myers Squibb | Jan 2018 |
| NCT04480502 | ENVASARC | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | P2 | unknown | 207 | Tracon Pharmaceuticals Inc. | Dec 2020 |
| NCT02477826 | CheckMate 227 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 2,747 | Bristol-Myers Squibb | Aug 2015 |
| NCT02060188 | CheckMate142 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | P2 | completed | 385 | Bristol-Myers Squibb | Mar 2014 |
| NCT03215706 | CheckMate 9LA | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | P3 | completed | 719 | Bristol-Myers Squibb | Aug 2017 |
| NCT02388906 | CheckMate 238 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma | P3 | completed | 906 | Bristol-Myers Squibb | Mar 2015 |
| NCT03404960 | Parpvax | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | P1/P2 | completed | 104 | University of Pennsylvania | Jan 2018 |
| NCT05144529 | TOP2101 | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC | P2 | terminated | 19 | Eziafa Oduah, MD, PhD, MPH | Mar 2022 |
| NCT02419495 | KPT-330 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | P1 | terminated | 221 | M.D. Anderson Cancer Center | Jun 2015 |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | P1 | terminated | 79 | National Cancer Institute (NCI) | Oct 2015 | |
| NCT05655715 | CheckPRO | Checkpoint Inhibitors and SBRT for MCRPC | P2 | completed | 90 | Herlev and Gentofte Hospital | Nov 2019 |
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Early P1 | completed | 1 | H. Lee Moffitt Cancer Center and Research Institute | Jun 2023 | |
| NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | P2 | completed | 20 | Dan Zandberg | May 2020 | |
| NCT04256213 | COLIBRI | COL Immunotherapy Before Radiochimio + Ipilimumab | N/A | completed | 40 | ARCAGY/ GINECO GROUP | Jul 2020 |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | P1/P2 | terminated | 23 | TriSalus Life Sciences, Inc. | Mar 2022 | |
| NCT04463368 | SCANDIUM II | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases | P1 | completed | 18 | Vastra Gotaland Region | Mar 2021 |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | P2 | terminated | 4 | Providence Health & Services | Jun 2022 | |
| NCT03647969 | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | P2 | completed | 262 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Nov 2018 | |
| NCT04855929 | ANV419-001 | A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. | P1 | completed | 55 | Anaveon AG | May 2021 |
| NCT05169957 | HAMMER I | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | P1 | completed | 2 | University of Michigan Rogel Cancer Center | Aug 2022 |
| NCT04935229 | PERIO | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | P1 | terminated | 67 | TriSalus Life Sciences, Inc. | Aug 2021 |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | P1/P2 | completed | 320 | Bristol-Myers Squibb | Aug 2012 | |
| NCT05088889 | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | P1 | unknown | 10 | Sheba Medical Center | Jan 2022 | |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | P1/P2 | completed | 39 | Salma Sabbour | Sep 2018 | |
| NCT04575922 | Nivolumab+Ipilimumab+RT in MSS mCRC | P2 | unknown | 32 | Massachusetts General Hospital | Oct 2020 | |
| NCT02017717 | CheckMate 143 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients | P3 | completed | 529 | Bristol-Myers Squibb | Feb 2014 |
| NCT02833233 | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer | N/A | completed | 5 | Memorial Sloan Kettering Cancer Center | Jun 2016 | |
| NCT02872116 | CheckMate649 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | P3 | completed | 2,031 | Bristol-Myers Squibb | Oct 2016 |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | P1 | terminated | 1 | Emory University | Oct 2022 | |
| NCT03510871 | HCC | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | P2 | completed | 43 | National Health Research Institutes, Taiwan | Feb 2019 |
| NCT03700905 | IMSTAR-HN | Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy | P3 | unknown | 276 | Universitätsklinikum Hamburg-Eppendorf | Aug 2018 |
| NCT02631447 | SECOMBIT | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | P2 | completed | 251 | Fondazione Melanoma Onlus | Nov 2016 |
| NCT06159101 | A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects | P1 | unknown | 304 | Shanghai Henlius Biotech | Nov 2023 | |
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | P1/P2 | completed | 110 | Hoffmann-La Roche | Feb 2022 | |
| NCT01585194 | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | P2 | completed | 67 | M.D. Anderson Cancer Center | Nov 2012 | |
| NCT02681302 | CPIT001 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence | P1/P2 | terminated | 46 | Hackensack Meridian Health | Jun 2016 |
| NCT01919619 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | P2 | completed | 41 | M.D. Anderson Cancer Center | Nov 2013 | |
| NCT03739710 | NSCLC | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | P2 | completed | 175 | GlaxoSmithKline | Jan 2019 |
| NCT03818685 | BreastImmune03 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | P2 | unknown | 95 | Centre Leon Berard | Jul 2019 |
| NCT02553642 | CA209-260 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | P2 | completed | 81 | Memorial Sloan Kettering Cancer Center | Sep 2015 |
| NCT03956680 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | P1 | completed | 54 | Bristol-Myers Squibb | Mar 2019 | |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | P3 | completed | 945 | Bristol-Myers Squibb | Jun 2013 | |
| NCT04967196 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | P1 | terminated | 6 | Mayo Clinic | Sep 2021 | |
| NCT02027935 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | P2 | completed | 16 | M.D. Anderson Cancer Center | Jan 2015 | |
| NCT04382664 | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | P2 | completed | 156 | Ultimovacs ASA | May 2020 | |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | — | completed | 327 | Bristol-Myers Squibb | Feb 2024 | |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | P1/P2 | terminated | 376 | Bristol-Myers Squibb | May 2017 | |
| NCT07436390 | MAK | IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | N/A | completed | 132 | Institute of Oncology Ljubljana | Mar 2024 |
| NCT03570619 | IMPACT | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | P2 | completed | 56 | University of Michigan Rogel Cancer Center | Dec 2018 |
| NCT03033576 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | P2 | completed | 94 | National Cancer Institute (NCI) | Oct 2017 | |
| NCT04124601 | CHINOREC | Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer | P2 | completed | 80 | Johannes Laengle, MD, PhD | Jun 2020 |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | P2 | completed | 5 | Children's National Research Institute | Feb 2022 | |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | P1/P2 | terminated | 6 | Inge Marie Svane | Apr 2021 | |
| NCT03784040 | da VINci | Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. | P1 | unknown | 40 | National University Hospital, Singapore | Feb 2019 |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | P1 | terminated | 19 | Dana-Farber Cancer Institute | Jan 2020 | |
| NCT03752398 | DUET-3 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | P1 | completed | 198 | Xencor, Inc. | May 2019 |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | P2 | terminated | 12 | Roberto Pili | Jul 2018 | |
| NCT03285321 | NSCLC | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | P2 | completed | 105 | Greg Durm, MD | Sep 2017 |
| NCT03138512 | CheckMate 914 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney | P3 | completed | 1,641 | Bristol-Myers Squibb | Jul 2017 |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | P1 | terminated | 1 | Abramson Cancer Center at Penn Medicine | Aug 2020 | |
| NCT02913313 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | P1/P2 | completed | 101 | Bristol-Myers Squibb | Nov 2016 | |
| NCT03195478 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | P1/P2 | completed | 37 | Bristol-Myers Squibb | Aug 2017 | |
| NCT04513522 | CheckMate 7C9 | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India | P4 | completed | 101 | Bristol-Myers Squibb | Dec 2020 |
| NCT04571632 | Luscid | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | P2 | unknown | 36 | Universitair Ziekenhuis Brussel | Sep 2020 |
| NCT03161756 | CHARLI | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | P1/P2 | unknown | 72 | Melanoma and Skin Cancer Trials Limited | Dec 2017 |
| NCT02278887 | TIL | Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | P3 | completed | 168 | The Netherlands Cancer Institute | Sep 2014 |
| NCT04060407 | CINDI | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | P1/P2 | withdrawn | 0 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Jun 2021 |
| NCT02846376 | CPIT-002 | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant | P1 | terminated | 8 | Hackensack Meridian Health | Mar 2019 |
| NCT03829111 | CBM588 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | P1 | completed | 30 | City of Hope Medical Center | May 2019 |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | P1 | completed | 68 | M.D. Anderson Cancer Center | Feb 2013 | |
| NCT04340193 | CheckMate 74W | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer | P3 | completed | 26 | Bristol-Myers Squibb | Sep 2020 |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | P2 | completed | 120 | Olivia Newton-John Cancer Research Institute | Aug 2017 | |
| NCT03682276 | PRIME-HCC | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma | P1/P2 | unknown | 32 | Imperial College London | Mar 2019 |
| NCT03075423 | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | P2 | completed | 316 | Goethe University | Nov 2017 | |
| NCT03083691 | BIOLUMA | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | P2 | completed | 90 | Lung Cancer Group Cologne | Apr 2017 |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | P1/P2 | completed | 21 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2017 | |
| NCT06163170 | A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | — | completed | 100 | Bristol-Myers Squibb | Aug 2023 | |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | P1/P2 | completed | 20 | University of Washington | Jan 2019 | |
| NCT04892043 | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | P1 | terminated | 5 | SQZ Biotechnologies | Aug 2021 | |
| NCT03728179 | RACIN | RACIN in Patients With Advanced TIL-negative Solid Tumors | P1 | completed | 40 | Centre Hospitalier Universitaire Vaudois | Jan 2019 |
| NCT03425292 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | P1 | completed | 49 | Saint John's Cancer Institute | Mar 2018 | |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | P2 | completed | 26 | Case Comprehensive Cancer Center | Aug 2017 | |
| NCT05116917 | INFLUENCE | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. | P2 | terminated | 19 | Herlev Hospital | Nov 2021 |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | P2 | completed | 150 | M.D. Anderson Cancer Center | Apr 2015 | |
| NCT03241186 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | P2 | active not recruiting | 36 | Robert R. McWilliams, MD | Sep 2017 | |
| NCT04203901 | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | P2 | terminated | 16 | CoImmune | Jul 2020 | |
| NCT04270864 | PRIMO | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers | P1 | terminated | 25 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2020 |
| NCT03190265 | Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | P2 | completed | 61 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Dec 2017 | |
| NCT03293784 | TICIMEL | TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma | P1 | completed | 33 | Institut Claudius Regaud | Oct 2017 |
| NCT03668119 | CheckMate 848 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | P2 | completed | 212 | Bristol-Myers Squibb | Oct 2018 |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | P1 | terminated | 11 | Bristol-Myers Squibb | Dec 2021 | |
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | P1 | completed | 22 | Mirati Therapeutics Inc. | Aug 2020 | |
| NCT03651271 | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | P2 | completed | 100 | Parker Institute for Cancer Immunotherapy | Oct 2018 | |
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | P2 | unknown | 52 | Suthee Rapisuwon | Jul 2018 | |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | P1/P2 | unknown | 26 | David Minor, MD | Oct 2016 | |
| NCT03573947 | TOP1705 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | P2 | completed | 46 | Jeffrey Clarke | Oct 2018 |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | P2 | terminated | 1 | Dana-Farber Cancer Institute | Jun 2021 | |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | P1 | terminated | 6 | Jonsson Comprehensive Cancer Center | Jul 2019 | |
| NCT05074992 | NeAT Glio | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma | P2 | terminated | 1 | University College, London | Aug 2022 |
| NCT02899299 | CheckMate743 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | P3 | completed | 605 | Bristol-Myers Squibb | Nov 2016 |
| NCT03001882 | CheckMate 592 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | P2 | completed | 230 | Bristol-Myers Squibb | Mar 2017 |
| NCT05041062 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | P2 | completed | 2 | University of Chicago | Dec 2021 | |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | P2 | completed | 164 | National Cancer Institute (NCI) | Aug 2015 | |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | P1/P2 | completed | 140 | National Cancer Institute (NCI) | Mar 2015 | |
| NCT04610658 | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | P1 | terminated | 9 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2020 | |
| NCT04721301 | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | P1 | completed | 50 | University Hospital Heidelberg | Jan 2017 | |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | P1/P2 | completed | 39 | Gritstone bio, Inc. | Jul 2019 | |
| NCT03219775 | TITAN-TCC | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma | P2 | unknown | 169 | AIO-Studien-gGmbH | Jul 2017 |
| NCT04084951 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | P1 | completed | 30 | SQZ Biotechnologies | Jan 2020 | |
| NCT04635735 | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | P1/P2 | terminated | 3 | Memorial Sloan Kettering Cancer Center | Jan 2020 | |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | P2 | completed | 53 | M.D. Anderson Cancer Center | Feb 2016 | |
| NCT03922880 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | P1 | completed | 9 | Memorial Sloan Kettering Cancer Center | Apr 2019 | |
| NCT04311710 | CheckMate 76U | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types | P1 | terminated | 21 | Bristol-Myers Squibb | Jun 2020 |
| NCT02403778 | Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | P2 | completed | 10 | University of Colorado, Denver | Dec 2015 | |
| NCT01176474 | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | P1 | completed | 73 | H. Lee Moffitt Cancer Center and Research Institute | Aug 2010 | |
| NCT04319224 | JTX-2011 | Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors | P1/P2 | terminated | 4 | Jounce Therapeutics, Inc. | Mar 2020 |
| NCT04131621 | CheCUP | Nivolumab/Ipilimumab in Second Line CUP-syndrome | P2 | unknown | 194 | University Hospital Heidelberg | Dec 2019 |
| NCT03126461 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | P2 | withdrawn | 0 | University of Texas Southwestern Medical Center | Mar 2018 | |
| NCT03177239 | UNISoN | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | P2 | unknown | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Oct 2017 |
| NCT03453892 | ST-ICI | Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | — | completed | 150 | University of Erlangen-Nürnberg Medical School | Apr 2017 |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | P2 | completed | 1 | Bristol-Myers Squibb | Oct 2022 | |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | P1 | completed | 32 | National Cancer Institute (NCI) | Apr 2015 | |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | P2 | completed | 3 | National Cancer Institute (NCI) | May 2018 | |
| NCT03850691 | Radiation and Combination Immunotherapy for Melanoma | P2 | completed | 4 | Masonic Cancer Center, University of Minnesota | May 2019 | |
| NCT03798639 | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | P1 | completed | 7 | Claire Verschraegen | Jan 2019 | |
| NCT02866383 | CheckPAC | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | P2 | completed | 160 | Herlev Hospital | Nov 2016 |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | P1 | completed | 33 | H. Lee Moffitt Cancer Center and Research Institute | Aug 2016 | |
| NCT03162731 | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer | Early P1 | completed | 24 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | May 2017 | |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | P1/P2 | completed | 29 | Gritstone bio, Inc. | Feb 2019 | |
| NCT02917772 | TITAN-RCC | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma | P2 | completed | 200 | AIO-Studien-gGmbH | Oct 2016 |
| NCT02488759 | CheckMate358 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | P1/P2 | completed | 578 | Bristol-Myers Squibb | Oct 2015 |
| NCT02864251 | CheckMate722 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | P3 | completed | 367 | Bristol-Myers Squibb | Mar 2017 |
| NCT03437200 | CRUCIAL | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer | P2 | terminated | 8 | European Organisation for Research and Treatment of Cancer - EORTC | Jan 2019 |
| NCT02741570 | CheckMate 651 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | P3 | completed | 947 | Bristol-Myers Squibb | Oct 2016 |
| NCT04655157 | QUAD01 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma | P1/P2 | terminated | 2 | Jason J. Luke, MD | May 2021 |
| NCT03222076 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | P2 | completed | 30 | M.D. Anderson Cancer Center | Sep 2017 | |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | P2 | terminated | 6 | RAPT Therapeutics, Inc. | Sep 2021 | |
| NCT03302234 | NSCLC | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | P3 | completed | 568 | Merck Sharp & Dohme LLC | Dec 2017 |
| NCT05456165 | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | P2 | withdrawn | 0 | Gritstone bio, Inc. | May 2022 | |
| NCT03219671 | CKS | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | P2 | unknown | 20 | Alona Zer | Apr 2018 |
| NCT02948348 | Study to Nivolumab Following Preoperative Chemoradiotherapy | P1/P2 | unknown | 90 | Takayuki Yoshino | Oct 2016 | |
| NCT04132817 | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread | P1 | completed | 12 | Bristol-Myers Squibb | Sep 2020 | |
| NCT02880020 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | P2 | completed | 36 | Jonsson Comprehensive Cancer Center | Dec 2016 | |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | P2 | terminated | 14 | Georgetown University | Jul 2017 | |
| NCT03351361 | eNERGY | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients | P3 | completed | 217 | Rennes University Hospital | Feb 2018 |
| NCT03532217 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | P1 | completed | 19 | Washington University School of Medicine | Sep 2018 | |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | P2 | completed | 27 | University of California, San Francisco | Apr 2018 | |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | P1 | withdrawn | 0 | National Cancer Institute (NCI) | May 2021 | |
| NCT03620123 | OPTIM | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | P2 | completed | 54 | AIO-Studien-gGmbH | Jul 2018 |
| NCT02977156 | ISI-JX | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. | P1 | completed | 22 | Centre Leon Berard | Jan 2017 |
| NCT03507699 | Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer | P1 | completed | 19 | Sheba Medical Center | Dec 2018 | |
| NCT02857569 | NIVIPIT | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma | P1/P2 | completed | 90 | Gustave Roussy, Cancer Campus, Grand Paris | Dec 2016 |
| NCT03406715 | SCLC | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | P2 | terminated | 14 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2018 |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | P4 | completed | 1,041 | Bristol-Myers Squibb | Oct 2016 | |
| NCT03409198 | ICON | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | P2 | completed | 82 | Oslo University Hospital | Jan 2018 |
| NCT02935634 | FRACTION-GC | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | P2 | completed | 190 | Bristol-Myers Squibb | Nov 2016 |
| NCT04868760 | A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male Volunteers | P1 | completed | 148 | Innovent Biologics (Suzhou) Co. Ltd. | May 2021 | |
| NCT02970981 | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | P2 | completed | 18 | NYU Langone Health | Nov 2016 | |
| NCT03865082 | ILLUMINATE-206 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | P2 | active not recruiting | 30 | Idera Pharmaceuticals, Inc. | Oct 2019 |
| NCT02983045 | PIVOT-02 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | P1/P2 | completed | 557 | Nektar Therapeutics | Dec 2016 |
| NCT04118166 | Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | P2 | completed | 30 | Kristen Ganjoo | Oct 2019 | |
| NCT02823574 | CheckMate 714 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | P2 | completed | 425 | Bristol-Myers Squibb | Nov 2016 |
| NCT02154490 | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | — | completed | 1,864 | SWOG Cancer Research Network | Jul 2014 | |
| NCT03949153 | CRIRIN | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis | P1/P2 | completed | 19 | University Hospital, Strasbourg, France | Aug 2019 |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | P2 | completed | 10 | NYU Langone Health | Feb 2018 | |
| NCT03989362 | EMERGE | Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer | P2 | completed | 61 | Jounce Therapeutics, Inc. | Jun 2019 |
| NCT03168464 | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | P1/P2 | terminated | 15 | Weill Medical College of Cornell University | Oct 2017 | |
| NCT02659059 | CheckMate 568 | Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer | P2 | completed | 324 | Bristol-Myers Squibb | Feb 2016 |
| NCT03409848 | INTEGA | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma | P2 | completed | 97 | AIO-Studien-gGmbH | Mar 2018 |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | P1 | terminated | 15 | National Cancer Institute (NCI) | Aug 2013 | |
| NCT03313323 | Zirconipi | Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma | P2 | unknown | 29 | Amsterdam UMC, location VUmc | Feb 2017 |
| NCT03444753 | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed | P1 | terminated | 82 | Bristol-Myers Squibb | Apr 2018 | |
| NCT03461952 | NIMBLe | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | P2 | terminated | 4 | Canadian Cancer Trials Group | Mar 2019 |
| NCT02046733 | STIMULI | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | P2 | completed | 222 | ETOP IBCSG Partners Foundation | Dec 2015 |
| NCT05714371 | Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | — | completed | 618 | Novartis Pharmaceuticals | Oct 2021 | |
| NCT03130959 | CheckMate 908 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | P2 | completed | 166 | Bristol-Myers Squibb | Jun 2017 |
| NCT03262779 | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | P2 | completed | 20 | Yale University | Jul 2017 | |
| NCT04840615 | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | P1 | terminated | 2 | National Cancer Institute (NCI) | Jun 2021 | |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | P2 | unknown | 8 | Kidney Cancer Research Bureau | Oct 2019 | |
| NCT03251924 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | P1/P2 | terminated | 80 | Bristol-Myers Squibb | Sep 2017 | |
| NCT05611229 | Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | completed | 1,975 | Novartis Pharmaceuticals | Jun 2020 | |
| NCT03711188 | A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | P2 | completed | 16 | Immodulon Therapeutics Ltd | Oct 2018 | |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | P2 | terminated | 5 | Dana-Farber Cancer Institute | Apr 2018 | |
| NCT03420521 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | P2 | terminated | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2018 | |
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | P2 | completed | 42 | National Cancer Institute (NCI) | Dec 2012 | |
| NCT04258150 | TRIPPLE-R | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | P2 | terminated | 26 | Herlev Hospital | Apr 2020 |
| NCT02996110 | FRACTION-RCC | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma | P2 | completed | 182 | Bristol-Myers Squibb | Feb 2017 |
| NCT03416244 | RAMONA | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer | P2 | completed | 66 | AIO-Studien-gGmbH | Feb 2018 |
| NCT04088500 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | P2 | terminated | 5 | Bristol-Myers Squibb | Sep 2020 | |
| NCT02538666 | CheckMate 451 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | P3 | completed | 907 | Bristol-Myers Squibb | Oct 2015 |
| NCT03126110 | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | P1/P2 | completed | 145 | Incyte Biosciences International Sàrl | Apr 2017 | |
| NCT03903640 | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | P2 | terminated | 2 | Washington University School of Medicine | Oct 2019 | |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | P1 | completed | 10 | Emory University | Dec 2017 | |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | P1/P2 | completed | 627 | Bristol-Myers Squibb | Apr 2016 | |
| NCT03663166 | NSCLC | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | P1/P2 | terminated | 19 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2018 |
| NCT02039674 | MK-3475 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | P1/P2 | completed | 267 | Merck Sharp & Dohme LLC | Feb 2014 |
| NCT02982954 | CHECKMATE 920 | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer | P4 | completed | 211 | Bristol-Myers Squibb | Jan 2017 |
| NCT02601014 | STARVE-PC | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | P2 | completed | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2016 |
| NCT03832621 | MAYA | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | P2 | completed | 135 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Mar 2019 |
| NCT06790303 | NSCLC | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2 | P2 | terminated | 8 | GlaxoSmithKline | Mar 2021 |
| NCT03335540 | ADVISE | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | P1 | completed | 20 | Bristol-Myers Squibb | May 2018 |
| NCT02107755 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | P2 | completed | 8 | Ohio State University Comprehensive Cancer Center | Sep 2014 | |
| NCT03246958 | Nivolumab Plus Ipilimumab in Thyroid Cancer | P2 | completed | 53 | Dana-Farber Cancer Institute | Oct 2017 | |
| NCT01454102 | BMS-936558 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | P1 | completed | 472 | Bristol-Myers Squibb | Dec 2011 |
| NCT02939300 | Ipilimumab and Nivolumab in Leptomeningeal Metastases | P2 | completed | 18 | Massachusetts General Hospital | Feb 2018 | |
| NCT02626962 | GEM1402 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | P2 | completed | 52 | Grupo Español Multidisciplinar de Melanoma | Apr 2016 |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Nov 2017 | |
| NCT02523313 | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | P2 | completed | 167 | Prof. Dr. med. Dirk Schadendorf | Sep 2015 | |
| NCT04434560 | Neoadjuvant Immunotherapy in Brain Metastases | P2 | terminated | 1 | Sarah Sammons, MD | Nov 2020 | |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | P1 | completed | 71 | National Cancer Institute (NCI) | May 2013 | |
| NCT03101566 | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | P2 | completed | 75 | University of Michigan Rogel Cancer Center | Sep 2017 | |
| NCT01472081 | RCC | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | P1 | completed | 194 | Bristol-Myers Squibb | Feb 2012 |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | P3 | terminated | 481 | Idera Pharmaceuticals, Inc. | May 2018 | |
| NCT02644967 | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | P2 | completed | 53 | Idera Pharmaceuticals, Inc. | Dec 2015 | |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | P3 | completed | 387 | Bristol-Myers Squibb | Apr 2016 | |
| NCT03305445 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | P1 | completed | 6 | Icahn School of Medicine at Mount Sinai | May 2018 | |
| NCT02089685 | MK-3475 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | P1/P2 | completed | 295 | Merck Sharp & Dohme LLC | Mar 2014 |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | P1/P2 | completed | 217 | Amgen | Feb 2013 | |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | P2 | terminated | 11 | Abramson Cancer Center at Penn Medicine | Feb 2019 | |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | P1 | terminated | 6 | Jonsson Comprehensive Cancer Center | Jun 2018 | |
| NCT04149275 | Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma | P2 | withdrawn | 0 | University of Alabama at Birmingham | Feb 2021 | |
| NCT03823625 | SQUINT | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) | P2 | unknown | 112 | Fondazione Ricerca Traslazionale | Sep 2017 |
| NCT01927419 | CheckMate 069 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma | P2 | completed | 142 | Bristol-Myers Squibb | Aug 2013 |
| NCT03271047 | MSS | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | P2 | completed | 75 | Pfizer | Oct 2017 |
| NCT02960906 | BIONIKK | A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer | P2 | completed | 200 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | May 2017 |
| NCT03003637 | IMCISION | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | P1/P2 | completed | 33 | The Netherlands Cancer Institute | Feb 2017 |
| NCT03068455 | CheckMate 915 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma | P3 | completed | 1,844 | Bristol-Myers Squibb | Apr 2017 |
| NCT03347123 | ECHO-208 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | P1/P2 | terminated | 11 | Incyte Corporation | Mar 2018 |
| NCT02467361 | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | P1 | completed | 104 | Sumitomo Pharma America, Inc. | Aug 2015 | |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | P2 | completed | 20 | National Cancer Institute (NCI) | May 2015 | |
| NCT03430791 | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | P2 | terminated | 5 | Baptist Health South Florida | Dec 2018 | |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | P2 | terminated | 47 | NewLink Genetics Corporation | Jun 2014 | |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | P2 | terminated | 6 | University Hospital Tuebingen | Apr 2018 | |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | P1 | terminated | 3 | Washington University School of Medicine | Oct 2018 | |
| NCT02982486 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | P2 | unknown | 60 | Assaf-Harofeh Medical Center | Dec 2017 | |
| NCT03963518 | SURROGATE-ICI | Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI) | — | completed | 631 | Institut Bergonié | Jan 2017 |
| NCT03878524 | SMMART | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | P1 | terminated | 2 | OHSU Knight Cancer Institute | Apr 2020 |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | Early P1 | terminated | 6 | Yale University | Feb 2018 | |
| NCT03065179 | RADVAX | SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients | P2 | completed | 29 | University of Texas Southwestern Medical Center | Mar 2017 |
| NCT02275416 | Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma | P1/P2 | completed | 12 | Ultimovacs ASA | Feb 2015 | |
| NCT02737475 | An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread | P1/P2 | completed | 166 | Bristol-Myers Squibb | Jun 2016 | |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT03354962 | BOOSTER MELANOMA | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | P1/P2 | terminated | 6 | Institut Claudius Regaud | Oct 2018 |
| NCT03013491 | PROCLAIM-CX-072 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | P1/P2 | terminated | 196 | CytomX Therapeutics | Jan 2017 |
| NCT01827111 | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | P2 | completed | 21 | M.D. Anderson Cancer Center | Apr 2013 | |
| NCT02320058 | CheckMate204 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself | P2 | completed | 119 | Bristol-Myers Squibb | Mar 2015 |
| NCT01804465 | CTLA-4 | Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | P2 | completed | 50 | University of California, San Francisco | Apr 2014 |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | P2 | completed | 138 | Bristol-Myers Squibb | Apr 2013 | |
| NCT03597282 | NEO-PV-01 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | P1 | terminated | 22 | BioNTech US Inc. | Oct 2018 |
| NCT03203876 | A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors | P1 | completed | 10 | Bristol-Myers Squibb | Jul 2017 | |
| NCT02675439 | ADU-S100 | Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | P1 | terminated | 47 | Chinook Therapeutics, Inc. (formerly Aduro) | Apr 2016 |
| NCT02097732 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | P2 | terminated | 4 | University of Michigan Rogel Cancer Center | Apr 2014 | |
| NCT02659540 | Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | P1 | completed | 20 | Ludwig Institute for Cancer Research | Oct 2016 | |
| NCT01711515 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer | P1 | completed | 34 | National Cancer Institute (NCI) | Oct 2012 | |
| NCT03296137 | Adoptive Cell Therapy Across Cancer Diagnoses | P1/P2 | completed | 25 | Inge Marie Svane | Oct 2017 | |
| NCT02904226 | ICONIC | JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | P1/P2 | completed | 242 | Jounce Therapeutics, Inc. | Aug 2016 |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | P1 | terminated | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2019 | |
| NCT03287674 | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | P1/P2 | completed | 7 | Inge Marie Svane | Oct 2017 | |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | P2 | terminated | 2 | Elizabeth Davis | Jan 2019 | |
| NCT03993379 | PROCLAIM | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | P2 | terminated | 3 | CytomX Therapeutics | Nov 2019 |
| NCT02506114 | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | P2 | terminated | 15 | Lawrence Fong | Oct 2016 | |
| NCT03767439 | Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | P2 | withdrawn | 0 | Columbia University | Jul 2019 | |
| NCT01840579 | MK-3475 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | P1 | completed | 57 | Merck Sharp & Dohme LLC | Apr 2013 |
| NCT03982121 | ISILI | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy | P1 | withdrawn | 0 | Gustave Roussy, Cancer Campus, Grand Paris | Jun 2019 |
| NCT02599402 | CheckMate 401 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | P3 | completed | 533 | Bristol-Myers Squibb | Dec 2015 |
| NCT03297463 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | P1/P2 | withdrawn | 0 | Masonic Cancer Center, University of Minnesota | Jan 2018 | |
| NCT02460068 | NIBIT-M2 | A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis | P3 | unknown | 168 | Italian Network for Tumor Biotherapy Foundation | Dec 2012 |
| NCT02750514 | FRACTION-Lung | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | P2 | terminated | 295 | Bristol-Myers Squibb | May 2016 |
| NCT02203604 | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | P2 | terminated | 9 | CINJRegulatory | Nov 2014 | |
| NCT03565406 | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | P1 | terminated | 11 | NYU Langone Health | Apr 2018 | |
| NCT03527251 | SEQUENCE | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC | P1 | unknown | 10 | Sun Yat-sen University | May 2018 |
| NCT03048474 | INITIATE | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma | P2 | completed | 36 | The Netherlands Cancer Institute | Sep 2016 |
| NCT04007588 | BMS-986205 | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | P2 | withdrawn | 0 | Dana-Farber Cancer Institute | Sep 2019 |
| NCT01714739 | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | P1/P2 | completed | 337 | Bristol-Myers Squibb | Oct 2012 | |
| NCT02174172 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 158 | Hoffmann-La Roche | Aug 2014 | |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | P2 | terminated | 31 | National Cancer Centre, Singapore | Apr 2017 | |
| NCT02307149 | MITCI | Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) | P1 | completed | 50 | Viralytics | May 2015 |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | P1 | withdrawn | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Dec 2018 | |
| NCT02113657 | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Early P1 | completed | 30 | M.D. Anderson Cancer Center | Aug 2014 | |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | P2 | completed | 24 | Academic and Community Cancer Research United | Oct 2013 | |
| NCT02905266 | A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | P3 | completed | 106 | Bristol-Myers Squibb | Oct 2016 | |
| NCT02239900 | SBRT | Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | P1 | completed | 143 | M.D. Anderson Cancer Center | Aug 2014 |
| NCT03048136 | CheckMate 955 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer | P3 | withdrawn | 0 | Bristol-Myers Squibb | Mar 2018 |
| NCT02032810 | HDAC | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | P1 | completed | 17 | H. Lee Moffitt Cancer Center and Research Institute | Jan 2014 |
| NCT02385669 | Mel62; 6PAC | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | P1/P2 | terminated | 3 | Craig L Slingluff, Jr | Apr 2015 |
| NCT03241173 | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | P1/P2 | completed | 52 | Incyte Biosciences International Sàrl | Oct 2017 | |
| NCT03256136 | Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC | P2 | completed | 9 | Massachusetts General Hospital | Nov 2017 | |
| NCT02423928 | CryoIT | Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer | P1 | completed | 18 | Alden Cancer Therapy II | May 2015 |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | P1/P2 | terminated | 42 | AbbVie | Mar 2017 | |
| NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | P1/P2 | completed | 131 | NewLink Genetics Corporation | Jul 2014 | |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | P2 | completed | 40 | Bristol-Myers Squibb | Aug 2012 | |
| NCT03509584 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | P1 | terminated | 6 | Assistance Publique Hopitaux De Marseille | Jun 2018 | |
| NCT02716272 | MAPS2 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients | P2 | completed | 125 | Intergroupe Francophone de Cancerologie Thoracique | Mar 2016 |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | P2 | terminated | 23 | University of Washington | Mar 2014 | |
| NCT03525795 | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | P1 | completed | 24 | Constellation Pharmaceuticals | Dec 2017 | |
| NCT01866319 | MK-3475 | Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | P3 | completed | 834 | Merck Sharp & Dohme LLC | Aug 2013 |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | P2 | terminated | 5 | ExcellaBio LLC | Feb 2018 | |
| NCT03408587 | CLEVER | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) | P1 | completed | 11 | Viralytics | Jan 2018 |
| NCT01896869 | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer | P2 | completed | 83 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2013 | |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | P1 | unknown | 69 | Threshold Pharmaceuticals | May 2017 | |
| NCT02545075 | A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | P3 | completed | 182 | Bristol-Myers Squibb | Oct 2015 | |
| NCT01024231 | MDX-1106 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | P1 | completed | 127 | Bristol-Myers Squibb | Dec 2009 |
| NCT03203304 | SBRT | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | P1 | terminated | 14 | University of Chicago | Aug 2017 |
| NCT01750983 | Ipilimumab and Lenalidomide in Advanced Cancer | P1 | completed | 101 | M.D. Anderson Cancer Center | Mar 2013 | |
| NCT02731729 | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | P2 | completed | 20 | Parker Institute for Cancer Immunotherapy | Jun 2016 | |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | P2 | terminated | 3 | Northwestern University | Sep 2017 | |
| NCT02941744 | ipniv | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases | P1/P2 | completed | 56 | Universitair Ziekenhuis Brussel | Mar 2016 |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | P2 | completed | 10 | OHSU Knight Cancer Institute | Feb 2012 | |
| NCT02452281 | HSPPC-96 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | P1/P2 | withdrawn | 0 | Rabih Said | Dec 2015 |
| NCT01530984 | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | P2 | withdrawn | 0 | Lawrence Fong | Jun 2015 | |
| NCT01524991 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | P2 | completed | 36 | Hoosier Cancer Research Network | Jan 2012 | |
| NCT03153085 | HF10 | A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma | P2 | completed | 28 | Takara Bio Inc. | May 2017 |
| NCT02117362 | GR-MD-02 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | P1 | completed | 8 | Providence Health & Services | May 2014 |
| NCT00636168 | Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma | P3 | completed | 1,211 | Bristol-Myers Squibb | Jun 2008 | |
| NCT02608437 | NIBIT-M4 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients | P1 | unknown | 19 | Italian Network for Tumor Biotherapy Foundation | Oct 2015 |
| NCT01988077 | Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients | P2 | terminated | 2 | Sheba Medical Center | Oct 2013 | |
| NCT01621490 | PD-1 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | P1 | completed | 170 | Bristol-Myers Squibb | Sep 2012 |
| NCT02381314 | MGA271 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | P1 | completed | 24 | MacroGenics | Mar 2015 |
| NCT02516527 | A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors | P1 | completed | 25 | Bristol-Myers Squibb | Oct 2015 | |
| NCT02272855 | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma | P2 | completed | 46 | Takara Bio Inc. | Apr 2014 | |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | P1 | completed | 80 | Lytix Biopharma AS | Nov 2013 | |
| NCT02115139 | GRAY-B | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases | P2 | completed | 58 | Grupo Español Multidisciplinar de Melanoma | Apr 2014 |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | P1/P2 | completed | 41 | Biogen | Oct 2014 | |
| NCT01935921 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | P1 | completed | 19 | National Cancer Institute (NCI) | Apr 2013 | |
| NCT00790010 | Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | P1 | completed | 46 | Dana-Farber Cancer Institute | Feb 2009 | |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | P1 | terminated | 22 | Millennium Pharmaceuticals, Inc. | Jun 2016 | |
| NCT01473940 | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | P1 | completed | 21 | Northwestern University | Jun 2012 | |
| NCT02279732 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | P3 | completed | 342 | Bristol-Myers Squibb | Oct 2014 | |
| NCT01820754 | TOP1201 IPI | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | P2 | completed | 24 | Duke University | Mar 2013 |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Apr 2018 | |
| NCT01703507 | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma | P1 | completed | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Nov 2012 | |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | P2 | withdrawn | 0 | Medical University of South Carolina | Apr 2018 | |
| NCT01729806 | Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | P1 | completed | 32 | National Cancer Institute (NCI) | Nov 2012 | |
| NCT01998126 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | P1 | completed | 14 | University of Utah | Dec 2013 | |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | — | no longer available | 0 | Center Trials & Treatment | — | |
| NCT01565837 | SART | Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | P2 | unknown | 50 | Wolfram Samlowski | Aug 2012 |
| NCT01715077 | Study of Ipilimumab in the Immune System | N/A | completed | 4 | University Health Network, Toronto | Oct 2012 | |
| NCT03165409 | Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread | — | completed | 1,828 | Bristol-Myers Squibb | Feb 2017 | |
| NCT00972933 | Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma | Early P1 | completed | 59 | Diwakar Davar | Dec 2009 | |
| NCT03009058 | MODULATE | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | P1/P2 | terminated | 2 | Immodulon Therapeutics Ltd | May 2017 |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | P3 | completed | 1,289 | Bristol-Myers Squibb | Jan 2011 | |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | P3 | completed | 831 | Bristol-Myers Squibb | Feb 2012 | |
| NCT01323517 | MDX-010 | Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | P2 | completed | 26 | Memorial Sloan Kettering Cancer Center | Feb 2011 |
| NCT01450761 | ED-SCLC | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | P3 | completed | 1,351 | Bristol-Myers Squibb | Dec 2011 |
| NCT02935790 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | P1 | completed | 1 | Celgene | Sep 2016 | |
| NCT01377389 | Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | P2 | terminated | 30 | M.D. Anderson Cancer Center | Jun 2011 | |
| NCT02739386 | Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases | — | completed | 370 | Bristol-Myers Squibb | Feb 2016 | |
| NCT01608594 | Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma | P1 | completed | 30 | Diwakar Davar | May 2013 | |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | P1/P2 | withdrawn | 0 | University of Pittsburgh | Oct 2016 | |
| NCT01302496 | TriMix-Ipi | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | P2 | completed | 39 | Bart Neyns | Feb 2011 |
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | P1/P2 | completed | 9 | Robert Lowsky | Sep 2014 | |
| NCT02200562 | Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma | P1 | terminated | 6 | University of Utah | Dec 2014 | |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | P1/P2 | terminated | 50 | Incyte Corporation | Mar 2012 | |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Dec 2016 | |
| NCT02279862 | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | P2 | completed | 82 | Bristol-Myers Squibb | Dec 2014 | |
| NCT01449279 | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | P2 | completed | 22 | Stanford University | Oct 2011 | |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | P1/P2 | completed | 27 | University of Louisville | Feb 2012 | |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | P1/P2 | terminated | 9 | Celldex Therapeutics | Apr 2015 | |
| NCT02406183 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | P1 | completed | 13 | Radiotherapie | Mar 2015 | |
| NCT01216696 | CTLA4 NY-ESO-1 | Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 | P2 | completed | 25 | National Center for Tumor Diseases, Heidelberg | Nov 2010 |
| NCT01119508 | Ipilimumab + Temozolomide in Metastatic Melanoma | P2 | completed | 64 | M.D. Anderson Cancer Center | May 2010 | |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | P2 | terminated | 14 | Bristol-Myers Squibb | Nov 2012 | |
| NCT01643278 | Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic | P1 | completed | 29 | National Cancer Institute (NCI) | Jul 2012 | |
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | P1 | terminated | 19 | M.D. Anderson Cancer Center | Feb 2013 | |
| NCT01810016 | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | P1 | terminated | 8 | Ludwig Institute for Cancer Research | Jan 2014 | |
| NCT01984255 | A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients | P1 | terminated | 3 | University of Texas Southwestern Medical Center | Apr 2014 | |
| NCT01557114 | Mel-Ipi-Rx | Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma | P1 | terminated | 19 | Gustave Roussy, Cancer Campus, Grand Paris | Mar 2011 |
| NCT02094391 | ILP+/-IPI | Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma | P2 | completed | 4 | Gustave Roussy, Cancer Campus, Grand Paris | Mar 2014 |
| NCT01832870 | Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | P1 | completed | 9 | Prostate Oncology Specialists, Inc. | Apr 2013 | |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases | Early P1 | terminated | 6 | Case Comprehensive Cancer Center | Dec 2012 | |
| NCT02662725 | IPI+RTS | Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases | P2 | completed | 73 | University Hospital, Lille | Sep 2012 |
| NCT02115243 | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | P1 | completed | 4 | Duke University | May 2014 | |
| NCT02224768 | YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey | — | completed | 158 | Bristol-Myers Squibb | Jul 2015 | |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | P1 | completed | 33 | National Cancer Institute (NCI) | Oct 2007 | |
| NCT01194271 | Neoadjuvant Ipilimumab in Prostate Cancer | P2 | completed | 19 | M.D. Anderson Cancer Center | Sep 2010 | |
| NCT02221739 | NSCLC | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | P1/P2 | completed | 39 | NYU Langone Health | Jul 2014 |
| NCT01497808 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | P1/P2 | completed | 22 | Abramson Cancer Center at Penn Medicine | Nov 2011 | |
| NCT01767454 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | P1 | completed | 38 | GlaxoSmithKline | Feb 2013 | |
| NCT00861614 | Study of Immunotherapy to Treat Advanced Prostate Cancer | P3 | completed | 988 | Bristol-Myers Squibb | May 2009 | |
| NCT01838200 | BCG | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | P1 | terminated | 5 | Ludwig Institute for Cancer Research | Mar 2014 |
| NCT01856023 | PROCLIVITY02 | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma | P4 | terminated | 29 | Clinigen, Inc. | May 2013 |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | P1/P2 | terminated | 12 | M.D. Anderson Cancer Center | Nov 2012 | |
| NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | P3 | completed | 837 | Bristol-Myers Squibb | Jul 2010 | |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | P1 | terminated | 3 | Stanford University | Feb 2013 | |
| NCT01480323 | A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 | P2 | completed | 15 | University Hospital Tuebingen | Feb 2012 | |
| NCT01331525 | ICE | The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer | P2 | completed | 42 | University Hospital Southampton NHS Foundation Trust | Jun 2011 |
| NCT01363206 | GIPI | Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma | P2 | completed | 29 | Lynn E. Spitler, MD | May 2011 |
| NCT01673854 | Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | P2 | completed | 70 | Bristol-Myers Squibb | Sep 2012 | |
| NCT01750580 | Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | P1 | completed | 22 | Bristol-Myers Squibb | Dec 2012 | |
| NCT01585987 | An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | P2 | completed | 143 | Bristol-Myers Squibb | Jul 2012 | |
| NCT01689974 | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | P2 | terminated | 10 | NYU Langone Health | Jan 2013 | |
| NCT02050594 | Ipilimumab 12-month Intensive Pharmacovigilance Protocol | — | completed | 6 | Bristol-Myers Squibb | Feb 2014 | |
| NCT01990859 | Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients | P2 | completed | 20 | Bristol-Myers Squibb | Dec 2013 | |
| NCT01502592 | Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer | P1 | completed | 19 | Memorial Sloan Kettering Cancer Center | Dec 2011 | |
| NCT02009384 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | P2 | terminated | 2 | University of Louisville | Jan 2012 | |
| NCT01654692 | NIBIT-M1 | A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma | P2 | completed | 86 | Italian Network for Tumor Biotherapy | Jun 2010 |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | P1/P2 | withdrawn | 0 | Ludwig Institute for Cancer Research | Mar 2014 | |
| NCT01672450 | A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma | P1 | completed | 12 | University of Utah | Sep 2012 | |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | P2 | terminated | 31 | Bristol-Myers Squibb | Mar 2013 | |
| NCT02186249 | CheckMate218 | Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma | — | no longer available | 0 | Bristol-Myers Squibb | — |
| NCT01489059 | Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | P1 | completed | 42 | Bristol-Myers Squibb | Dec 2011 | |
| NCT01681212 | Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma | P2 | completed | 21 | Bristol-Myers Squibb | Oct 2012 | |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | P2 | completed | 248 | Bristol-Myers Squibb | May 2006 | |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Jul 2013 | |
| NCT01400451 | BRAF | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | P1 | terminated | 18 | Bristol-Myers Squibb | Nov 2011 |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | P1/P2 | completed | 10 | Fred Hutchinson Cancer Center | Feb 2009 | |
| NCT00324155 | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma | P3 | completed | 681 | Bristol-Myers Squibb | Aug 2006 | |
| NCT01950195 | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | P1 | terminated | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2013 | |
| NCT01355120 | DeCOG | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease | P2 | completed | 171 | Prof. Dr. med. Dirk Schadendorf | Oct 2011 |
| NCT01165216 | Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | P1 | completed | 15 | Bristol-Myers Squibb | Sep 2010 | |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | P2 | completed | 112 | Mayo Clinic | Jun 2004 | |
| NCT01743157 | BBI | Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma | P1/P2 | completed | 24 | California Pacific Medical Center Research Institute | Dec 2010 |
| NCT01471197 | Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer | P2 | terminated | 9 | Bristol-Myers Squibb | Jul 2012 | |
| NCT00803374 | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | P1 | withdrawn | 0 | Bristol-Myers Squibb | Nov 2010 | |
| NCT01757639 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | P1 | completed | 42 | National Cancer Institute (NCI) | Dec 2012 | |
| NCT01245556 | Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma | P1 | completed | 8 | Bristol-Myers Squibb | Jan 2011 | |
| NCT00920907 | Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma | P1 | completed | 99 | Bristol-Myers Squibb | Aug 2009 | |
| NCT00796991 | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | P1 | completed | 72 | Bristol-Myers Squibb | Feb 2009 | |
| NCT00623766 | Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases | P2 | completed | 99 | Bristol-Myers Squibb | Jul 2008 | |
| NCT00064129 | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | P1 | completed | 42 | National Cancer Institute (NCI) | May 2003 | |
| NCT00836407 | Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer | P1 | completed | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Feb 2009 | |
| NCT00527735 | NSCLC | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | P2 | completed | 334 | Bristol-Myers Squibb | Feb 2008 |
| NCT01510288 | Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer | P1 | terminated | 28 | Amsterdam UMC, location VUmc | Nov 2004 | |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2011 | |
| NCT00732186 | Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia | P1 | withdrawn | 0 | Bristol-Myers Squibb | Aug 2009 | |
| NCT00047164 | Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy | P1 | completed | 89 | National Institutes of Health Clinical Center (CC) | Sep 2002 | |
| NCT00362713 | Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection | P1 | completed | 12 | Bristol-Myers Squibb | Mar 2007 | |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | P1/P2 | terminated | 18 | National Cancer Institute (NCI) | Jun 2004 | |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | P2 | completed | 77 | Bristol-Myers Squibb | May 2004 | |
| NCT00112580 | MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery | P2 | completed | 27 | Bristol-Myers Squibb | Jul 2005 | |
| NCT00077532 | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | P2 | completed | 179 | National Institutes of Health Clinical Center (CC) | Mar 2004 | |
| NCT00057889 | Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer | P2 | completed | 0 | National Institutes of Health Clinical Center (CC) | Feb 2003 | |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | P1 | terminated | 26 | National Cancer Institute (NCI) | Mar 2002 | |
| NCT00261365 | MDX-010 | Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) | P1/P2 | completed | 80 | Bristol-Myers Squibb | Nov 2005 |
| NCT00289640 | MDX-010 | Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | P2 | completed | 210 | Bristol-Myers Squibb | Apr 2006 |
| NCT00289627 | A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | P2 | completed | 155 | Bristol-Myers Squibb | Apr 2006 | |
| NCT00135408 | BMS-734016 | A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide | P2 | completed | 115 | Bristol-Myers Squibb | Dec 2005 |
| NCT00495066 | Compassionate Use Trial for Unresectable Melanoma With Ipilimumab | — | no longer available | 0 | Bristol-Myers Squibb | — | |
| NCT00140855 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | P2 | terminated | 6 | Ludwig Institute for Cancer Research | Jun 2005 | |
| NCT00058279 | Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma | P1/P2 | completed | 0 | National Cancer Institute (NCI) | Feb 2003 | |
| NCT00032045 | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | P2 | completed | 0 | National Cancer Institute (NCI) | Jan 2002 | |
| NCT00357461 | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | P2 | withdrawn | 0 | Bristol-Myers Squibb | May 2006 | |
| NCT00025181 | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | P1 | completed | 19 | University of Southern California | Oct 2001 | |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | P1 | completed | 21 | National Cancer Institute (NCI) | Apr 2003 |
Ipilimumab clinical trials: frequently asked questions
- How many Ipilimumab clinical trials are there?
- 791 Ipilimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 108 are actively recruiting participants. 340 are marked completed.
- Are Ipilimumab clinical trials recruiting in 2026?
- Yes — 108 Ipilimumab trials are actively recruiting in 2026, with 1761 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ipilimumab being studied for?
- Ipilimumab is being studied for Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Unresectable Melanoma, Non Small Cell Lung Cancer and 1352 more. The trials are grouped by indication on this page.
- What phase is Ipilimumab in?
- Ipilimumab clinical trials span 7 Phase 4, 64 Phase 3, 344 Phase 2, 198 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ipilimumab clinical trials?
- The lead sponsor across the most Ipilimumab trials is Bristol-Myers Squibb, with 280 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ipilimumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: